<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Short‐acting inhaled bronchodilators for cystic fibrosis - Smith, S - 2022 | Cochrane Library</title> <meta content="Short‐acting inhaled bronchodilators for cystic fibrosis - Smith, S - 2022 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013666.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Short‐acting inhaled bronchodilators for cystic fibrosis - Smith, S - 2022 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013666.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD013666.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Short‐acting inhaled bronchodilators for cystic fibrosis" name="citation_title"/> <meta content="Sherie Smith" name="citation_author"/> <meta content="University of Nottingham" name="citation_author_institution"/> <meta content="Sherie.Smith@nottingham.ac.uk" name="citation_author_email"/> <meta content="Nicola J Rowbotham" name="citation_author"/> <meta content="University of Nottingham" name="citation_author_institution"/> <meta content="Christopher T Edwards" name="citation_author"/> <meta content="A Floor, Clarendon Wing, Leeds Children's Hospital" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="6" name="citation_issue"/> <meta content="10.1002/14651858.CD013666.pub2" name="citation_doi"/> <meta content="2022" name="citation_date"/> <meta content="2022/06/24" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013666.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013666.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013666.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Administration, Inhalation; *Bronchodilator Agents [therapeutic use]; *Cystic Fibrosis [complications, drug therapy]; Forced Expiratory Volume; Muscarinic Antagonists" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013666.pub2&amp;doi=10.1002/14651858.CD013666.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013666.pub2&amp;doi=10.1002/14651858.CD013666.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013666.pub2&amp;doi=10.1002/14651858.CD013666.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013666.pub2&amp;doi=10.1002/14651858.CD013666.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013666.pub2&amp;doi=10.1002/14651858.CD013666.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013666.pub2&amp;doi=10.1002/14651858.CD013666.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013666.pub2&amp;doi=10.1002/14651858.CD013666.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013666.pub2&amp;doi=10.1002/14651858.CD013666.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013666.pub2&amp;doi=10.1002/14651858.CD013666.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013666.pub2&amp;doi=10.1002/14651858.CD013666.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013666.pub2&amp;doi=10.1002/14651858.CD013666.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013666.pub2&amp;doi=10.1002/14651858.CD013666.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013666.pub2&amp;doi=10.1002/14651858.CD013666.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013666.pub2&amp;doi=10.1002/14651858.CD013666.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013666.pub2&amp;doi=10.1002/14651858.CD013666.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013666.pub2&amp;doi=10.1002/14651858.CD013666.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013666.pub2&amp;doi=10.1002/14651858.CD013666.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013666.pub2&amp;doi=10.1002/14651858.CD013666.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013666.pub2&amp;doi=10.1002/14651858.CD013666.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013666.pub2&amp;doi=10.1002/14651858.CD013666.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013666.pub2&amp;doi=10.1002/14651858.CD013666.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013666.pub2&amp;doi=10.1002/14651858.CD013666.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013666.pub2&amp;doi=10.1002/14651858.CD013666.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="mV7VuqgF";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD013666\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD013666\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013666\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013666\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANT","ko","ms","ja","hr","fa","fr"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD013666.pub2",title:"Short\\u2010acting inhaled bronchodilators for cystic fibrosis",firstPublishedDate:"Jun 24, 2022 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Cystic Fibrosis and Genetic Disorders Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=mV7VuqgF&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013666.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD013666.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD013666.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD013666.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013666.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD013666.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD013666.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD013666.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD013666.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD013666.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;초록&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;一般語訳&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;쉬운 말 요약&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD013666.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD013666.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD013666.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD013666.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>2239 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD013666.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013666.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013666.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013666.pub2/full#CD013666-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013666.pub2/full#CD013666-sec-0132"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013666.pub2/full#CD013666-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013666.pub2/full#CD013666-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013666.pub2/full#CD013666-sec-0016"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013666.pub2/full#CD013666-sec-0017"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013666.pub2/full#CD013666-sec-0041"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013666.pub2/full#CD013666-sec-0123"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD013666.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013666.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013666.pub2/appendices#CD013666-sec-0137"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013666.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013666.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD013666.pub2/media/CDSR/CD013666/table_n/CD013666StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD013666.pub2/media/CDSR/CD013666/table_n/CD013666StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013666.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013666.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013666.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD013666.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD013666.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD013666.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2022 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD013666.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Short‐acting inhaled bronchodilators for cystic fibrosis</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013666.pub2/information#CD013666-cr-0004"><i class="icon corresponding-author fa fa-envelope"></i>Sherie Smith</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013666.pub2/information#CD013666-cr-0005">Nicola J Rowbotham</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013666.pub2/information#CD013666-cr-0006">Christopher T Edwards</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD013666.pub2/information/en#CD013666-sec-0142">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 24 June 2022 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD013666.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD013666.pub2">https://doi.org/10.1002/14651858.CD013666.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD013666-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD013666-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD013666-abs-0013">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD013666-abs-0009">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD013666-abs-0011">Français</a> </li> <li class="section-language"> <a class="" href="full/ko#CD013666-abs-0004">한국어</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD013666-abs-0001" lang="en"> <section id="CD013666-sec-0001"> <h3 class="title" id="CD013666-sec-0001">Background</h3> <p>Respiratory disease is the main cause of morbidity and mortality in cystic fibrosis (CF), and many different therapies are used by people with CF in the management of respiratory problems. Bronchodilator therapy is used to relieve symptoms of shortness of breath and to open the airways to allow clearance of mucus. Despite the widespread use of inhaled bronchodilators in CF, there is little objective evidence of their efficacy. A Cochrane Review looking at both short‐ and long‐acting inhaled bronchodilators for CF was withdrawn from the Cochrane Library in 2016. That review has been replaced by two separate Cochrane Reviews: one on long‐acting inhaled bronchodilators for CF, and this review on short‐acting inhaled bronchodilators for CF. For this review 'inhaled' includes the use of pressurised metered dose inhalers (MDIs), with or without a spacer, dry powder devices and nebulisers. </p> </section> <section id="CD013666-sec-0002"> <h3 class="title" id="CD013666-sec-0002">Objectives</h3> <p>To evaluate short‐acting inhaled bronchodilators in children and adults with CF in terms of clinical outcomes and safety. </p> </section> <section id="CD013666-sec-0003"> <h3 class="title" id="CD013666-sec-0003">Search methods</h3> <p>We searched the Cochrane Cystic Fibrosis Trials Register, compiled from electronic database searches and handsearching of journals and conference abstract books on 28 March 2022 and searched trial registries for any new or ongoing trials on 12 April 2022. We also searched the reference lists of relevant articles and reviews. </p> </section> <section id="CD013666-sec-0004"> <h3 class="title" id="CD013666-sec-0004">Selection criteria</h3> <p>We searched for randomised controlled trials (RCTs) or quasi‐RCTs that looked at the effect of any short‐acting inhaled bronchodilator delivered by any device, at any dose, at any frequency and for any duration compared to either placebo or another short‐acting inhaled bronchodilator in people with CF. We screened references as per standard Cochrane methodology. </p> </section> <section id="CD013666-sec-0005"> <h3 class="title" id="CD013666-sec-0005">Data collection and analysis</h3> <p>Two review authors extracted data and assessed risk of bias using the Cochrane RoB 1 tool. Where we were not able to enter data into our analyses we reported results directly from the papers. We assessed the certainty of evidence using GRADE. </p> </section> <section id="CD013666-sec-0006"> <h3 class="title" id="CD013666-sec-0006">Main results</h3> <p>We included 11 trials from our systematic search, with 191 participants meeting our inclusion criteria; three of these trials had three treatment arms. Eight trials compared short‐acting inhaled beta‐2 agonists to placebo and four trials compared short‐acting inhaled muscarinic antagonists to placebo. Three trials compared short‐acting inhaled beta‐2 agonists to short‐acting inhaled muscarinic antagonists. All were cross‐over trials with only small numbers of participants. We were only able to enter data into the analysis from three trials comparing short‐acting inhaled beta‐2 agonists to placebo. </p> <p>Short‐acting inhaled beta‐2 agonists versus placebo </p> <p>All eight trials (six single‐dose trials and two longer‐term trials) reporting on this comparison reported on forced expiratory volume in 1 second (FEV<sub>1</sub>), either as per cent predicted (% predicted) or L. We were able to combine the data from two trials in a meta‐analysis which showed a greater per cent change from baseline in FEV<sub>1</sub> L after beta‐2 agonists compared to placebo (mean difference (MD) 6.95%, 95% confidence interval (CI) 1.88 to 12.02; 2 trials, 82 participants). Only one of the longer‐term trials reported on exacerbations, as measured by hospitalisations and courses of antibiotics. Only the second longer‐term trial presented results for participant‐reported outcomes. Three trials narratively reported adverse events, and these were all mild. Three single‐dose trials and the two longer trials reported on forced vital capacity (FVC), and five trials reported on peak expiratory flow, i.e. forced expiratory flow between 25% and 75% (FEF<sub>25-75</sub>). One trial reported on airway clearance in terms of sputum weight. We judged the certainty of evidence for each of these outcomes to be very low, meaning we are very uncertain about the effect of short‐acting inhaled beta‐2 agonists on any of the outcomes we assessed. </p> <p>Short‐acting inhaled muscarinic antagonists versus placebo </p> <p>All four trials reporting on this comparison looked at the effects of ipratropium bromide, but in different doses and via different delivery methods. One trial reported FEV<sub>1</sub> % predicted; three trials measured this in L. Two trials reported adverse events, but these were few and mild. One trial reported FVC and three trials reported FEF<sub>25-75</sub>. None of the trials reported on quality of life, exacerbations or airway clearance. We judged the certainty of evidence for each of these outcomes to be very low, meaning we are very uncertain about the effect of short‐acting inhaled muscarinic antagonists on any of the outcomes we assessed. </p> <p>Short‐acting inhaled beta‐2 agonists versus short‐acting inhaled muscarinic antagonists  </p> <p>None of the three single‐dose trials reporting on this comparison provided data we could analyse. The original papers from three trials report that both treatments lead to an improvement in FEV<sub>1</sub> L. Only one trial reported on adverse events; but none were experienced by any participant. No trial reported on any of our other outcomes. We judged the certainty of evidence to be very low, meaning we are very uncertain about the effect of short‐acting inhaled beta‐2 agonists compared to short‐acting inhaled muscarinic antagonists on any of the outcomes we assessed. </p> </section> <section id="CD013666-sec-0007"> <h3 class="title" id="CD013666-sec-0007">Authors' conclusions</h3> <p>All included trials in this review are small and of a cross‐over design. Most trials looked at very short‐term effects of inhaled bronchodilators, and therefore did not measure longer‐term outcomes. The certainty of evidence across all outcomes was very low, and therefore we have been unable to describe any effects with certainty. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD013666-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD013666-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD013666-abs-0014">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD013666-abs-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD013666-abs-0012">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD013666-abs-0008">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ja#CD013666-abs-0007">日本語</a> </li> <li class="section-language"> <a class="" href="full/ko#CD013666-abs-0005">한국어</a> </li> <li class="section-language"> <a class="" href="full/ms#CD013666-abs-0006">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD013666-abs-0003">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD013666-abs-0002" lang="en"> <h3>Short‐acting inhaled bronchodilators for cystic fibrosis</h3> <p><b>Review question</b> </p> <p>We reviewed the evidence for using short‐acting inhaled bronchodilators (treatments which widen and open the airways, making it easier to breathe) in people with cystic fibrosis. Short‐acting bronchodilators take effect quickly and generally last 4 to 6 hours. We were interested in any type of short‐acting inhaled bronchodilator, given at any dose, and by any type of device (inhalers or nebulisers). </p> <p>Both nebulisers and inhalers deliver medicine. Nebulisers turn liquid medication into an easily‐inhaled mist. They vary in type but need a power source, e.g. a rechargeable battery, to function. Inhalers deliver short bursts of medicine (as an aerosol or dry powder) via a manual handheld device. The most common type of inhaler is a metered‐dose inhaler. Inhalers can be used with spacers (empty tubes, usually made from plastic that slot onto the mouthpiece of the inhaler).  </p> <p>Inhaled bronchodilators are used by many people with cystic fibrosis to help them breathe, and to make it easier to clear mucus from their lungs. We wanted to know if these treatments were better than a placebo (dummy) treatment or another type of short‐acting inhaled bronchodilator. </p> <p><b>Search date</b> </p> <p>The evidence is current to 28 March 2022.</p> <p><b>Trial characteristics</b> </p> <p>The review included 11 trials with 191<i> </i> people with cystic fibrosis aged between 5<i> </i> and 40<i> </i> years of age<i>.</i> Trials compared two different types of short‐acting inhaled bronchodilator (beta‐2 agonists such as salbutamol or albuterol, and muscarinic antagonists such as ipratropium bromide) against a placebo substance which contained no medication, or a different short‐acting inhaled bronchodilator; three of the trials had three comparison groups ‐ beta‐2 agonists versus muscarinic antagonists versus placebo. All trials were cross‐over trials, so all of the people included in the trial received both treatments at different times, and the order that they received the treatments was random.<i> </i>The trials lasted from a single‐dose trial to 6 months. Eight trials looked at the effects of short‐acting inhaled beta‐2 agonists versus placebo, four trials at the effects of a short‐acting inhaled muscarinic antagonist versus placebo, and three trials looked at the effects of a short‐acting inhaled beta‐2 agonist with a short‐acting inhaled muscarinic antagonist. </p> <p><b>Key results</b> </p> <p>All trials looked at the effect of short‐acting inhaled bronchodilators on lung function, measured as forced expiratory volume in one second (FEV<sub>1</sub>), but this was reported in different ways and at different time points.  </p> <p>We are uncertain whether any of the short‐acting inhaled bronchodilators have an effect on FEV<sub>1</sub> compared to placebo. The trials were too small and there were not enough data to show if there was an effect or not. </p> <p>Only six of the 11 trials reported on harmful effects of treatment: one trial reported no harmful effects and five trials reported mild tremors, dry mouth and fatigue. </p> <p><b>Certainty of the evidence</b> </p> <p>The certainty of the evidence across all trials was very low. All trials used a cross‐over design where the participants are given one treatment and then swapped to the other treatment with a washout period (the length of time for a drug to be eliminated from the body) in between. It is possible that the clinical status of participants was not the same at the beginning of the first treatment phase as at the beginning of the second treatment phase. The trials were also very small and were carried out more than 10 years ago. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD013666-sec-0132" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD013666-sec-0132"></div> <h3 class="title" id="CD013666-sec-0133">Implications for practice</h3> <section id="CD013666-sec-0133"> <p>There is only very low‐certainty evidence regarding the practice of regular use of short‐acting inhaled bronchodilators in people with cystic fibrosis (CF), despite their widespread, and often long‐term use. We suggest that initiation of such therapies should be considered on an individual basis, with bronchodilator responsiveness, assessed prior to starting and perceived benefit and burden reviewed regularly. </p> <p>Short‐acting inhaled bronchodilators are often given before airway clearance to open the airways and allow better expectoration of mucus. Only two included trials administered the intervention before physiotherapy and then measured the outcomes after physiotherapy (<a href="./references#CD013666-bbs2-0002" title="DuncanFR , PenkethAR , HodsonME , BattenJC . The use of bronchodilators as an adjunct to physiotherapy, in adults with cystic fibrosis. In: 11th European Cystic Fibrosis Conference, 1982; Brussels. 1982:48. [CFGD REGISTER: IB70] ">Duncan 1982</a>; <a href="./references#CD013666-bbs2-0004" title="HordvikNL , SammutPH , JudyCG , StrizekSJ , ColomboJL . The effects of albuterol on the lung function of hospitalized patients with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine1996;154(1):156-60. [CFGD REGISTER: IB75] ">Hordvik 1996</a>). We are uncertain whether beta‐2 agonists improve FEV<sub>1</sub>, as we assessed the certainty of evidence as very low. Two trials looked at the effect of giving a beta‐2 agonist before exercise (<a href="./references#CD013666-bbs2-0001" title="DoddJ , BarryS , GallagherC . The effects of inhaled B2 agonists on maximal exercise in patients with cystic fibrosis . American Journal of Respiratory and Critical Care Medicine2001;163(5 Suppl):A88. [CFGD REGISTER: IB84a] DoddJD , BarrySC , DalyLE , GallagherCG . Inhaled beta-agonists improve lung function but not maximal exercise capacity in cystic fibrosis. Journal of Cystic Fibrosis2005;4(2):101-5. [CFGD REGISTER: IB84b] ">Dodd 2005</a>; <a href="./references#CD013666-bbs2-0008" title="SerisierDJ , CaotesAD , BowlerSD . Inhaled salbutamol does not improve maximal exercise performance in cystic fibrosis . Respirology2006;11(Suppl 2):A58. [CFGD REGISTER: IB81c] SerisierDJ , CoatesAD , BowlerSD . Effect of albuterol on maximal exercise capacity in cystic fibrosis. Chest2007;131(4):1181-7. [CFGD REGISTER: IB81b] SerisierDJ , Rice-McDonaldG , BowlerSD , CoatesAC . ß-adrenergic agonists do not improve exercise capacity in cystic fibrosis. Pediatric Pulmonology2000;30 Suppl 20:305. [CFGD REGISTER: IB81a] ">Serisier 2000</a>); but again we are uncertain whether the beta‐2 agonist improved bronchodilation following bronchodilator administration and after exercise due to the very low certainty‐evidence.  </p> </section> <h3 class="title" id="CD013666-sec-0134">Implications for research</h3> <section id="CD013666-sec-0134"> <p>Despite widespread use of short‐acting inhaled bronchodilators, particularly beta‐2 agonists, in people with CF we found only very low‐certainty evidence to support such treatment. Most included trials looked at the very short‐term effects of short‐acting bronchodilator therapy and therefore did not measure longer‐term outcomes, such as quality of life, symptom scores and exacerbations. Nebulised therapies (which also include nebulised antibiotics, hypertonic saline and other mucolytic agents) are commonly reported to be time‐consuming and burdensome to people with CF and so it is important that their efficacy is confirmed (<a href="./references#CD013666-bbs2-0042" title="DaviesG , RowbothamNJ , SmithS , ElliotZC , GathercoleK , RaynerO , et al. Characterising burden of treatment in cystic fibrosis to identify priority areas for clinical trials. Journal of Cystic Fibrosis2019;19(3):499-502.">Davies 2019</a>). Longer‐term trials of parallel design with larger participant numbers would be useful to determine the use of bronchodilator therapy as an adjunct to airway clearance techniques in opening the airways to improve removal of secretions. This would also allow the collection of information on the longer‐term outcomes mentioned above which may be more important outcomes for people with CF. </p> <p>In practice, bronchodilators are frequently used before airway clearance techniques, and a trial which explicitly looked at the effect of bronchodilator therapy given before any airway clearance technique on the effectiveness of airway clearance for people with CF would be an important addition to the evidence base. There is much interest currently as to whether exercise can replace some or all airway clearance techniques; therefore more information regarding the use of short‐acting bronchodilators in conjunction with both exercise and airway clearance techniques to improve outcomes would be welcome. </p> <p>Due to their widespread use, it may not be ethical to carry out a RCT comparing the use of bronchodilators to no intervention; and with the advent of novel modulator therapies for the underlying condition, it may be more appropriate to carry out a stopping trial to look at the effect of removing or reducing the use of bronchodilators in CF. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD013666-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD013666-sec-0008"></div> <div class="table" id="CD013666-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Short‐acting inhaled beta‐2 agonists compared with placebo for cystic fibrosis</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Short‐acting inhaled beta‐2 agonists compared with placebo for cystic fibrosis</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> children and adults with cystic fibrosis </p> <p><b>Settings:</b> inpatient and outpatient </p> <p><b>Intervention:</b> inhaled beta‐2 agonist (albuterol or salbutamol) </p> <p><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>No of Participants<br/>(trials)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Inhaled beta‐2 agonist</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Change from baseline in FEV<sub>1</sub> (% predicted)</b> </p> <p> </p> <p>Follow‐up: single dose, 2 weeks, 6 months</p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p><i>Single‐dose trials</i> </p> <p>FEV<sub>1</sub> % predicted was shown to improve after inhaled albuterol (or salbutamol) compared to placebo (<a href="./references#CD013666-bbs2-0001" title="DoddJ , BarryS , GallagherC . The effects of inhaled B2 agonists on maximal exercise in patients with cystic fibrosis . American Journal of Respiratory and Critical Care Medicine2001;163(5 Suppl):A88. [CFGD REGISTER: IB84a] DoddJD , BarrySC , DalyLE , GallagherCG . Inhaled beta-agonists improve lung function but not maximal exercise capacity in cystic fibrosis. Journal of Cystic Fibrosis2005;4(2):101-5. [CFGD REGISTER: IB84b] ">Dodd 2005</a>). A further trial showed an improvement after salbutamol, but did not report the effect in the placebo group (<a href="./references#CD013666-bbs2-0002" title="DuncanFR , PenkethAR , HodsonME , BattenJC . The use of bronchodilators as an adjunct to physiotherapy, in adults with cystic fibrosis. In: 11th European Cystic Fibrosis Conference, 1982; Brussels. 1982:48. [CFGD REGISTER: IB70] ">Duncan 1982</a>). </p> <p> </p> <p><i>Short‐term trial</i> </p> <p>FEV<sub>1</sub> % predicted increased by 3% after albuterol and decreased by 3% in the placebo arm in methacholine challenge responders, but analysis showed this difference not to be significant. No improvement was seen in either group in the methacholine non‐responder group (<a href="./references#CD013666-bbs2-0003" title="EgglestonPA , RosensteinBJ , StackhouseCM , MellitsED , BaumgardnerRA . A controlled trial of long-term bronchodilator therapy in cystic fibrosis. Chest1991;99(5):1088-92. [CFGD REGISTER: IB61a] OrensteinD . Long-term inhaled bronchodilator therapy in cystic fibrosis. Comment on Eggleston PA, Rosenstein BJ, Stackhouse CM, Mellits ED, Baumgardner RA. A controlled trial of long-term bronchodilator therapy in cystic fibrosis. Chest 1991;99(5):1088-92. Chest1991;99(5):1061. [CFGD REGISTER: IB61b] ">Eggleston 1991</a>). </p> <p> </p> <p><i>Long‐term trial</i> </p> <p>Between‐group comparisons showed there to be no statistically significant difference between albuterol and placebo (<a href="./references#CD013666-bbs2-0005" title="KonigP , PoehlerJ , BarberoGJ . A placebo-controlled, double-blind trial of the long-term effects of albuterol administration in patients with cystic fibrosis. Pediatric Pulmonology1998;25(1):32-6. [CFGD REGISTER: IB74b] KonigP , PoehlerJ , BarberoGJ . Long-term effects of albuterol (A) in cystic fibrosis (CF) - A controlled trial. Pediatric Pulmonology1996;Suppl 13:302. [CFGD REGISTER: IB74a] ">Konig 1996</a>). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>67<br/>(4) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low<sup>a,b</sup> </b> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We were not able to enter any of the data into our analyses due to the cross‐over design and few data in the original papers. </p> <p> </p> <p>The <a href="./references#CD013666-bbs2-0002" title="DuncanFR , PenkethAR , HodsonME , BattenJC . The use of bronchodilators as an adjunct to physiotherapy, in adults with cystic fibrosis. In: 11th European Cystic Fibrosis Conference, 1982; Brussels. 1982:48. [CFGD REGISTER: IB70] ">Duncan 1982</a> trial was presented only as an abstract; we have not found a full paper. </p> <p>Four further trials reported FEV<sub>1</sub> (L); all reported an improvement in FEV<sub>1</sub> compared to placebo, but all were small cross‐over trials with limited data available. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life</b> </p> <p> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>This outcome was not reported.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of exacerbations</b> <b>(as reported by number of hospitalisations and number of courses and days on antibiotics)</b> </p> <p> </p> <p>Follow‐up: 6 months</p> <p> </p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>There were no statistically significant differences between albuterol and placebo with respect to the number of hospitalisations, although there was a trend in favour of albuterol (1 day/participant on albuterol versus 2.6 days/participant on placebo). </p> <p>There were no differences in the number of courses or days of antibiotics between the albuterol and placebo group (<a href="./references#CD013666-bbs2-0005" title="KonigP , PoehlerJ , BarberoGJ . A placebo-controlled, double-blind trial of the long-term effects of albuterol administration in patients with cystic fibrosis. Pediatric Pulmonology1998;25(1):32-6. [CFGD REGISTER: IB74b] KonigP , PoehlerJ , BarberoGJ . Long-term effects of albuterol (A) in cystic fibrosis (CF) - A controlled trial. Pediatric Pulmonology1996;Suppl 13:302. [CFGD REGISTER: IB74a] ">Konig 1996</a>). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21<br/>(1) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Very low<sup>c,d</sup> </b> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Only 1 trial looked at the effects of inhaled beta‐2 agonists on a longer‐term basis and was therefore able to capture information on exacerbations. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participant‐reported symptom score: cough, wheeze and exercise tolerance</b> </p> <p> </p> <p>Follow‐up: 2 weeks</p> <p> </p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>Symptom scores were low on average and did not change with treatment. Scores did not improve during the albuterol treatment periods in either methacholine challenge responders or non‐responders. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22<br/>(1) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Very</b> <b>low<sup>d,e</sup> </b> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events</b> </p> <p> </p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>Very few adverse effects were reported and there was little difference between the active treatment and placebo arms. In 1 trial, 2 participants reported mild tremors when taking albuterol and 2 participants reported fatigue, difficulty concentrating or nervousness whilst taking albuterol; but 1 of these participants reported the same symptoms when taking the placebo (<a href="./references#CD013666-bbs2-0003" title="EgglestonPA , RosensteinBJ , StackhouseCM , MellitsED , BaumgardnerRA . A controlled trial of long-term bronchodilator therapy in cystic fibrosis. Chest1991;99(5):1088-92. [CFGD REGISTER: IB61a] OrensteinD . Long-term inhaled bronchodilator therapy in cystic fibrosis. Comment on Eggleston PA, Rosenstein BJ, Stackhouse CM, Mellits ED, Baumgardner RA. A controlled trial of long-term bronchodilator therapy in cystic fibrosis. Chest 1991;99(5):1088-92. Chest1991;99(5):1061. [CFGD REGISTER: IB61b] ">Eggleston 1991</a>). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>47<br/>(3) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low<sup>a,b</sup> </b> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The original papers reported all adverse effects narratively and there were no data to extract. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Change from baseline in FVC (% predicted)</b> </p> <p> </p> <p>Follow‐up: single dose, 2 weeks, 6 months</p> <p> </p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p><i>Single‐dose trials</i> </p> <p>Two out of three trials reported an improvement in FVC after albuterol (or salbutamol), with the third reporting no difference. </p> <p> </p> <p><i>Short‐term trial</i> </p> <p>No difference in FVC was reported between treatment groups (<a href="./references#CD013666-bbs2-0003" title="EgglestonPA , RosensteinBJ , StackhouseCM , MellitsED , BaumgardnerRA . A controlled trial of long-term bronchodilator therapy in cystic fibrosis. Chest1991;99(5):1088-92. [CFGD REGISTER: IB61a] OrensteinD . Long-term inhaled bronchodilator therapy in cystic fibrosis. Comment on Eggleston PA, Rosenstein BJ, Stackhouse CM, Mellits ED, Baumgardner RA. A controlled trial of long-term bronchodilator therapy in cystic fibrosis. Chest 1991;99(5):1088-92. Chest1991;99(5):1061. [CFGD REGISTER: IB61b] ">Eggleston 1991</a>). </p> <p> </p> <p><i>Long‐term trial</i> </p> <p>There was no difference in FVC between groups (<a href="./references#CD013666-bbs2-0005" title="KonigP , PoehlerJ , BarberoGJ . A placebo-controlled, double-blind trial of the long-term effects of albuterol administration in patients with cystic fibrosis. Pediatric Pulmonology1998;25(1):32-6. [CFGD REGISTER: IB74b] KonigP , PoehlerJ , BarberoGJ . Long-term effects of albuterol (A) in cystic fibrosis (CF) - A controlled trial. Pediatric Pulmonology1996;Suppl 13:302. [CFGD REGISTER: IB74a] ">Konig 1996</a>). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100<br/>(5) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low<sup>a,b</sup> </b> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We were not able to enter any of the data into our analyses due to the cross‐over design and there being little data in the original papers. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Sputum volume (mL)</b> </p> <p> </p> <p>Follow‐up: single dose</p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>One trial reported little change in sputum weight on either salbutamol or placebo.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16<br/>(1) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low<sup>b,f</sup> </b> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across trials) is provided in footnotes. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>FEV<sub>1</sub> </b> : forced expiratory volume in 1 second; <b>FVC</b>: forced vital capacity. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence</p> <p><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect. </p> <p><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different. </p> <p><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect. </p> <p><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded twice due to risk of bias. All trials had a cross‐over design and reported limited data. Some trials reported within‐group differences as evidence of an effect.<br/><sup>b</sup>Downgraded once due to imprecision caused by very small numbers of participants.<br/><sup>c</sup>Downgraded once due to risk of bias from the trial design. This is a cross‐over trial and although there was a washout period between treatments, the progressive nature of CF may mean there were inherent differences between groups if the active treatment was given in the first phase rather than the second. There is also an issue around risk of bias due to incomplete outcome data as more than 15% of participants dropped out of the trial.<br/><sup>d</sup>Downgraded twice due to very small participant numbers causing imprecision.<br/><sup>e</sup>Downgraded once due to risk of bias from the trial design as more methacholine responders than non‐responders were included in the trial, which would introduce a bias in favour of active treatment.<br/><sup>f</sup>Downgraded twice due to risk of bias in this single trial. There was an unclear or a high risk of bias across all domains and very little data to include. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD013666-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Short‐acting inhaled muscarinic antagonists compared with placebo for cystic fibrosis</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Short‐acting inhaled muscarinic antagonists compared with placebo for cystic fibrosis</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> children and adults with cystic fibrosis </p> <p><b>Settings:</b> outpatient </p> <p><b>Intervention:</b> inhaled muscarinic antagonist (ipratropium bromide) </p> <p><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>No of Participants<br/>(trials)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Inhaled muscarinic antagonist</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Change from baseline in FEV<sub>1</sub> (% predicted)</b> </p> <p> </p> <p>Follow‐up: single dose (120 min)</p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>Mean values after inhalation of ipratropium or placebo were not significantly different</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11<br/>(1) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low<sup>a,b</sup> </b> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We were not able to enter any of the data into our analyses due to the cross‐over design and there being little data in the original paper (<a href="./references#CD013666-bbs2-0010" title="WiebickeW , PoynterA , MontgomeryM , PagtakhanR . The effect of ipratropium bromide on lung function in patients with cystic fibrosis. Pneumologie1990;44 Suppl 1(1):277-8. [CFGD REGISTER: IB59] ">Wiebicke 1990</a>). </p> <p> </p> <p>Four trials reported FEV<sub>1</sub> (L) and all found ipratropium to improve FEV<sub>1</sub>; however, there were very few data that we could analyse and the trial reported within‐group differences. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life</b> </p> <p> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>This outcome was not reported.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of exacerbations</b> </p> <p> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>This outcome was not reported.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participant‐reported symptom score</b> </p> <p> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>This outcome was not reported.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events</b> </p> <p> </p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>The only reported adverse effect of treatment was mild and resolved quickly (oral dryness). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27<br/>(2) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low<sup>a,b</sup> </b> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No data were available for analysis and results have been taken directly from the original papers (<a href="./references#CD013666-bbs2-0009" title="WeintraubSJ , EschenbacherWL . The inhaled bronchodilators ipratropium bromide and metaproterenol in adults with CF. Chest1989;95(4):861-4. [CFGD REGISTER: IB58] ">Weintraub 1989</a>; <a href="./references#CD013666-bbs2-0011" title="ZiebachR , Pietsch-BreitfeldB , BichlerM , BuschA , RiethmullerJ , SternM . Bronchodilatory effects of salbutamol, ipratropium bromide, and their combination: double-blind, placebo-controlled crossover study in cystic fibrosis. Pediatric Pulmonology2001;31(6):431-5. [CFGD REGISTER: IB82] ">Ziebach 2001</a>). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Change from baseline in FVC (% predicted)</b> </p> <p> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>This outcome was not reported.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>One trial reported FVC (L) and found no change after ipratropium compared to placebo (<a href="./references#CD013666-bbs2-0011" title="ZiebachR , Pietsch-BreitfeldB , BichlerM , BuschA , RiethmullerJ , SternM . Bronchodilatory effects of salbutamol, ipratropium bromide, and their combination: double-blind, placebo-controlled crossover study in cystic fibrosis. Pediatric Pulmonology2001;31(6):431-5. [CFGD REGISTER: IB82] ">Ziebach 2001</a>). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Sputum volume (mL)</b> </p> <p> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>This outcome was not reported.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across trials) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>FEV<sub>1</sub> </b> : forced expiratory volume in 1 second; <b>FVC</b>: forced vital capacity. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence</p> <p><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect. </p> <p><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different. </p> <p><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect. </p> <p><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded due to imprecision resulting from very small participant numbers and a single trial reporting this outcome.<br/><sup>b</sup>Downgraded twice due to risk of bias within the cross‐over trial design and an unclear risk of bias across 5 of the 7 domains. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD013666-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Short‐acting inhaled beta‐2 agonists compared with short‐acting inhaled muscarinic antagonists for cystic fibrosis</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Short‐acting inhaled beta‐2 agonists compared with short‐acting inhaled muscarinic antagonists for cystic fibrosis</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> children and adults with cystic fibrosis </p> <p><b>Settings:</b> outpatients </p> <p><b>Intervention:</b> inhaled muscarinic antagonist </p> <p><b>Comparison:</b> inhaled beta‐2 agonist </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>No of Participants<br/>(trials)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Beta‐2 agonist</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Muscarinic antagonist</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Change from baseline in FEV<sub>1</sub> (% predicted)</b> </p> <p> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>This outcome was not reported ‐ see comments.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None of the trials for this outcome reported FEV<sub>1</sub> % predicted, but 3 reported FEV<sub>1</sub> (L). 2 trials stated that FEV<sub>1</sub> improved after both treatments (<a href="./references#CD013666-bbs2-0006" title="Pitcher-WilmottRW , MatthewDJ , IngramD , TysonSL . Improvement in lung function after nebulised salbutamol and ipratropium bromide in children with cystic fibrosis. In: 11th European Cystic Fibrosis Conference, 1982. Brussels. 1982:251. [CFGD REGISTER: IB77] ">Pitcher‐Wilmott 1982</a>; <a href="./references#CD013666-bbs2-0007" title="SanchezI , HolbrowJ , ChernickV . Acute bronchodilator response to a combination of beta-adrenergic and anticholinergic agents in patients with cystic fibrosis. Journal of Pediatrics1992;120(3):486-8. [CFGD REGISTER: IB63] ">Sanchez 1992</a>), whilst 1 trial stated that ipratropium tended to be less effective than salbutamol (<a href="./references#CD013666-bbs2-0011" title="ZiebachR , Pietsch-BreitfeldB , BichlerM , BuschA , RiethmullerJ , SternM . Bronchodilatory effects of salbutamol, ipratropium bromide, and their combination: double-blind, placebo-controlled crossover study in cystic fibrosis. Pediatric Pulmonology2001;31(6):431-5. [CFGD REGISTER: IB82] ">Ziebach 2001</a>). None of these trials provided data for analysis. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life</b> </p> <p> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>This outcome was not reported.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of exacerbations</b> </p> <p> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>This outcome was not reported.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participant‐reported symptom score</b> </p> <p> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>This outcome was not reported.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events</b> </p> <p> </p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>No adverse effects were experienced by participants on either treatment (<a href="./references#CD013666-bbs2-0011" title="ZiebachR , Pietsch-BreitfeldB , BichlerM , BuschA , RiethmullerJ , SternM . Bronchodilatory effects of salbutamol, ipratropium bromide, and their combination: double-blind, placebo-controlled crossover study in cystic fibrosis. Pediatric Pulmonology2001;31(6):431-5. [CFGD REGISTER: IB82] ">Ziebach 2001</a>). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17<br/>(1) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very</b> <b>low<sup>a,b</sup> </b> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Change from baseline in FVC (% predicted)</b> </p> <p> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>This outcome was not reported.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Sputum volume (mL)</b> </p> <p> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>This outcome was not reported.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across trials) is provided in footnotes. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>FEV<sub>1</sub> </b> : forced expiratory volume in 1 second; <b>FVC</b>: forced vital capacity. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence</p> <p><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect. </p> <p><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different. </p> <p><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect. </p> <p><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded twice due to imprecision resulting from very small participant numbers and a single trial reporting this outcome.<br/><sup>b</sup>Downgraded once due to risk of bias within the cross‐over trial design. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD013666-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD013666-sec-0009"></div> <section id="CD013666-sec-0010"> <h3 class="title" id="CD013666-sec-0010">Description of the condition</h3> <p>Cystic fibrosis (CF) is the most common autosomal recessive condition in people of North European descent (<a href="./references#CD013666-bbs2-0045" title="FarrellP , FérecC , MacekM , FrischerT , RennerS , RissK , et al. Estimating the age of p.(Phe508del) with family studies of geographically distinct European populations and the early spread of cystic fibrosis. European Journal of Human Genetics2018;26(12):1832-9. [DOI: 10.1038/s41431-018-0234-z]">Farrell 2018</a>). More than 10,000 people in the UK have CF (<a href="./references#CD013666-bbs2-0067" title="UK CF Trust. UK Cystic Fibrosis Registry Annual Data Report 2017. www.cysticfibrosis.org.uk/the-work-we-do/uk-cf-registry/reporting-and-resources (accessed 17 June 2019).">UK CF Trust 2018</a>), and worldwide it affects more than 70,000 people (<a href="./references#CD013666-bbs2-0038" title="Cystic Fibrosis Foundation. About cystic fibrosis. www.cff.org (accessed 17 June 2019).">CF Foundation 2019</a>). Respiratory disease remains the major cause of morbidity and mortality in CF, and many different therapies are used in the management of respiratory problems, including: oral, intravenous and nebulised antibiotics; physiotherapy; dornase alfa; mucolytic therapy; inhaled corticosteroids; cystic fibrosis transmembrane conductance regulator (CFTR) potentiators; and bronchodilators. </p> <p>The symptoms of airway obstruction in CF are similar to those of other obstructive airways diseases such as asthma, although the underlying mechanisms are different. In CF, the lack of CFTRs in smooth muscle cells may lead to a more persistent contracted state so that there is less reversibility, and over time, this can lead to more severe bronchiectasis (<a href="./references#CD013666-bbs2-0053" title="LevineH , Cohen-CymberknohM , KleinN , HoshenM , MussaffiH , StaflerP , et al. Reversible airway obstruction in cystic fibrosis: common, but not associated with characteristics of asthma. Journal of Cystic Fibrosis2016;15(5):652-9.">Levine 2016</a>). Inhaled bronchodilators improve individuals' symptoms, and in the short term at least, partially reverse airflow obstruction in asthma (<a href="./references#CD013666-bbs2-0035" title="British Thoracic Society, Scottish Intercollegiate Guidelines Network. British Guideline on the Management of Asthma 2019. www.sign.ac.uk/sign-158-british-guideline-on-the-management-of-asthma.html (accessed prior to 20 February 2020). [DOI: 10.1136/thx.2008.097741]">BTS 2019</a>). It is unclear to what extent this is also true for people with CF. However, a proportion of people with CF will have evidence of atopic asthma on lung function testing (CF asthma), particularly with sensitisation to aspergillus and other moulds. The North American Epidemiologic Study of Cystic Fibrosis suggested that CF asthma is present when there are "episodes of acute airway obstruction reversed by bronchodilators, a strong family history of asthma or evidence of atopy (or both), or laboratory evidence of allergy such as eosinophilia or elevated IgE"; they reported a prevalence of 17.0% to 31.5% (<a href="./references#CD013666-bbs2-0030" title='Balffour-LynnIM , ElbournJS . "CF Asthma": what is it and what do we do about it?Thorax2002;57(8):742-8.'>Balfour‐Lynn 2002</a>). Although CF and atopy, with or without asthma, may coexist, it is not known if these individuals will derive a greater benefit from the use of inhaled bronchodilators. </p> <p>One of the predominant treatments for CF is airway clearance, either via manual physiotherapy, or airway clearance devices. Bronchodilators are often used before airway clearance to open the airways and improve the removal of secretions (<a href="./references#CD013666-bbs2-0069" title="UK CF Trust. Cystic fibrosis treatments and medications. www.cysticfibrosis.org.uk/what-is-cystic-fibrosis/cystic-fibrosis-care/treatments-and-medication (accessed 30 May 2020).">UK CF Trust 2020</a>). Current guidelines for inhaled therapies recommend the use of bronchodilators to open airways before physiotherapy as an aid to clearing secretions (<a href="./references#CD013666-bbs2-0039" title="Cystic Fibrosis Medicine Team Leeds Regional Adult and Paediatric Cystic Fibrosis Units. Bronchodilators. www.cfmedicine.com/htmldocs/CFText/bronchodilators.htm (accessed 27 May 2020).">CF Medicine 2020</a>; <a href="./references#CD013666-bbs2-0066" title="Cystic Fibrosis Centre at Stanford. Inhaled medications and nebulisers. www.med.stanford.edu/cfcenter/education/english/Meds-Nebs.html (accessed 27 May 2020).">Stanford Medicine 2020</a>). </p> <p>Please see glossary for scientific terms (<a href="./appendices#CD013666-sec-0138">Appendix 1</a>). </p> </section> <section id="CD013666-sec-0011"> <h3 class="title" id="CD013666-sec-0011">Description of the intervention</h3> <p>Short‐acting inhaled bronchodilators are typically used for acute relief of symptoms or before airway clearance therapy. There are two distinct classes of short‐acting inhaled bronchodilators: beta‐2 agonists (e.g. salbutamol or albuterol, terbutaline, fenoterol) and muscarinic antagonists (e.g. ipratropium bromide). </p> <p>It is possible to deliver inhaled bronchodilators into the lungs via two methods. Firstly, using a dry powder device or a metered dose inhaler (MDI), with or without the use of a spacer to increase deposition in the lungs; and secondly, as an aerosol via a nebuliser which usually requires a larger starting dose but delivers an equivocal dose to the lungs. This second method has the added advantage of being able to supply oxygen, if needed, at the same time. </p> <p>For the purpose of this review 'inhaled' shall implies any route that delivers the bronchodilator to the lungs via inhalation, i.e. via inhaler or nebuliser. </p> <p>Recurrent wheeze, hyperinflation and other features of airway obstruction are common in both children and adults with CF, and bronchodilators are among the most widely prescribed medications for these people (<a href="./references#CD013666-bbs2-0032" title="BarryPJ , FlumePA . Bronchodilators in cystic fibrosis: a critical analysis. Expert Review of Respiratory Medicine2017;11(1):13-20.">Barry 2017</a>). In a large survey of North American CF centres, the use of inhaled bronchodilators increased from 72% in 1995 to 84% in 2005 (<a href="./references#CD013666-bbs2-0034" title="BrandP . Bronchodilators in cystic fibrosis. Journal of the Royal Society of Medicine2000;93(Suppl 38):37-9.">Brand 2000</a>; <a href="./references#CD013666-bbs2-0052" title="KonstanMW , VanDevanterDR , RasouliyanL , PastaDJ , YeginA , MorganWJ , et al. Trends in the use of routine therapies in cystic fibrosis: 1995-2005. Pediatric Pulmonology2010;45(12):1167-72. [DOI: 10.1002/ppul.21315]">Konstan 2010</a>). A more recent study looking at reversible airway disease in CF reported that 63% (112 out of 177) of participants asked were using bronchodilator therapy (<a href="./references#CD013666-bbs2-0053" title="LevineH , Cohen-CymberknohM , KleinN , HoshenM , MussaffiH , StaflerP , et al. Reversible airway obstruction in cystic fibrosis: common, but not associated with characteristics of asthma. Journal of Cystic Fibrosis2016;15(5):652-9.">Levine 2016</a>). In the UK, the CF Trust collects data via the CF Registry which reports that in 2019, 5933 of 10,070 (58.9%) registered people with CF were using a type of inhaled bronchodilator therapy. The majority of registered people with CF are prescribed a short‐acting beta‐2 agonist (5731 out of 10,070; 56.9%), with a much smaller number prescribed a muscarinic antagonist (293 out of 10,070; 2.9%) (<a href="./references#CD013666-bbs2-0068" title="UK CF Trust. Additional data from UK CF Registry 2019. Email to: S Smith 15 September 2020.">UK CF Trust 2019 [pers comm]</a>). Several different mechanisms can contribute to wheeze and reversible airways obstruction in CF, including airways mucosal oedema caused by infections and inflammation; stimulation of autonomic nerve fibres as the result of epithelial damage; contraction of airway smooth muscle, caused by mediators of airway infection; inflammation and autonomic nerve stimulation; bronchiectasis; and airway collapse (<a href="./references#CD013666-bbs2-0041" title="CroppGJ . Effectiveness of bronchodilators in cystic fibrosis. American Journal of Medicine1996;100(1A):19-29S.">Cropp 1996</a>). </p> </section> <section id="CD013666-sec-0012"> <h3 class="title" id="CD013666-sec-0012">How the intervention might work</h3> <p>Both beta‐2 agonists and muscarinic antagonists work by causing the relaxation of the bronchial wall muscle leading to the opening of the airways (<a href="./references#CD013666-bbs2-0034" title="BrandP . Bronchodilators in cystic fibrosis. Journal of the Royal Society of Medicine2000;93(Suppl 38):37-9.">Brand 2000</a>). There is some evidence that beta‐2 agonists improve mucociliary clearance, although the effect seen in CF is not as great as other respiratory conditions or healthy lungs (<a href="./references#CD013666-bbs2-0033" title="BennettWD . Effect of beta-adrenergic agonists on mucociliary clearance. Journal of Allergy &amp; Clinical Immunology2002;110(6 Suppl):S291-7.">Bennett 2002</a>). Short‐acting bronchodilators are useful for relieving exacerbations of airways obstruction, and before therapeutic interventions, such as mucolytic therapy and physiotherapy, to aid airway clearance. </p> <section id="CD013666-sec-0013"> <h4 class="title">Short‐acting inhaled beta‐2 agonists</h4> <p>Beta‐2 agonist bronchodilators work by binding to beta‐2 receptors found on smooth muscle. This activates a cascade of intracellular messenger systems through the cyclic adenosine monophosphate mechanism, which results in airway relaxation via phosphorylation of muscle regulatory proteins and a change in cellular calcium concentrations (<a href="./references#CD013666-bbs2-0050" title="JohnsonM . Beta2-adrenoceptors: mechanisms of action of beta2-agonists. Paediatric Respiratory Reviews2001;2(1):57-62.">Johnson 2001</a>). This action occurs within 15 minutes in short‐acting beta‐2 agonists and usually lasts about 4 hours. </p> </section> <section id="CD013666-sec-0014"> <h4 class="title">Short‐acting inhaled muscarinic antagonists</h4> <p>Muscarinic antagonists increase airflow by blocking cholinergic tone at airway smooth muscle and blocking acetylcholine binding to M3 muscarinic receptors. Acetylcholine induces smooth muscle contraction and mucus secretion, the effect of muscarinic antagonists is therefore to prevent this from happening. Short‐acting muscarinic antagonists take slightly longer to reach maximum effect (30 to 45 minutes after administration) and the effect lasts for 4 to 6 hours (<a href="./references#CD013666-bbs2-0036" title="BuelsKS , FryerAD . Muscarinic receptor antagonists: effects on pulmonary function. Handbook of Experimental Pharmacology2012;208:317-41. [DOI: 10.1007/978-3-642-23274-9_14]">Buels 2012</a>). </p> <p>All bronchodilators have the potential to worsen rather than improve airway function in CF compared to other respiratory conditions such as asthma. This 'paradoxical bronchoconstriction' is the result of the abnormal airway compliance associated with the bronchiectasis in severe lung disease in CF (<a href="./references#CD013666-bbs2-0034" title="BrandP . Bronchodilators in cystic fibrosis. Journal of the Royal Society of Medicine2000;93(Suppl 38):37-9.">Brand 2000</a>). </p> </section> </section> <section id="CD013666-sec-0015"> <h3 class="title" id="CD013666-sec-0015">Why it is important to do this review</h3> <p>This Cochrane Review on short‐acting inhaled bronchodilators for CF and a parallel Cochrane Review on long‐acting inhaled bronchodilators for CF (<a href="./references#CD013666-bbs2-0065" title="SmithS , EdwardsCT . Long-acting inhaled bronchodilators for cystic fibrosis. Cochrane Database of Systematic Reviews2017, Issue 12. Art. No: CD012102. [DOI: 10.1002/14651858.CD012102.pub2]">Smith 2017</a>) have replaced a broader Cochrane Review that included both short‐acting and long‐acting inhaled bronchodilators for CF (<a href="./references#CD013666-bbs2-0071" title="HalfhideC , EvansHJ , CourielJ . Inhaled bronchodilators for cystic fibrosis. Cochrane Database of Systematic Reviews2016, Issue 2. Art. No: CD003428. [DOI: 10.1002/14651858.CD003428.pub3]">Halfhide 2016</a>). This decision was made in order to improve accessibility of information. </p> <p>Despite the wide‐scale and often long‐term use of bronchodilators in CF, there is little objective evidence of their efficacy (<a href="./references#CD013666-bbs2-0055" title="Mogayzel PJ Jr, NaureckasET , RobinsonKA , MuellerG , HadjiliadisD , HoagJB , et al. Cystic fibrosis pulmonary guidelines. Chronic medications for maintenance of lung health. American Journal of Respiratory &amp; Critical Care Medicine2013;187(7):680-9.">Mogayzel 2013</a>). In addition to the efficacy of short‐acting inhaled bronchodilators in terms of lung function, it is important to place this in the context of patient‐reported symptom control and adverse effects related to the treatment. Simplifying treatment regimens to reduce treatment burden was recently voted as the top priority for research in a James Lind Alliance Priority Setting Partnership (<a href="./references#CD013666-bbs2-0061" title="RowbothamNJ , SmithS , LeightonPA , RaynerOC , GathercoleK , ElliottZC , et al. The top 10 research priorities in cystic fibrosis developed by a partnership between people with CF and healthcare providers. Thorax2018;73(4):388-90.">Rowbotham 2018</a>). It is therefore important to review the evidence for short‐acting inhaled bronchodilators to avoid unnecessary treatments in an already burdensome regimen. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD013666-sec-0016" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD013666-sec-0016"></div> <p>To evaluate short‐acting inhaled bronchodilators in children and adults with CF in terms of clinical outcomes and safety. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD013666-sec-0017" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD013666-sec-0017"></div> <section id="CD013666-sec-0018"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD013666-sec-0019"> <h4 class="title">Types of studies</h4> <p>Randomised controlled trials (RCTs) or quasi‐RCTs. Two review authors assessed quasi‐RCTs and only included them if the allocation method was described and participants in the intervention groups were judged to be similar based on demographic characteristics at baseline. </p> <p>All included trials are cross‐over trials and we have commented on the appropriateness of the analysis. We have only included data from these cross‐over trials where the investigators appropriately analysed their cross‐over data, or if first treatment phase data were available (<a href="./references#CD013666-bbs2-0044" title="ElbourneDR , AltmanDG , HigginsJP , CurtinF , WorthingtonHV , VailA . Meta-analysis involving cross-over trials: methodological issues. International Journal of Epidemiology2002;31(1):140-9.">Elbourne 2002</a>). As short‐acting inhaled bronchodilators have an action lasting up to 8 hours, we only included cross‐over trials which had a washout period of 8 hours or more between treatments. </p> </section> <section id="CD013666-sec-0020"> <h4 class="title">Types of participants</h4> <p>Children and adults with CF diagnosed by sweat test or genetic testing, with all stages and severity of lung disease, and with or without concomitant asthma. </p> </section> <section id="CD013666-sec-0021"> <h4 class="title">Types of interventions</h4> <p>Short‐acting inhaled bronchodilators, delivered by any device, at any dose, at any frequency and for any duration compared to either placebo or another inhaled short‐acting bronchodilator in people with CF. This includes trials which looked at intermittent use and regular use. </p> <p>The bronchodilators include:</p> <p> <ol id="CD013666-list-0001"> <li> <p>short‐acting beta‐2 agonists (salbutamol (also known as albuterol), terbutaline and fenoterol); and </p> </li> <li> <p>short‐acting muscarinic antagonists (ipratropium bromide).</p> </li> </ol> </p> <p>We included single‐use trials (e.g. pre‐airway clearance therapy) and trials up to 7 days, short‐term trials up to 28 days, and longer‐term trials lasting for more than 28 days. </p> <p>We did not include combined inhalers (with inhaled steroids or another bronchodilator) or long‐acting bronchodilators (e.g. tiotropium, salmeterol). </p> <p>For this review 'inhaled' includes the use of pressurised MDIs, with or without a spacer, dry powder devices and nebulisers. </p> </section> <section id="CD013666-sec-0022"> <h4 class="title">Types of outcome measures</h4> <p>We planned to assess the following outcome measures.</p> <section id="CD013666-sec-0023"> <h5 class="title">Primary outcomes</h5> <p> <ol id="CD013666-list-0002"> <li> <p>Change from baseline in forced expiratory volume in 1 second (FEV<sub>1</sub>) (L and per cent (%) predicted)* </p> </li> <li> <p>Quality of life (as measured by a validated tool such as Cystic Fibrosis Quality of Life (CFQoL) (<a href="./references#CD013666-bbs2-0046" title="GeeL , AbbottJ , ConwaySP , EtheringtonC , WebbAK . Development of a disease specific health related quality of life measure for adults and adolescents with cystic fibrosis. Thorax2000;55(11):946-54.">Gee 2000</a>) or Cystic Fibrosis Questionnaire‐Revised (CFQ‐R) (<a href="./references#CD013666-bbs2-0059" title="QuittnerAL , ModiAC , WainwrightC , OttoK , KiriharaJ , MontgomeryAB . Determination of the minimal clinically important difference scores for the Cystic Fibrosis Questionnaire-Revised respiratory symptom scale in two populations of patients with cystic fibrosis and chronic Pseudomonas aeruginosa airway infection. Chest2009;135(6):1610-8.">Quittner 2009</a>)) </p> </li> <li> <p>Number of exacerbations of respiratory symptoms, as defined by:</p> <ol id="CD013666-list-0003"> <li> <p>individual clinicians or the use of a scoring system, such as the Respiratory and Systemic Symptoms Questionnaire (RSSQ) (<a href="./references#CD013666-bbs2-0054" title="LympJ , HilliardK , RosenfeldM , KokerP , HamiltonA , KonstanM . Pulmonary exacerbations in a phase 2 clinical trial of Biil284 Bs in Cf: development and implementation of a Respiratory and Systemic Symptoms Questionnaire (RSSQ). Pediatric Pulmonology2009;44(Suppl 32):288. [ABSTRACT NO.: 221]">Lymp 2009</a>) (or both) </p> </li> <li> <p>need for hospitalisation or antibiotics (or both)</p> </li> </ol> </li> </ol> </p> <p>* if FEV<sub>1</sub> is reported using any other unit of measurement than % predicted or L, we will consider how to report it on a case‐by‐case basis. </p> </section> <section id="CD013666-sec-0024"> <h5 class="title">Secondary outcomes</h5> <p> <ol id="CD013666-list-0004"> <li> <p>Participant‐reported outcomes, using standardised and validated symptom scores (e.g. RSSQ (<a href="./references#CD013666-bbs2-0054" title="LympJ , HilliardK , RosenfeldM , KokerP , HamiltonA , KonstanM . Pulmonary exacerbations in a phase 2 clinical trial of Biil284 Bs in Cf: development and implementation of a Respiratory and Systemic Symptoms Questionnaire (RSSQ). Pediatric Pulmonology2009;44(Suppl 32):288. [ABSTRACT NO.: 221]">Lymp 2009</a>), Respiratory Symptom Score (RSS) (<a href="./references#CD013666-bbs2-0047" title="GossCH , QuittnerAL . Patient-reported outcomes in cystic fibrosis. Proceedings of the American Thoracic Society2007;4(4):378-86.">Goss 2007</a>), CFQ‐R (respiratory symptoms) (<a href="./references#CD013666-bbs2-0059" title="QuittnerAL , ModiAC , WainwrightC , OttoK , KiriharaJ , MontgomeryAB . Determination of the minimal clinically important difference scores for the Cystic Fibrosis Questionnaire-Revised respiratory symptom scale in two populations of patients with cystic fibrosis and chronic Pseudomonas aeruginosa airway infection. Chest2009;135(6):1610-8.">Quittner 2009</a>)) </p> </li> <li> <p>Adverse events</p> <ol id="CD013666-list-0005"> <li> <p>frequency of treatment‐related adverse effects, particularly those that are associated with bronchodilators (for beta‐2 agonists: dizziness, headache, arrhythmias and palpitations, nausea and tremor; for muscarinic antagonists: cough, dizziness, dry mouth, headache, nausea) </p> </li> <li> <p>severity of adverse effects where reported (mild: resulting in no change to treatment, e.g. cough; moderate: resulting in change in treatment, e.g. arrhythmias; severe: needs hospital admission or is life‐threatening, e.g. anaphylaxis) </p> </li> </ol> </li> <li> <p>Change from baseline in any other relevant measurements of lung function</p> <ol id="CD013666-list-0006"> <li> <p>forced vital capacity (FVC) (L or % predicted)</p> </li> <li> <p>forced expiratory flow between 25% and 75% (FEF<sub>25-75</sub>) </p> </li> <li> <p>lung clearance index</p> </li> <li> <p>measures of bronchial hyper‐responsiveness and bronchodilator responsiveness, e.g. reversibility, methacholine challenge or equivalent (histamine or mannitol), exercise testing </p> </li> </ol> </li> <li> <p>Airway clearance as measured by:</p> <ol id="CD013666-list-0007"> <li> <p>sputum volume (mL)</p> </li> <li> <p>weight (dry or wet) (g)</p> </li> </ol> </li> </ol> </p> </section> </section> </section> <section id="CD013666-sec-0025"> <h3 class="title">Search methods for identification of studies</h3> <p>We searched for all relevant published and unpublished trials without restrictions on language, year or publication status. </p> <section id="CD013666-sec-0026"> <h4 class="title">Electronic searches</h4> <p>We identified relevant trials from the Group's Cystic Fibrosis Trials Register using the terms: bronchodilator AND inhaled. </p> <p>The Cystic Fibrosis Trials Register is compiled from electronic searches of the Cochrane Central Register of Controlled Trials (CENTRAL) (updated each new issue of the Cochrane Library), weekly searches of MEDLINE, a search of Embase to 1995 and the prospective handsearching of two journals ‐ <i>Pediatric Pulmonology</i> and the <i>Journal of Cystic Fibrosis</i>. Unpublished work is identified by searching the abstract books of three major cystic fibrosis conferences: the International Cystic Fibrosis Conference, the European Cystic Fibrosis Conference, and the North American Cystic Fibrosis Conference. For full details of all searching activities for the register, please see the relevant section of the Cochrane Cystic Fibrosis and Genetic Disorders Group's <a href="http://cfgd.cochrane.org/our-specialised-trials-registers" target="_blank">website</a>. </p> <p>Date of last search: 28 March 2022.</p> <p>We also searched the following trial registries and registers.</p> <p> <ol id="CD013666-list-0008"> <li> <p>US National Institutes of Health Ongoing Trials Register ClinicalTrials.gov (<a href="http://www.clinicaltrials.gov" target="_blank">www.clinicaltrials.gov</a>; searched 12 April 2022). </p> </li> <li> <p>Australian New Zealand Clinical Trials Registry (<a href="http://www.anzctr.org.au" target="_blank">www.anzctr.org.au</a>; searched 12 April 2022). </p> </li> <li> <p>World Health Organization International Clinical Trials Registry Platform (WHO ICTRP) (<a href="https://trialsearch.who.int/" target="_blank">trialsearch.who.int/</a>; searched 12 April 2022). </p> </li> </ol> </p> <p>For details of our trial registry search strategies, please see <a href="./appendices#CD013666-sec-0139">Appendix 2</a>.  </p> </section> <section id="CD013666-sec-0027"> <h4 class="title">Searching other resources</h4> <p>We checked the bibliographies of included trials and any relevant systematic reviews identified from the searches above for further references to relevant trials. </p> </section> </section> <section id="CD013666-sec-0028"> <h3 class="title" id="CD013666-sec-0028">Data collection and analysis</h3> <section id="CD013666-sec-0029"> <h4 class="title">Selection of studies</h4> <p>For the original review of both short‐acting and long‐acting inhaled bronchodilators (<a href="./references#CD013666-bbs2-0071" title="HalfhideC , EvansHJ , CourielJ . Inhaled bronchodilators for cystic fibrosis. Cochrane Database of Systematic Reviews2016, Issue 2. Art. No: CD003428. [DOI: 10.1002/14651858.CD003428.pub3]">Halfhide 2016</a>), three review authors (Drs Halfhide, Evans and Couriel) independently selected the references to be included in the review from those identified by the search. For this new review, we included any trials from the original review where they fitted the current inclusion criteria. </p> <p>Two review authors (SS, NR or CE) independently reviewed all articles on title and abstract and discarded any that clearly did not meet the inclusion criteria. We found the full text for each of the remaining references and two authors (SS, NR or CE) again filtered against the inclusion criteria. At this point, we added to the list of excluded trials any references that we discarded and gave reasons for this. We referred any disagreements between authors to a third review author (NR or CE depending on who did the original screening). We used Covidence for this process (<a href="./references#CD013666-bbs2-0040" title="Veritas Health InnovationCovidence. Melbourne, Australia: Veritas Health Innovation, accessed prior to 13 Januray 2020. Available at covidence.org.">Covidence 2019</a>). </p> </section> <section id="CD013666-sec-0030"> <h4 class="title">Data extraction and management</h4> <p>Two review authors (SS, NR or CE) independently extracted data from the identified trials using a specially designed data extraction form developed by the Cochrane Cystic Fibrosis and Genetic Disorders Review Group and adapted to this review. We set up a form in Covidence to allow independent data extraction by two review authors and the inbuilt comparison of responses (<a href="./references#CD013666-bbs2-0040" title="Veritas Health InnovationCovidence. Melbourne, Australia: Veritas Health Innovation, accessed prior to 13 Januray 2020. Available at covidence.org.">Covidence 2019</a>). </p> <p>We collected data on:</p> <p> <ol id="CD013666-list-0009"> <li> <p>participant characteristics;</p> </li> <li> <p>trial characteristics and trial design;</p> </li> <li> <p>intervention and comparator;</p> </li> <li> <p>outcome data ‐ we reported each outcome separately.</p> </li> </ol> </p> <p>We extracted data for all trials identified for the review, whether they were included in the original review or not. We attempted to come to an agreement by discussion where there were discrepancies and where the issue still could not be resolved, we brought in a third review author to arbitrate (NR or CE depending on who did the original extraction). </p> <p>We exported the extracted data from Covidence into the Review Manager 5.4 software for analysis (<a href="./references#CD013666-bbs2-0040" title="Veritas Health InnovationCovidence. Melbourne, Australia: Veritas Health Innovation, accessed prior to 13 Januray 2020. Available at covidence.org.">Covidence 2019</a>; <a href="./references#CD013666-bbs2-0060" title="Nordic Cochrane Centre, The Cochrane CollaborationReview Manager 5 (RevMan 5). Version 5.4. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2020.">Review Manager 2020</a>). We presented the data for beta‐2 agonists and muscarinic antagonists separately as the agents have different modes of action. Where possible we carried out the following comparisons. </p> <p> <ol id="CD013666-list-0010"> <li> <p>Short‐acting inhaled beta‐2 agonists versus placebo, usual treatment or another short‐acting inhaled beta‐2 agonist </p> </li> <li> <p>Short‐acting inhaled muscarinic antagonists versus placebo, usual treatment or another short‐acting inhaled muscarinic antagonist </p> </li> <li> <p>Short‐acting inhaled beta‐2 agonists versus short‐acting inhaled muscarinic antagonists</p> </li> </ol> </p> <p>We planned to present data at ≤ 7 days (including single‐dose trials), &gt; 7 days and ≤ 28 days, &gt; 28 days and ≤ 6 months, &gt; 6 months and ≤ 1 year and annually thereafter to distinguish between single‐use or short‐term trials and longer‐term trials. We have only been able to analyse data from single‐dose trials and present results as such. </p> </section> <section id="CD013666-sec-0031"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors (SS, NR or CE) assessed all included trials for risk of bias regardless of whether they were previously assessed for the original version of the review or not. </p> <p>We used the RoB 1 tool, as described in the <i>Cochrane Handbook for Systematic Reviews of Interventions,</i> to assess the risk of bias across the following six domains (<a href="./references#CD013666-bbs2-0048" title="HigginsJP , AltmanDG , SterneJA , editor(s). Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Churchill R, Chandler J, Cumpston MS, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.2.0 (updated June 2017), Cochrane, 2017. Available from www.training.cochrane.org/handbook.">Higgins 2017</a>). </p> <p> <ol id="CD013666-list-0011"> <li> <p>Sequence generation</p> </li> <li> <p>Allocation concealment</p> </li> <li> <p>Blinding (of participants, outcome assessors and trial personnel)</p> </li> <li> <p>Incomplete outcome data</p> </li> <li> <p>Selective reporting</p> </li> <li> <p>Other potential sources of bias</p> </li> </ol> </p> <p>We assessed each of the domains and ranked them as being at high, low or unclear risk of bias. We qualified our judgements in the risk of bias tables and have presented the information in a summary figure. </p> </section> <section id="CD013666-sec-0032"> <h4 class="title">Measures of treatment effect</h4> <p>We have only been able to analyse data from three of our included trials, and for the remaining trials we have reported results from the original trial papers. Where data were available, we have reported measures of treatment effect for each outcome and each type of short‐acting inhaled bronchodilator separately, and followed the guidelines in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD013666-bbs2-0043" title="DeeksJJ , HigginsJP , AltmanDG , editor(s). Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). The Cochrane Collaboration, 2021. Available from training.cochrane.org/handbook.">Deeks 2021</a>). </p> <p>For continuous data (FEV<sub>1</sub>, FVC, FEF<sub>25-75</sub>, lung clearance index, symptom scores, quality of life), we  recorded the mean change and standard deviation (SD) from baseline in each group. Where there was more than one trial, we calculated a pooled estimate of treatment effect using the mean difference (MD) and 95% confidence intervals (CIs). If there are more data available in future updates, where they have used different measurement scales or units of measurement (e.g. for symptom scores) we will use the standardised mean difference (SMD) to report the results. Where the trial authors only presented a baseline mean (SD) and a postintervention mean (SD) we were unable to calculate the SD of the change, and so we reported these results narratively. </p> <p>For our primary outcome, we looked for a change of &gt; 12% from baseline to show a meaningful effect (<a href="./references#CD013666-bbs2-0031" title="BarreiroTJ , PerilloI . An approach to interpreting spirometry. American Family Physician2004;69(5):1107-14.">Barreiro 2004</a>). </p> <p>There were no dichotomous data to enter into our analyses, but if there are data to present in future updates (adverse events, number of exacerbations), we will calculate a pooled estimate of the treatment effects for each outcome across trials using the risk ratio (RR) and 95% CIs. </p> </section> <section id="CD013666-sec-0033"> <h4 class="title">Unit of analysis issues</h4> <p>All of our included trials are cross‐over trials and we assessed each one to establish whether we could include any data in the analysis. Where we believe the trial authors have carried out an appropriate analysis for cross‐over trials, taking into account carry‐over effect and within‐person differences, we have included their results in our analyses (<a href="./references#CD013666-bbs2-0004" title="HordvikNL , SammutPH , JudyCG , StrizekSJ , ColomboJL . The effects of albuterol on the lung function of hospitalized patients with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine1996;154(1):156-60. [CFGD REGISTER: IB75] ">Hordvik 1996</a>; <a href="./references#CD013666-bbs2-0008" title="SerisierDJ , CaotesAD , BowlerSD . Inhaled salbutamol does not improve maximal exercise performance in cystic fibrosis . Respirology2006;11(Suppl 2):A58. [CFGD REGISTER: IB81c] SerisierDJ , CoatesAD , BowlerSD . Effect of albuterol on maximal exercise capacity in cystic fibrosis. Chest2007;131(4):1181-7. [CFGD REGISTER: IB81b] SerisierDJ , Rice-McDonaldG , BowlerSD , CoatesAC . ß-adrenergic agonists do not improve exercise capacity in cystic fibrosis. Pediatric Pulmonology2000;30 Suppl 20:305. [CFGD REGISTER: IB81a] ">Serisier 2000</a>; <a href="./references#CD013666-bbs2-0011" title="ZiebachR , Pietsch-BreitfeldB , BichlerM , BuschA , RiethmullerJ , SternM . Bronchodilatory effects of salbutamol, ipratropium bromide, and their combination: double-blind, placebo-controlled crossover study in cystic fibrosis. Pediatric Pulmonology2001;31(6):431-5. [CFGD REGISTER: IB82] ">Ziebach 2001</a>). Where investigators have not analysed the data appropriately, no first‐phase data were available to analyse, or it is unclear how the investigators have analysed data, we have reported results narratively. This method means, however, that the advantage of using participants as their own controls is lost (<a href="./references#CD013666-bbs2-0044" title="ElbourneDR , AltmanDG , HigginsJP , CurtinF , WorthingtonHV , VailA . Meta-analysis involving cross-over trials: methodological issues. International Journal of Epidemiology2002;31(1):140-9.">Elbourne 2002</a>).  </p> <p>Where any of the trials have multiple arms, we have separated out the different arms and reported in the appropriate comparison. For example, in a trial reporting a muscarinic antagonist versus beta‐2 agonist versus placebo, we have analysed each treatment arm separately against placebo, and where appropriate, included in a meta‐analysis. </p> </section> <section id="CD013666-sec-0034"> <h4 class="title">Dealing with missing data</h4> <p>The review authors attempted to contact the primary trial investigators for any missing data. We also assessed the use of intention‐to‐treat (ITT) analysis in the individual trials and the information given to explain the numbers of participants who dropped out of each arm of the trial. </p> </section> <section id="CD013666-sec-0035"> <h4 class="title">Assessment of heterogeneity</h4> <p>Where we were able to include trials reporting the same outcome in a meta‐analysis, we tested for heterogeneity using visual inspection of the forest plots and the I² statistic. We looked for similar point estimates and overlapping CIs on the forest plots as an indication of low heterogeneity. We reported high levels of heterogeneity when point estimates varied and the CIs did not overlap. The I² statistic describes the percentage of total variation across trials which is due to heterogeneity rather than chance. We based our definitions of levels of heterogeneity on the levels given in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD013666-bbs2-0049" title="HigginsJP , SavovićJ , PageMJ , ElbersRG , SterneJA . Chapter 8: Assessing risk of bias in a randomised trial. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). The Cochrane Collaboration, 2021. Available from training.cochrane.org/handbook/archive/v6.2.">Higgins 2021</a>): </p> <p> <ol id="CD013666-list-0012"> <li> <p>0% to 40%: might not be important;</p> </li> <li> <p>30% to 60%: may represent moderate heterogeneity;</p> </li> <li> <p>50% to 90%: may represent substantial heterogeneity;</p> </li> <li> <p>75% to 100%: considerable heterogeneity.</p> </li> </ol> </p> <p>We also reported on the magnitude and direction of the effects contributing to any heterogeneity found (<a href="./references#CD013666-bbs2-0043" title="DeeksJJ , HigginsJP , AltmanDG , editor(s). Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). The Cochrane Collaboration, 2021. Available from training.cochrane.org/handbook.">Deeks 2021</a>). </p> </section> <section id="CD013666-sec-0036"> <h4 class="title">Assessment of reporting biases</h4> <p>We did not find sufficient trials with data to attempt to identify publication bias. If this changes at a future update, we will attempt to identify any publication bias in the included trials by generating a funnel plot. If there is asymmetry in the funnel plot, we will attempt to discover the reason, including reasons not related to publication bias (<a href="./references#CD013666-bbs2-0058" title="PageMJ , HigginsJP , SterneJA . Chapter 13: Assessing risk of bias due to missing results in a synthesis. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). The Cochrane Collaboration, 2021. Available from training.cochrane.org/handbook.">Page 2021</a>). </p> <p>We attempted to identify any selective reporting in the included publications by careful examination of the trial publications and consideration of reporting of both positive and negative effects of the intervention. We looked at competing interests of the authors to determine the role of external bias being introduced. </p> </section> <section id="CD013666-sec-0037"> <h4 class="title">Data synthesis</h4> <p>We were only able to combine two trials in a meta‐analysis, and only produced three forest plots. If more data are available at a future update we will generate forest plots for each outcome. We will report each outcome on a separate forest plot and also separate out the different comparisons, e.g. short‐acting inhaled beta‐2 agonists versus placebo, short‐acting inhaled muscarinic antagonists versus placebo, etc. </p> <p>Where there is low heterogeneity (I² &lt; 40%) we will use a fixed‐effect model, but if heterogeneity &gt; 40% we will use a random‐effects model (<a href="./references#CD013666-bbs2-0043" title="DeeksJJ , HigginsJP , AltmanDG , editor(s). Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). The Cochrane Collaboration, 2021. Available from training.cochrane.org/handbook.">Deeks 2021</a>). </p> </section> <section id="CD013666-sec-0038"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We were unable to add any data into one meta‐analysis and therefore could not examine heterogeneity between trial results. In future updates if this becomes possible, where we find at least moderate statistical heterogeneity (I² &gt; 50%) between the included trials, we will investigate the possible causes of this further by performing subgroup analyses looking at the effects of: </p> <p> <ol id="CD013666-list-0013"> <li> <p>age;</p> </li> <li> <p>severity of lung disease;</p> </li> <li> <p>the presence of atopy; and</p> </li> <li> <p>the presence of reversible airway obstruction (based on reversibility or methacholine challenge or exercise testing). </p> </li> </ol> </p> </section> <section id="CD013666-sec-0039"> <h4 class="title">Sensitivity analysis</h4> <p>If we are able to include more data in a meta‐analysis in a future update we will carry out a sensitivity analysis to look at the effects of risk of bias on the trial results. We will look at the effect of adding in and taking out trials where there is high risk of bias.  </p> </section> <section id="CD013666-sec-0040"> <h4 class="title">Summary of findings and assessment of the certainty of the evidence</h4> <p>We have presented a summary of findings table for each comparison that we have included in the review. We have selected the following outcomes to present, which we consider to be the most clinically relevant. </p> <p> <ol id="CD013666-list-0014"> <li> <p>Change from baseline in FEV<sub>1</sub> % predicted </p> </li> <li> <p>Quality of life (using a validated measure such as CFQ‐R (<a href="./references#CD013666-bbs2-0059" title="QuittnerAL , ModiAC , WainwrightC , OttoK , KiriharaJ , MontgomeryAB . Determination of the minimal clinically important difference scores for the Cystic Fibrosis Questionnaire-Revised respiratory symptom scale in two populations of patients with cystic fibrosis and chronic Pseudomonas aeruginosa airway infection. Chest2009;135(6):1610-8.">Quittner 2009</a>), CFQoL (<a href="./references#CD013666-bbs2-0046" title="GeeL , AbbottJ , ConwaySP , EtheringtonC , WebbAK . Development of a disease specific health related quality of life measure for adults and adolescents with cystic fibrosis. Thorax2000;55(11):946-54.">Gee 2000</a>)) </p> </li> <li> <p>Number of exacerbations</p> </li> <li> <p>Participant‐reported respiratory symptom score (using a validated score such as RSS, RSSQ (<a href="./references#CD013666-bbs2-0047" title="GossCH , QuittnerAL . Patient-reported outcomes in cystic fibrosis. Proceedings of the American Thoracic Society2007;4(4):378-86.">Goss 2007</a>)) </p> </li> <li> <p>Adverse events (all treatment‐related adverse effects)</p> </li> <li> <p>Change from baseline in FVC % predicted</p> </li> <li> <p>Sputum volume (mL)</p> </li> </ol> </p> <p>For each outcome we have reported the illustrative risk with and without the intervention and the magnitude of effect (RR or MD) (<a href="./references#CD013666-bbs2-0063" title="SchünemannHJ , VistGE , HigginsJP , SantessoN , DeeksJJ , GlasziouP , et al. Chapter 15: Interpreting results and drawing conclusions. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). The Cochrane Collaboration, 2021. Available from training.cochrane.org/handbook/archive/v6.2.">Schünemann 2021a</a>). We also presented the number of trials contributing to the outcome and a grade for the overall certainty of the body of evidence. To do this we used the GRADE approach (<a href="./references#CD013666-bbs2-0064" title="SchünemannHJ , HigginsJP , VistGE , GlasziouP , AklEA , SkoetzN , et al. Chapter 14: Completing ‘Summary of findings’ tables and grading the certainty of the evidence. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). The Cochrane Collaboration, 2021. Available from training.cochrane.org/handbook/archive/v6.2.">Schünemann 2021b</a>). We assessed the certainty of evidence based on the risk of bias within the trials contributing to the outcome, relevance to our population of interest (indirectness), unexplained heterogeneity or inconsistency, imprecision of the results and risk of publication bias. As a starting point we have labelled all of the evidence as high certainty, but we downgraded the evidence where there were issues in any of the aforementioned categories. We downgraded the evidence once where the risk was serious and twice where we deemed the risk to be very serious. We graded the body of evidence for each outcome as either high, moderate, low or very low certainty. We added reasons and supporting information for our decisions in the footnotes to the summary of findings tables. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD013666-sec-0041" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD013666-sec-0041"></div> <section id="CD013666-sec-0042"> <h3 class="title">Description of studies</h3> <section id="CD013666-sec-0043"> <h4 class="title">Results of the search</h4> <p>Our searches identified 280 unique references after duplicates had been removed, which we then screened on title and abstract. We excluded 234 references on this basis leaving 46 references to 28 trials for which we reviewed the full text. We have included 11 trials (17 references) which met our inclusion criteria, and excluded the remaining 17 trials (29 references). We have described the reason for exclusion of the trials that did not fulfil our inclusion criteria (<a href="./references#CD013666-sec-0150" title="">Characteristics of excluded studies</a>), and described the flow of references through the screening process in a PRISMA flowchart (<a href="#CD013666-fig-0001">Figure 1</a>; <a href="./references#CD013666-bbs2-0057" title="PageMJ , McKenzieJE , BossuytPM , BoutronI , HoffmannTC , MulrowCD , et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ2021;372:n71. [DOI: 10.1136/bmj.n71]">Page 2020</a>). </p> <div class="figure" id="CD013666-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD013666-fig-0001" src="/cdsr/doi/10.1002/14651858.CD013666.pub2/media/CDSR/CD013666/image_n/nCD013666-FIG-01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> </section> <section id="CD013666-sec-0044"> <h4 class="title">Included studies</h4> <p>We included 11 trials with a total of 191 participants (<a href="./references#CD013666-bbs2-0001" title="DoddJ , BarryS , GallagherC . The effects of inhaled B2 agonists on maximal exercise in patients with cystic fibrosis . American Journal of Respiratory and Critical Care Medicine2001;163(5 Suppl):A88. [CFGD REGISTER: IB84a] DoddJD , BarrySC , DalyLE , GallagherCG . Inhaled beta-agonists improve lung function but not maximal exercise capacity in cystic fibrosis. Journal of Cystic Fibrosis2005;4(2):101-5. [CFGD REGISTER: IB84b] ">Dodd 2005</a>; <a href="./references#CD013666-bbs2-0002" title="DuncanFR , PenkethAR , HodsonME , BattenJC . The use of bronchodilators as an adjunct to physiotherapy, in adults with cystic fibrosis. In: 11th European Cystic Fibrosis Conference, 1982; Brussels. 1982:48. [CFGD REGISTER: IB70] ">Duncan 1982</a>; <a href="./references#CD013666-bbs2-0003" title="EgglestonPA , RosensteinBJ , StackhouseCM , MellitsED , BaumgardnerRA . A controlled trial of long-term bronchodilator therapy in cystic fibrosis. Chest1991;99(5):1088-92. [CFGD REGISTER: IB61a] OrensteinD . Long-term inhaled bronchodilator therapy in cystic fibrosis. Comment on Eggleston PA, Rosenstein BJ, Stackhouse CM, Mellits ED, Baumgardner RA. A controlled trial of long-term bronchodilator therapy in cystic fibrosis. Chest 1991;99(5):1088-92. Chest1991;99(5):1061. [CFGD REGISTER: IB61b] ">Eggleston 1991</a>; <a href="./references#CD013666-bbs2-0004" title="HordvikNL , SammutPH , JudyCG , StrizekSJ , ColomboJL . The effects of albuterol on the lung function of hospitalized patients with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine1996;154(1):156-60. [CFGD REGISTER: IB75] ">Hordvik 1996</a>; <a href="./references#CD013666-bbs2-0005" title="KonigP , PoehlerJ , BarberoGJ . A placebo-controlled, double-blind trial of the long-term effects of albuterol administration in patients with cystic fibrosis. Pediatric Pulmonology1998;25(1):32-6. [CFGD REGISTER: IB74b] KonigP , PoehlerJ , BarberoGJ . Long-term effects of albuterol (A) in cystic fibrosis (CF) - A controlled trial. Pediatric Pulmonology1996;Suppl 13:302. [CFGD REGISTER: IB74a] ">Konig 1996</a>; <a href="./references#CD013666-bbs2-0006" title="Pitcher-WilmottRW , MatthewDJ , IngramD , TysonSL . Improvement in lung function after nebulised salbutamol and ipratropium bromide in children with cystic fibrosis. In: 11th European Cystic Fibrosis Conference, 1982. Brussels. 1982:251. [CFGD REGISTER: IB77] ">Pitcher‐Wilmott 1982</a>; <a href="./references#CD013666-bbs2-0007" title="SanchezI , HolbrowJ , ChernickV . Acute bronchodilator response to a combination of beta-adrenergic and anticholinergic agents in patients with cystic fibrosis. Journal of Pediatrics1992;120(3):486-8. [CFGD REGISTER: IB63] ">Sanchez 1992</a>; <a href="./references#CD013666-bbs2-0008" title="SerisierDJ , CaotesAD , BowlerSD . Inhaled salbutamol does not improve maximal exercise performance in cystic fibrosis . Respirology2006;11(Suppl 2):A58. [CFGD REGISTER: IB81c] SerisierDJ , CoatesAD , BowlerSD . Effect of albuterol on maximal exercise capacity in cystic fibrosis. Chest2007;131(4):1181-7. [CFGD REGISTER: IB81b] SerisierDJ , Rice-McDonaldG , BowlerSD , CoatesAC . ß-adrenergic agonists do not improve exercise capacity in cystic fibrosis. Pediatric Pulmonology2000;30 Suppl 20:305. [CFGD REGISTER: IB81a] ">Serisier 2000</a>; <a href="./references#CD013666-bbs2-0009" title="WeintraubSJ , EschenbacherWL . The inhaled bronchodilators ipratropium bromide and metaproterenol in adults with CF. Chest1989;95(4):861-4. [CFGD REGISTER: IB58] ">Weintraub 1989</a>; <a href="./references#CD013666-bbs2-0010" title="WiebickeW , PoynterA , MontgomeryM , PagtakhanR . The effect of ipratropium bromide on lung function in patients with cystic fibrosis. Pneumologie1990;44 Suppl 1(1):277-8. [CFGD REGISTER: IB59] ">Wiebicke 1990</a>; <a href="./references#CD013666-bbs2-0011" title="ZiebachR , Pietsch-BreitfeldB , BichlerM , BuschA , RiethmullerJ , SternM . Bronchodilatory effects of salbutamol, ipratropium bromide, and their combination: double-blind, placebo-controlled crossover study in cystic fibrosis. Pediatric Pulmonology2001;31(6):431-5. [CFGD REGISTER: IB82] ">Ziebach 2001</a>). </p> <section id="CD013666-sec-0045"> <h5 class="title">Design and sample size</h5> <p>All of the 11 included trials were cross‐over RCTs with small numbers of participants. Nine trials were single‐dose trials with a washout of at least 12 hours between treatments (<a href="./references#CD013666-bbs2-0001" title="DoddJ , BarryS , GallagherC . The effects of inhaled B2 agonists on maximal exercise in patients with cystic fibrosis . American Journal of Respiratory and Critical Care Medicine2001;163(5 Suppl):A88. [CFGD REGISTER: IB84a] DoddJD , BarrySC , DalyLE , GallagherCG . Inhaled beta-agonists improve lung function but not maximal exercise capacity in cystic fibrosis. Journal of Cystic Fibrosis2005;4(2):101-5. [CFGD REGISTER: IB84b] ">Dodd 2005</a>; <a href="./references#CD013666-bbs2-0002" title="DuncanFR , PenkethAR , HodsonME , BattenJC . The use of bronchodilators as an adjunct to physiotherapy, in adults with cystic fibrosis. In: 11th European Cystic Fibrosis Conference, 1982; Brussels. 1982:48. [CFGD REGISTER: IB70] ">Duncan 1982</a>; <a href="./references#CD013666-bbs2-0004" title="HordvikNL , SammutPH , JudyCG , StrizekSJ , ColomboJL . The effects of albuterol on the lung function of hospitalized patients with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine1996;154(1):156-60. [CFGD REGISTER: IB75] ">Hordvik 1996</a>; <a href="./references#CD013666-bbs2-0006" title="Pitcher-WilmottRW , MatthewDJ , IngramD , TysonSL . Improvement in lung function after nebulised salbutamol and ipratropium bromide in children with cystic fibrosis. In: 11th European Cystic Fibrosis Conference, 1982. Brussels. 1982:251. [CFGD REGISTER: IB77] ">Pitcher‐Wilmott 1982</a>; <a href="./references#CD013666-bbs2-0007" title="SanchezI , HolbrowJ , ChernickV . Acute bronchodilator response to a combination of beta-adrenergic and anticholinergic agents in patients with cystic fibrosis. Journal of Pediatrics1992;120(3):486-8. [CFGD REGISTER: IB63] ">Sanchez 1992</a>; <a href="./references#CD013666-bbs2-0008" title="SerisierDJ , CaotesAD , BowlerSD . Inhaled salbutamol does not improve maximal exercise performance in cystic fibrosis . Respirology2006;11(Suppl 2):A58. [CFGD REGISTER: IB81c] SerisierDJ , CoatesAD , BowlerSD . Effect of albuterol on maximal exercise capacity in cystic fibrosis. Chest2007;131(4):1181-7. [CFGD REGISTER: IB81b] SerisierDJ , Rice-McDonaldG , BowlerSD , CoatesAC . ß-adrenergic agonists do not improve exercise capacity in cystic fibrosis. Pediatric Pulmonology2000;30 Suppl 20:305. [CFGD REGISTER: IB81a] ">Serisier 2000</a>; <a href="./references#CD013666-bbs2-0009" title="WeintraubSJ , EschenbacherWL . The inhaled bronchodilators ipratropium bromide and metaproterenol in adults with CF. Chest1989;95(4):861-4. [CFGD REGISTER: IB58] ">Weintraub 1989</a>; <a href="./references#CD013666-bbs2-0010" title="WiebickeW , PoynterA , MontgomeryM , PagtakhanR . The effect of ipratropium bromide on lung function in patients with cystic fibrosis. Pneumologie1990;44 Suppl 1(1):277-8. [CFGD REGISTER: IB59] ">Wiebicke 1990</a>; <a href="./references#CD013666-bbs2-0011" title="ZiebachR , Pietsch-BreitfeldB , BichlerM , BuschA , RiethmullerJ , SternM . Bronchodilatory effects of salbutamol, ipratropium bromide, and their combination: double-blind, placebo-controlled crossover study in cystic fibrosis. Pediatric Pulmonology2001;31(6):431-5. [CFGD REGISTER: IB82] ">Ziebach 2001</a>), one trial was carried out over 4 weeks (<a href="./references#CD013666-bbs2-0003" title="EgglestonPA , RosensteinBJ , StackhouseCM , MellitsED , BaumgardnerRA . A controlled trial of long-term bronchodilator therapy in cystic fibrosis. Chest1991;99(5):1088-92. [CFGD REGISTER: IB61a] OrensteinD . Long-term inhaled bronchodilator therapy in cystic fibrosis. Comment on Eggleston PA, Rosenstein BJ, Stackhouse CM, Mellits ED, Baumgardner RA. A controlled trial of long-term bronchodilator therapy in cystic fibrosis. Chest 1991;99(5):1088-92. Chest1991;99(5):1061. [CFGD REGISTER: IB61b] ">Eggleston 1991</a>), and one over 6 months (<a href="./references#CD013666-bbs2-0005" title="KonigP , PoehlerJ , BarberoGJ . A placebo-controlled, double-blind trial of the long-term effects of albuterol administration in patients with cystic fibrosis. Pediatric Pulmonology1998;25(1):32-6. [CFGD REGISTER: IB74b] KonigP , PoehlerJ , BarberoGJ . Long-term effects of albuterol (A) in cystic fibrosis (CF) - A controlled trial. Pediatric Pulmonology1996;Suppl 13:302. [CFGD REGISTER: IB74a] ">Konig 1996</a>). Four of the trials were carried out in the USA (<a href="./references#CD013666-bbs2-0003" title="EgglestonPA , RosensteinBJ , StackhouseCM , MellitsED , BaumgardnerRA . A controlled trial of long-term bronchodilator therapy in cystic fibrosis. Chest1991;99(5):1088-92. [CFGD REGISTER: IB61a] OrensteinD . Long-term inhaled bronchodilator therapy in cystic fibrosis. Comment on Eggleston PA, Rosenstein BJ, Stackhouse CM, Mellits ED, Baumgardner RA. A controlled trial of long-term bronchodilator therapy in cystic fibrosis. Chest 1991;99(5):1088-92. Chest1991;99(5):1061. [CFGD REGISTER: IB61b] ">Eggleston 1991</a>; <a href="./references#CD013666-bbs2-0004" title="HordvikNL , SammutPH , JudyCG , StrizekSJ , ColomboJL . The effects of albuterol on the lung function of hospitalized patients with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine1996;154(1):156-60. [CFGD REGISTER: IB75] ">Hordvik 1996</a>; <a href="./references#CD013666-bbs2-0005" title="KonigP , PoehlerJ , BarberoGJ . A placebo-controlled, double-blind trial of the long-term effects of albuterol administration in patients with cystic fibrosis. Pediatric Pulmonology1998;25(1):32-6. [CFGD REGISTER: IB74b] KonigP , PoehlerJ , BarberoGJ . Long-term effects of albuterol (A) in cystic fibrosis (CF) - A controlled trial. Pediatric Pulmonology1996;Suppl 13:302. [CFGD REGISTER: IB74a] ">Konig 1996</a>; <a href="./references#CD013666-bbs2-0009" title="WeintraubSJ , EschenbacherWL . The inhaled bronchodilators ipratropium bromide and metaproterenol in adults with CF. Chest1989;95(4):861-4. [CFGD REGISTER: IB58] ">Weintraub 1989</a>), one in Ireland (<a href="./references#CD013666-bbs2-0001" title="DoddJ , BarryS , GallagherC . The effects of inhaled B2 agonists on maximal exercise in patients with cystic fibrosis . American Journal of Respiratory and Critical Care Medicine2001;163(5 Suppl):A88. [CFGD REGISTER: IB84a] DoddJD , BarrySC , DalyLE , GallagherCG . Inhaled beta-agonists improve lung function but not maximal exercise capacity in cystic fibrosis. Journal of Cystic Fibrosis2005;4(2):101-5. [CFGD REGISTER: IB84b] ">Dodd 2005</a>), one in the UK (<a href="./references#CD013666-bbs2-0002" title="DuncanFR , PenkethAR , HodsonME , BattenJC . The use of bronchodilators as an adjunct to physiotherapy, in adults with cystic fibrosis. In: 11th European Cystic Fibrosis Conference, 1982; Brussels. 1982:48. [CFGD REGISTER: IB70] ">Duncan 1982</a>), one in Canada (<a href="./references#CD013666-bbs2-0007" title="SanchezI , HolbrowJ , ChernickV . Acute bronchodilator response to a combination of beta-adrenergic and anticholinergic agents in patients with cystic fibrosis. Journal of Pediatrics1992;120(3):486-8. [CFGD REGISTER: IB63] ">Sanchez 1992</a>), one in Australia (<a href="./references#CD013666-bbs2-0008" title="SerisierDJ , CaotesAD , BowlerSD . Inhaled salbutamol does not improve maximal exercise performance in cystic fibrosis . Respirology2006;11(Suppl 2):A58. [CFGD REGISTER: IB81c] SerisierDJ , CoatesAD , BowlerSD . Effect of albuterol on maximal exercise capacity in cystic fibrosis. Chest2007;131(4):1181-7. [CFGD REGISTER: IB81b] SerisierDJ , Rice-McDonaldG , BowlerSD , CoatesAC . ß-adrenergic agonists do not improve exercise capacity in cystic fibrosis. Pediatric Pulmonology2000;30 Suppl 20:305. [CFGD REGISTER: IB81a] ">Serisier 2000</a>), one in Germany (<a href="./references#CD013666-bbs2-0011" title="ZiebachR , Pietsch-BreitfeldB , BichlerM , BuschA , RiethmullerJ , SternM . Bronchodilatory effects of salbutamol, ipratropium bromide, and their combination: double-blind, placebo-controlled crossover study in cystic fibrosis. Pediatric Pulmonology2001;31(6):431-5. [CFGD REGISTER: IB82] ">Ziebach 2001</a>), one in Germany and Canada (<a href="./references#CD013666-bbs2-0010" title="WiebickeW , PoynterA , MontgomeryM , PagtakhanR . The effect of ipratropium bromide on lung function in patients with cystic fibrosis. Pneumologie1990;44 Suppl 1(1):277-8. [CFGD REGISTER: IB59] ">Wiebicke 1990</a>), and the final trial did not state where it was conducted (<a href="./references#CD013666-bbs2-0006" title="Pitcher-WilmottRW , MatthewDJ , IngramD , TysonSL . Improvement in lung function after nebulised salbutamol and ipratropium bromide in children with cystic fibrosis. In: 11th European Cystic Fibrosis Conference, 1982. Brussels. 1982:251. [CFGD REGISTER: IB77] ">Pitcher‐Wilmott 1982</a>). Two of the trials were only presented in abstract form and we have not been able to identify a full paper (<a href="./references#CD013666-bbs2-0002" title="DuncanFR , PenkethAR , HodsonME , BattenJC . The use of bronchodilators as an adjunct to physiotherapy, in adults with cystic fibrosis. In: 11th European Cystic Fibrosis Conference, 1982; Brussels. 1982:48. [CFGD REGISTER: IB70] ">Duncan 1982</a>; <a href="./references#CD013666-bbs2-0006" title="Pitcher-WilmottRW , MatthewDJ , IngramD , TysonSL . Improvement in lung function after nebulised salbutamol and ipratropium bromide in children with cystic fibrosis. In: 11th European Cystic Fibrosis Conference, 1982. Brussels. 1982:251. [CFGD REGISTER: IB77] ">Pitcher‐Wilmott 1982</a>). </p> </section> <section id="CD013666-sec-0046"> <h5 class="title">Participants and setting</h5> <p>All of the trials included people with CF (whilst we only intended to include trials where the CF diagnosis was confirmed, this was not always reported in older trials or in abstracts and so we accepted the surrogate criteria that participants were enrolled from CF clinics). The age of participants ranged from 5 years to 40 years. Six trials included both adults and children (<a href="./references#CD013666-bbs2-0003" title="EgglestonPA , RosensteinBJ , StackhouseCM , MellitsED , BaumgardnerRA . A controlled trial of long-term bronchodilator therapy in cystic fibrosis. Chest1991;99(5):1088-92. [CFGD REGISTER: IB61a] OrensteinD . Long-term inhaled bronchodilator therapy in cystic fibrosis. Comment on Eggleston PA, Rosenstein BJ, Stackhouse CM, Mellits ED, Baumgardner RA. A controlled trial of long-term bronchodilator therapy in cystic fibrosis. Chest 1991;99(5):1088-92. Chest1991;99(5):1061. [CFGD REGISTER: IB61b] ">Eggleston 1991</a>; <a href="./references#CD013666-bbs2-0004" title="HordvikNL , SammutPH , JudyCG , StrizekSJ , ColomboJL . The effects of albuterol on the lung function of hospitalized patients with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine1996;154(1):156-60. [CFGD REGISTER: IB75] ">Hordvik 1996</a>; <a href="./references#CD013666-bbs2-0007" title="SanchezI , HolbrowJ , ChernickV . Acute bronchodilator response to a combination of beta-adrenergic and anticholinergic agents in patients with cystic fibrosis. Journal of Pediatrics1992;120(3):486-8. [CFGD REGISTER: IB63] ">Sanchez 1992</a>; <a href="./references#CD013666-bbs2-0008" title="SerisierDJ , CaotesAD , BowlerSD . Inhaled salbutamol does not improve maximal exercise performance in cystic fibrosis . Respirology2006;11(Suppl 2):A58. [CFGD REGISTER: IB81c] SerisierDJ , CoatesAD , BowlerSD . Effect of albuterol on maximal exercise capacity in cystic fibrosis. Chest2007;131(4):1181-7. [CFGD REGISTER: IB81b] SerisierDJ , Rice-McDonaldG , BowlerSD , CoatesAC . ß-adrenergic agonists do not improve exercise capacity in cystic fibrosis. Pediatric Pulmonology2000;30 Suppl 20:305. [CFGD REGISTER: IB81a] ">Serisier 2000</a>; <a href="./references#CD013666-bbs2-0010" title="WiebickeW , PoynterA , MontgomeryM , PagtakhanR . The effect of ipratropium bromide on lung function in patients with cystic fibrosis. Pneumologie1990;44 Suppl 1(1):277-8. [CFGD REGISTER: IB59] ">Wiebicke 1990</a>; <a href="./references#CD013666-bbs2-0011" title="ZiebachR , Pietsch-BreitfeldB , BichlerM , BuschA , RiethmullerJ , SternM . Bronchodilatory effects of salbutamol, ipratropium bromide, and their combination: double-blind, placebo-controlled crossover study in cystic fibrosis. Pediatric Pulmonology2001;31(6):431-5. [CFGD REGISTER: IB82] ">Ziebach 2001</a>), two trials included children only (<a href="./references#CD013666-bbs2-0005" title="KonigP , PoehlerJ , BarberoGJ . A placebo-controlled, double-blind trial of the long-term effects of albuterol administration in patients with cystic fibrosis. Pediatric Pulmonology1998;25(1):32-6. [CFGD REGISTER: IB74b] KonigP , PoehlerJ , BarberoGJ . Long-term effects of albuterol (A) in cystic fibrosis (CF) - A controlled trial. Pediatric Pulmonology1996;Suppl 13:302. [CFGD REGISTER: IB74a] ">Konig 1996</a>; <a href="./references#CD013666-bbs2-0006" title="Pitcher-WilmottRW , MatthewDJ , IngramD , TysonSL . Improvement in lung function after nebulised salbutamol and ipratropium bromide in children with cystic fibrosis. In: 11th European Cystic Fibrosis Conference, 1982. Brussels. 1982:251. [CFGD REGISTER: IB77] ">Pitcher‐Wilmott 1982</a>), two trials included adults only (<a href="./references#CD013666-bbs2-0001" title="DoddJ , BarryS , GallagherC . The effects of inhaled B2 agonists on maximal exercise in patients with cystic fibrosis . American Journal of Respiratory and Critical Care Medicine2001;163(5 Suppl):A88. [CFGD REGISTER: IB84a] DoddJD , BarrySC , DalyLE , GallagherCG . Inhaled beta-agonists improve lung function but not maximal exercise capacity in cystic fibrosis. Journal of Cystic Fibrosis2005;4(2):101-5. [CFGD REGISTER: IB84b] ">Dodd 2005</a>; <a href="./references#CD013666-bbs2-0009" title="WeintraubSJ , EschenbacherWL . The inhaled bronchodilators ipratropium bromide and metaproterenol in adults with CF. Chest1989;95(4):861-4. [CFGD REGISTER: IB58] ">Weintraub 1989</a>), and one trial report did not give any information on the age of the participants (<a href="./references#CD013666-bbs2-0002" title="DuncanFR , PenkethAR , HodsonME , BattenJC . The use of bronchodilators as an adjunct to physiotherapy, in adults with cystic fibrosis. In: 11th European Cystic Fibrosis Conference, 1982; Brussels. 1982:48. [CFGD REGISTER: IB70] ">Duncan 1982</a>). Numbers of participants ranged from eight in <a href="./references#CD013666-bbs2-0001" title="DoddJ , BarryS , GallagherC . The effects of inhaled B2 agonists on maximal exercise in patients with cystic fibrosis . American Journal of Respiratory and Critical Care Medicine2001;163(5 Suppl):A88. [CFGD REGISTER: IB84a] DoddJD , BarrySC , DalyLE , GallagherCG . Inhaled beta-agonists improve lung function but not maximal exercise capacity in cystic fibrosis. Journal of Cystic Fibrosis2005;4(2):101-5. [CFGD REGISTER: IB84b] ">Dodd 2005</a> to 30 in <a href="./references#CD013666-bbs2-0006" title="Pitcher-WilmottRW , MatthewDJ , IngramD , TysonSL . Improvement in lung function after nebulised salbutamol and ipratropium bromide in children with cystic fibrosis. In: 11th European Cystic Fibrosis Conference, 1982. Brussels. 1982:251. [CFGD REGISTER: IB77] ">Pitcher‐Wilmott 1982</a>, but as all the trials were cross‐over in design, the participants acted as their own controls. </p> <p>Nine of the 11 trials were performed on outpatients (<a href="./references#CD013666-bbs2-0001" title="DoddJ , BarryS , GallagherC . The effects of inhaled B2 agonists on maximal exercise in patients with cystic fibrosis . American Journal of Respiratory and Critical Care Medicine2001;163(5 Suppl):A88. [CFGD REGISTER: IB84a] DoddJD , BarrySC , DalyLE , GallagherCG . Inhaled beta-agonists improve lung function but not maximal exercise capacity in cystic fibrosis. Journal of Cystic Fibrosis2005;4(2):101-5. [CFGD REGISTER: IB84b] ">Dodd 2005</a>; <a href="./references#CD013666-bbs2-0003" title="EgglestonPA , RosensteinBJ , StackhouseCM , MellitsED , BaumgardnerRA . A controlled trial of long-term bronchodilator therapy in cystic fibrosis. Chest1991;99(5):1088-92. [CFGD REGISTER: IB61a] OrensteinD . Long-term inhaled bronchodilator therapy in cystic fibrosis. Comment on Eggleston PA, Rosenstein BJ, Stackhouse CM, Mellits ED, Baumgardner RA. A controlled trial of long-term bronchodilator therapy in cystic fibrosis. Chest 1991;99(5):1088-92. Chest1991;99(5):1061. [CFGD REGISTER: IB61b] ">Eggleston 1991</a>; <a href="./references#CD013666-bbs2-0005" title="KonigP , PoehlerJ , BarberoGJ . A placebo-controlled, double-blind trial of the long-term effects of albuterol administration in patients with cystic fibrosis. Pediatric Pulmonology1998;25(1):32-6. [CFGD REGISTER: IB74b] KonigP , PoehlerJ , BarberoGJ . Long-term effects of albuterol (A) in cystic fibrosis (CF) - A controlled trial. Pediatric Pulmonology1996;Suppl 13:302. [CFGD REGISTER: IB74a] ">Konig 1996</a>; <a href="./references#CD013666-bbs2-0006" title="Pitcher-WilmottRW , MatthewDJ , IngramD , TysonSL . Improvement in lung function after nebulised salbutamol and ipratropium bromide in children with cystic fibrosis. In: 11th European Cystic Fibrosis Conference, 1982. Brussels. 1982:251. [CFGD REGISTER: IB77] ">Pitcher‐Wilmott 1982</a>; <a href="./references#CD013666-bbs2-0007" title="SanchezI , HolbrowJ , ChernickV . Acute bronchodilator response to a combination of beta-adrenergic and anticholinergic agents in patients with cystic fibrosis. Journal of Pediatrics1992;120(3):486-8. [CFGD REGISTER: IB63] ">Sanchez 1992</a>; <a href="./references#CD013666-bbs2-0008" title="SerisierDJ , CaotesAD , BowlerSD . Inhaled salbutamol does not improve maximal exercise performance in cystic fibrosis . Respirology2006;11(Suppl 2):A58. [CFGD REGISTER: IB81c] SerisierDJ , CoatesAD , BowlerSD . Effect of albuterol on maximal exercise capacity in cystic fibrosis. Chest2007;131(4):1181-7. [CFGD REGISTER: IB81b] SerisierDJ , Rice-McDonaldG , BowlerSD , CoatesAC . ß-adrenergic agonists do not improve exercise capacity in cystic fibrosis. Pediatric Pulmonology2000;30 Suppl 20:305. [CFGD REGISTER: IB81a] ">Serisier 2000</a>; <a href="./references#CD013666-bbs2-0009" title="WeintraubSJ , EschenbacherWL . The inhaled bronchodilators ipratropium bromide and metaproterenol in adults with CF. Chest1989;95(4):861-4. [CFGD REGISTER: IB58] ">Weintraub 1989</a>; <a href="./references#CD013666-bbs2-0010" title="WiebickeW , PoynterA , MontgomeryM , PagtakhanR . The effect of ipratropium bromide on lung function in patients with cystic fibrosis. Pneumologie1990;44 Suppl 1(1):277-8. [CFGD REGISTER: IB59] ">Wiebicke 1990</a>; <a href="./references#CD013666-bbs2-0011" title="ZiebachR , Pietsch-BreitfeldB , BichlerM , BuschA , RiethmullerJ , SternM . Bronchodilatory effects of salbutamol, ipratropium bromide, and their combination: double-blind, placebo-controlled crossover study in cystic fibrosis. Pediatric Pulmonology2001;31(6):431-5. [CFGD REGISTER: IB82] ">Ziebach 2001</a>), whilst the remaining two trials were carried out during a hospital admission (<a href="./references#CD013666-bbs2-0002" title="DuncanFR , PenkethAR , HodsonME , BattenJC . The use of bronchodilators as an adjunct to physiotherapy, in adults with cystic fibrosis. In: 11th European Cystic Fibrosis Conference, 1982; Brussels. 1982:48. [CFGD REGISTER: IB70] ">Duncan 1982</a>; <a href="./references#CD013666-bbs2-0004" title="HordvikNL , SammutPH , JudyCG , StrizekSJ , ColomboJL . The effects of albuterol on the lung function of hospitalized patients with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine1996;154(1):156-60. [CFGD REGISTER: IB75] ">Hordvik 1996</a>). In the eight trials reporting on the numbers of male and female participants, there were approximately equal numbers of males and females (53% males; 47% females) (<a href="./references#CD013666-bbs2-0001" title="DoddJ , BarryS , GallagherC . The effects of inhaled B2 agonists on maximal exercise in patients with cystic fibrosis . American Journal of Respiratory and Critical Care Medicine2001;163(5 Suppl):A88. [CFGD REGISTER: IB84a] DoddJD , BarrySC , DalyLE , GallagherCG . Inhaled beta-agonists improve lung function but not maximal exercise capacity in cystic fibrosis. Journal of Cystic Fibrosis2005;4(2):101-5. [CFGD REGISTER: IB84b] ">Dodd 2005</a>; <a href="./references#CD013666-bbs2-0003" title="EgglestonPA , RosensteinBJ , StackhouseCM , MellitsED , BaumgardnerRA . A controlled trial of long-term bronchodilator therapy in cystic fibrosis. Chest1991;99(5):1088-92. [CFGD REGISTER: IB61a] OrensteinD . Long-term inhaled bronchodilator therapy in cystic fibrosis. Comment on Eggleston PA, Rosenstein BJ, Stackhouse CM, Mellits ED, Baumgardner RA. A controlled trial of long-term bronchodilator therapy in cystic fibrosis. Chest 1991;99(5):1088-92. Chest1991;99(5):1061. [CFGD REGISTER: IB61b] ">Eggleston 1991</a>; <a href="./references#CD013666-bbs2-0004" title="HordvikNL , SammutPH , JudyCG , StrizekSJ , ColomboJL . The effects of albuterol on the lung function of hospitalized patients with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine1996;154(1):156-60. [CFGD REGISTER: IB75] ">Hordvik 1996</a>; <a href="./references#CD013666-bbs2-0005" title="KonigP , PoehlerJ , BarberoGJ . A placebo-controlled, double-blind trial of the long-term effects of albuterol administration in patients with cystic fibrosis. Pediatric Pulmonology1998;25(1):32-6. [CFGD REGISTER: IB74b] KonigP , PoehlerJ , BarberoGJ . Long-term effects of albuterol (A) in cystic fibrosis (CF) - A controlled trial. Pediatric Pulmonology1996;Suppl 13:302. [CFGD REGISTER: IB74a] ">Konig 1996</a>; <a href="./references#CD013666-bbs2-0007" title="SanchezI , HolbrowJ , ChernickV . Acute bronchodilator response to a combination of beta-adrenergic and anticholinergic agents in patients with cystic fibrosis. Journal of Pediatrics1992;120(3):486-8. [CFGD REGISTER: IB63] ">Sanchez 1992</a>; <a href="./references#CD013666-bbs2-0008" title="SerisierDJ , CaotesAD , BowlerSD . Inhaled salbutamol does not improve maximal exercise performance in cystic fibrosis . Respirology2006;11(Suppl 2):A58. [CFGD REGISTER: IB81c] SerisierDJ , CoatesAD , BowlerSD . Effect of albuterol on maximal exercise capacity in cystic fibrosis. Chest2007;131(4):1181-7. [CFGD REGISTER: IB81b] SerisierDJ , Rice-McDonaldG , BowlerSD , CoatesAC . ß-adrenergic agonists do not improve exercise capacity in cystic fibrosis. Pediatric Pulmonology2000;30 Suppl 20:305. [CFGD REGISTER: IB81a] ">Serisier 2000</a>; <a href="./references#CD013666-bbs2-0009" title="WeintraubSJ , EschenbacherWL . The inhaled bronchodilators ipratropium bromide and metaproterenol in adults with CF. Chest1989;95(4):861-4. [CFGD REGISTER: IB58] ">Weintraub 1989</a>; <a href="./references#CD013666-bbs2-0011" title="ZiebachR , Pietsch-BreitfeldB , BichlerM , BuschA , RiethmullerJ , SternM . Bronchodilatory effects of salbutamol, ipratropium bromide, and their combination: double-blind, placebo-controlled crossover study in cystic fibrosis. Pediatric Pulmonology2001;31(6):431-5. [CFGD REGISTER: IB82] ">Ziebach 2001</a>). </p> </section> <section id="CD013666-sec-0047"> <h5 class="title">Interventions</h5> <p>Eight trials looked at the effects of short‐acting inhaled beta‐2 agonists compared to placebo (<a href="./references#CD013666-bbs2-0001" title="DoddJ , BarryS , GallagherC . The effects of inhaled B2 agonists on maximal exercise in patients with cystic fibrosis . American Journal of Respiratory and Critical Care Medicine2001;163(5 Suppl):A88. [CFGD REGISTER: IB84a] DoddJD , BarrySC , DalyLE , GallagherCG . Inhaled beta-agonists improve lung function but not maximal exercise capacity in cystic fibrosis. Journal of Cystic Fibrosis2005;4(2):101-5. [CFGD REGISTER: IB84b] ">Dodd 2005</a>; <a href="./references#CD013666-bbs2-0002" title="DuncanFR , PenkethAR , HodsonME , BattenJC . The use of bronchodilators as an adjunct to physiotherapy, in adults with cystic fibrosis. In: 11th European Cystic Fibrosis Conference, 1982; Brussels. 1982:48. [CFGD REGISTER: IB70] ">Duncan 1982</a>; <a href="./references#CD013666-bbs2-0003" title="EgglestonPA , RosensteinBJ , StackhouseCM , MellitsED , BaumgardnerRA . A controlled trial of long-term bronchodilator therapy in cystic fibrosis. Chest1991;99(5):1088-92. [CFGD REGISTER: IB61a] OrensteinD . Long-term inhaled bronchodilator therapy in cystic fibrosis. Comment on Eggleston PA, Rosenstein BJ, Stackhouse CM, Mellits ED, Baumgardner RA. A controlled trial of long-term bronchodilator therapy in cystic fibrosis. Chest 1991;99(5):1088-92. Chest1991;99(5):1061. [CFGD REGISTER: IB61b] ">Eggleston 1991</a>; <a href="./references#CD013666-bbs2-0004" title="HordvikNL , SammutPH , JudyCG , StrizekSJ , ColomboJL . The effects of albuterol on the lung function of hospitalized patients with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine1996;154(1):156-60. [CFGD REGISTER: IB75] ">Hordvik 1996</a>; <a href="./references#CD013666-bbs2-0005" title="KonigP , PoehlerJ , BarberoGJ . A placebo-controlled, double-blind trial of the long-term effects of albuterol administration in patients with cystic fibrosis. Pediatric Pulmonology1998;25(1):32-6. [CFGD REGISTER: IB74b] KonigP , PoehlerJ , BarberoGJ . Long-term effects of albuterol (A) in cystic fibrosis (CF) - A controlled trial. Pediatric Pulmonology1996;Suppl 13:302. [CFGD REGISTER: IB74a] ">Konig 1996</a>; <a href="./references#CD013666-bbs2-0006" title="Pitcher-WilmottRW , MatthewDJ , IngramD , TysonSL . Improvement in lung function after nebulised salbutamol and ipratropium bromide in children with cystic fibrosis. In: 11th European Cystic Fibrosis Conference, 1982. Brussels. 1982:251. [CFGD REGISTER: IB77] ">Pitcher‐Wilmott 1982</a>; <a href="./references#CD013666-bbs2-0008" title="SerisierDJ , CaotesAD , BowlerSD . Inhaled salbutamol does not improve maximal exercise performance in cystic fibrosis . Respirology2006;11(Suppl 2):A58. [CFGD REGISTER: IB81c] SerisierDJ , CoatesAD , BowlerSD . Effect of albuterol on maximal exercise capacity in cystic fibrosis. Chest2007;131(4):1181-7. [CFGD REGISTER: IB81b] SerisierDJ , Rice-McDonaldG , BowlerSD , CoatesAC . ß-adrenergic agonists do not improve exercise capacity in cystic fibrosis. Pediatric Pulmonology2000;30 Suppl 20:305. [CFGD REGISTER: IB81a] ">Serisier 2000</a>; <a href="./references#CD013666-bbs2-0011" title="ZiebachR , Pietsch-BreitfeldB , BichlerM , BuschA , RiethmullerJ , SternM . Bronchodilatory effects of salbutamol, ipratropium bromide, and their combination: double-blind, placebo-controlled crossover study in cystic fibrosis. Pediatric Pulmonology2001;31(6):431-5. [CFGD REGISTER: IB82] ">Ziebach 2001</a>); two of these trials and one further trial were three‐armed trials which looked at the effects of both a short‐acting inhaled beta‐2 agonist and a short‐acting inhaled muscarinic antagonist versus placebo and each other (<a href="./references#CD013666-bbs2-0006" title="Pitcher-WilmottRW , MatthewDJ , IngramD , TysonSL . Improvement in lung function after nebulised salbutamol and ipratropium bromide in children with cystic fibrosis. In: 11th European Cystic Fibrosis Conference, 1982. Brussels. 1982:251. [CFGD REGISTER: IB77] ">Pitcher‐Wilmott 1982</a>; <a href="./references#CD013666-bbs2-0009" title="WeintraubSJ , EschenbacherWL . The inhaled bronchodilators ipratropium bromide and metaproterenol in adults with CF. Chest1989;95(4):861-4. [CFGD REGISTER: IB58] ">Weintraub 1989</a>; <a href="./references#CD013666-bbs2-0011" title="ZiebachR , Pietsch-BreitfeldB , BichlerM , BuschA , RiethmullerJ , SternM . Bronchodilatory effects of salbutamol, ipratropium bromide, and their combination: double-blind, placebo-controlled crossover study in cystic fibrosis. Pediatric Pulmonology2001;31(6):431-5. [CFGD REGISTER: IB82] ">Ziebach 2001</a>). These trials are discussed under the appropriate comparisons separately, however, the <a href="./references#CD013666-bbs2-0009" title="WeintraubSJ , EschenbacherWL . The inhaled bronchodilators ipratropium bromide and metaproterenol in adults with CF. Chest1989;95(4):861-4. [CFGD REGISTER: IB58] ">Weintraub 1989</a> trial compared the beta‐2 agonist metaproterenol with placebo and ipratropium, and as this was not one of our predefined bronchodilators, we have not reported on this arm of the trial (<a href="./references#CD013666-bbs2-0009" title="WeintraubSJ , EschenbacherWL . The inhaled bronchodilators ipratropium bromide and metaproterenol in adults with CF. Chest1989;95(4):861-4. [CFGD REGISTER: IB58] ">Weintraub 1989</a>). One trial looked at the effects of a short‐acting inhaled muscarinic antagonist versus placebo (<a href="./references#CD013666-bbs2-0010" title="WiebickeW , PoynterA , MontgomeryM , PagtakhanR . The effect of ipratropium bromide on lung function in patients with cystic fibrosis. Pneumologie1990;44 Suppl 1(1):277-8. [CFGD REGISTER: IB59] ">Wiebicke 1990</a>), and one trial looked at the effects of a short‐acting inhaled beta‐2 agonist versus a short‐acting inhaled muscarinic antagonist (<a href="./references#CD013666-bbs2-0007" title="SanchezI , HolbrowJ , ChernickV . Acute bronchodilator response to a combination of beta-adrenergic and anticholinergic agents in patients with cystic fibrosis. Journal of Pediatrics1992;120(3):486-8. [CFGD REGISTER: IB63] ">Sanchez 1992</a>).  </p> <p>In summary, eight trials contributed to the comparison of short‐acting inhaled beta‐2 agonists to placebo (<a href="./references#CD013666-bbs2-0001" title="DoddJ , BarryS , GallagherC . The effects of inhaled B2 agonists on maximal exercise in patients with cystic fibrosis . American Journal of Respiratory and Critical Care Medicine2001;163(5 Suppl):A88. [CFGD REGISTER: IB84a] DoddJD , BarrySC , DalyLE , GallagherCG . Inhaled beta-agonists improve lung function but not maximal exercise capacity in cystic fibrosis. Journal of Cystic Fibrosis2005;4(2):101-5. [CFGD REGISTER: IB84b] ">Dodd 2005</a>; <a href="./references#CD013666-bbs2-0002" title="DuncanFR , PenkethAR , HodsonME , BattenJC . The use of bronchodilators as an adjunct to physiotherapy, in adults with cystic fibrosis. In: 11th European Cystic Fibrosis Conference, 1982; Brussels. 1982:48. [CFGD REGISTER: IB70] ">Duncan 1982</a>; <a href="./references#CD013666-bbs2-0003" title="EgglestonPA , RosensteinBJ , StackhouseCM , MellitsED , BaumgardnerRA . A controlled trial of long-term bronchodilator therapy in cystic fibrosis. Chest1991;99(5):1088-92. [CFGD REGISTER: IB61a] OrensteinD . Long-term inhaled bronchodilator therapy in cystic fibrosis. Comment on Eggleston PA, Rosenstein BJ, Stackhouse CM, Mellits ED, Baumgardner RA. A controlled trial of long-term bronchodilator therapy in cystic fibrosis. Chest 1991;99(5):1088-92. Chest1991;99(5):1061. [CFGD REGISTER: IB61b] ">Eggleston 1991</a>; <a href="./references#CD013666-bbs2-0004" title="HordvikNL , SammutPH , JudyCG , StrizekSJ , ColomboJL . The effects of albuterol on the lung function of hospitalized patients with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine1996;154(1):156-60. [CFGD REGISTER: IB75] ">Hordvik 1996</a>; <a href="./references#CD013666-bbs2-0005" title="KonigP , PoehlerJ , BarberoGJ . A placebo-controlled, double-blind trial of the long-term effects of albuterol administration in patients with cystic fibrosis. Pediatric Pulmonology1998;25(1):32-6. [CFGD REGISTER: IB74b] KonigP , PoehlerJ , BarberoGJ . Long-term effects of albuterol (A) in cystic fibrosis (CF) - A controlled trial. Pediatric Pulmonology1996;Suppl 13:302. [CFGD REGISTER: IB74a] ">Konig 1996</a>; <a href="./references#CD013666-bbs2-0006" title="Pitcher-WilmottRW , MatthewDJ , IngramD , TysonSL . Improvement in lung function after nebulised salbutamol and ipratropium bromide in children with cystic fibrosis. In: 11th European Cystic Fibrosis Conference, 1982. Brussels. 1982:251. [CFGD REGISTER: IB77] ">Pitcher‐Wilmott 1982</a>; <a href="./references#CD013666-bbs2-0008" title="SerisierDJ , CaotesAD , BowlerSD . Inhaled salbutamol does not improve maximal exercise performance in cystic fibrosis . Respirology2006;11(Suppl 2):A58. [CFGD REGISTER: IB81c] SerisierDJ , CoatesAD , BowlerSD . Effect of albuterol on maximal exercise capacity in cystic fibrosis. Chest2007;131(4):1181-7. [CFGD REGISTER: IB81b] SerisierDJ , Rice-McDonaldG , BowlerSD , CoatesAC . ß-adrenergic agonists do not improve exercise capacity in cystic fibrosis. Pediatric Pulmonology2000;30 Suppl 20:305. [CFGD REGISTER: IB81a] ">Serisier 2000</a>; <a href="./references#CD013666-bbs2-0011" title="ZiebachR , Pietsch-BreitfeldB , BichlerM , BuschA , RiethmullerJ , SternM . Bronchodilatory effects of salbutamol, ipratropium bromide, and their combination: double-blind, placebo-controlled crossover study in cystic fibrosis. Pediatric Pulmonology2001;31(6):431-5. [CFGD REGISTER: IB82] ">Ziebach 2001</a>), four trials contributed to the comparison of short‐acting inhaled muscarinic antagonists to placebo (<a href="./references#CD013666-bbs2-0006" title="Pitcher-WilmottRW , MatthewDJ , IngramD , TysonSL . Improvement in lung function after nebulised salbutamol and ipratropium bromide in children with cystic fibrosis. In: 11th European Cystic Fibrosis Conference, 1982. Brussels. 1982:251. [CFGD REGISTER: IB77] ">Pitcher‐Wilmott 1982</a>; <a href="./references#CD013666-bbs2-0009" title="WeintraubSJ , EschenbacherWL . The inhaled bronchodilators ipratropium bromide and metaproterenol in adults with CF. Chest1989;95(4):861-4. [CFGD REGISTER: IB58] ">Weintraub 1989</a>; <a href="./references#CD013666-bbs2-0010" title="WiebickeW , PoynterA , MontgomeryM , PagtakhanR . The effect of ipratropium bromide on lung function in patients with cystic fibrosis. Pneumologie1990;44 Suppl 1(1):277-8. [CFGD REGISTER: IB59] ">Wiebicke 1990</a>; <a href="./references#CD013666-bbs2-0011" title="ZiebachR , Pietsch-BreitfeldB , BichlerM , BuschA , RiethmullerJ , SternM . Bronchodilatory effects of salbutamol, ipratropium bromide, and their combination: double-blind, placebo-controlled crossover study in cystic fibrosis. Pediatric Pulmonology2001;31(6):431-5. [CFGD REGISTER: IB82] ">Ziebach 2001</a>), and three trials contributed to the comparison of a short‐acting inhaled beta‐2 agonist to a short‐acting inhaled muscarinic antagonist (<a href="./references#CD013666-bbs2-0006" title="Pitcher-WilmottRW , MatthewDJ , IngramD , TysonSL . Improvement in lung function after nebulised salbutamol and ipratropium bromide in children with cystic fibrosis. In: 11th European Cystic Fibrosis Conference, 1982. Brussels. 1982:251. [CFGD REGISTER: IB77] ">Pitcher‐Wilmott 1982</a>; <a href="./references#CD013666-bbs2-0007" title="SanchezI , HolbrowJ , ChernickV . Acute bronchodilator response to a combination of beta-adrenergic and anticholinergic agents in patients with cystic fibrosis. Journal of Pediatrics1992;120(3):486-8. [CFGD REGISTER: IB63] ">Sanchez 1992</a>; <a href="./references#CD013666-bbs2-0011" title="ZiebachR , Pietsch-BreitfeldB , BichlerM , BuschA , RiethmullerJ , SternM . Bronchodilatory effects of salbutamol, ipratropium bromide, and their combination: double-blind, placebo-controlled crossover study in cystic fibrosis. Pediatric Pulmonology2001;31(6):431-5. [CFGD REGISTER: IB82] ">Ziebach 2001</a>).  </p> <section id="CD013666-sec-0048"> <h6 class="title">Short‐acting inhaled beta‐2 agonists</h6> <p>Eight of the trials looked at the effects of short‐acting inhaled beta‐2 agonists compared to placebo (<a href="./references#CD013666-bbs2-0001" title="DoddJ , BarryS , GallagherC . The effects of inhaled B2 agonists on maximal exercise in patients with cystic fibrosis . American Journal of Respiratory and Critical Care Medicine2001;163(5 Suppl):A88. [CFGD REGISTER: IB84a] DoddJD , BarrySC , DalyLE , GallagherCG . Inhaled beta-agonists improve lung function but not maximal exercise capacity in cystic fibrosis. Journal of Cystic Fibrosis2005;4(2):101-5. [CFGD REGISTER: IB84b] ">Dodd 2005</a>; <a href="./references#CD013666-bbs2-0002" title="DuncanFR , PenkethAR , HodsonME , BattenJC . The use of bronchodilators as an adjunct to physiotherapy, in adults with cystic fibrosis. In: 11th European Cystic Fibrosis Conference, 1982; Brussels. 1982:48. [CFGD REGISTER: IB70] ">Duncan 1982</a>; <a href="./references#CD013666-bbs2-0003" title="EgglestonPA , RosensteinBJ , StackhouseCM , MellitsED , BaumgardnerRA . A controlled trial of long-term bronchodilator therapy in cystic fibrosis. Chest1991;99(5):1088-92. [CFGD REGISTER: IB61a] OrensteinD . Long-term inhaled bronchodilator therapy in cystic fibrosis. Comment on Eggleston PA, Rosenstein BJ, Stackhouse CM, Mellits ED, Baumgardner RA. A controlled trial of long-term bronchodilator therapy in cystic fibrosis. Chest 1991;99(5):1088-92. Chest1991;99(5):1061. [CFGD REGISTER: IB61b] ">Eggleston 1991</a>; <a href="./references#CD013666-bbs2-0004" title="HordvikNL , SammutPH , JudyCG , StrizekSJ , ColomboJL . The effects of albuterol on the lung function of hospitalized patients with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine1996;154(1):156-60. [CFGD REGISTER: IB75] ">Hordvik 1996</a>; <a href="./references#CD013666-bbs2-0005" title="KonigP , PoehlerJ , BarberoGJ . A placebo-controlled, double-blind trial of the long-term effects of albuterol administration in patients with cystic fibrosis. Pediatric Pulmonology1998;25(1):32-6. [CFGD REGISTER: IB74b] KonigP , PoehlerJ , BarberoGJ . Long-term effects of albuterol (A) in cystic fibrosis (CF) - A controlled trial. Pediatric Pulmonology1996;Suppl 13:302. [CFGD REGISTER: IB74a] ">Konig 1996</a>; <a href="./references#CD013666-bbs2-0006" title="Pitcher-WilmottRW , MatthewDJ , IngramD , TysonSL . Improvement in lung function after nebulised salbutamol and ipratropium bromide in children with cystic fibrosis. In: 11th European Cystic Fibrosis Conference, 1982. Brussels. 1982:251. [CFGD REGISTER: IB77] ">Pitcher‐Wilmott 1982</a>; <a href="./references#CD013666-bbs2-0008" title="SerisierDJ , CaotesAD , BowlerSD . Inhaled salbutamol does not improve maximal exercise performance in cystic fibrosis . Respirology2006;11(Suppl 2):A58. [CFGD REGISTER: IB81c] SerisierDJ , CoatesAD , BowlerSD . Effect of albuterol on maximal exercise capacity in cystic fibrosis. Chest2007;131(4):1181-7. [CFGD REGISTER: IB81b] SerisierDJ , Rice-McDonaldG , BowlerSD , CoatesAC . ß-adrenergic agonists do not improve exercise capacity in cystic fibrosis. Pediatric Pulmonology2000;30 Suppl 20:305. [CFGD REGISTER: IB81a] ">Serisier 2000</a>; <a href="./references#CD013666-bbs2-0011" title="ZiebachR , Pietsch-BreitfeldB , BichlerM , BuschA , RiethmullerJ , SternM . Bronchodilatory effects of salbutamol, ipratropium bromide, and their combination: double-blind, placebo-controlled crossover study in cystic fibrosis. Pediatric Pulmonology2001;31(6):431-5. [CFGD REGISTER: IB82] ">Ziebach 2001</a>). Albuterol was used in four trials (<a href="./references#CD013666-bbs2-0003" title="EgglestonPA , RosensteinBJ , StackhouseCM , MellitsED , BaumgardnerRA . A controlled trial of long-term bronchodilator therapy in cystic fibrosis. Chest1991;99(5):1088-92. [CFGD REGISTER: IB61a] OrensteinD . Long-term inhaled bronchodilator therapy in cystic fibrosis. Comment on Eggleston PA, Rosenstein BJ, Stackhouse CM, Mellits ED, Baumgardner RA. A controlled trial of long-term bronchodilator therapy in cystic fibrosis. Chest 1991;99(5):1088-92. Chest1991;99(5):1061. [CFGD REGISTER: IB61b] ">Eggleston 1991</a>; <a href="./references#CD013666-bbs2-0004" title="HordvikNL , SammutPH , JudyCG , StrizekSJ , ColomboJL . The effects of albuterol on the lung function of hospitalized patients with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine1996;154(1):156-60. [CFGD REGISTER: IB75] ">Hordvik 1996</a>; <a href="./references#CD013666-bbs2-0005" title="KonigP , PoehlerJ , BarberoGJ . A placebo-controlled, double-blind trial of the long-term effects of albuterol administration in patients with cystic fibrosis. Pediatric Pulmonology1998;25(1):32-6. [CFGD REGISTER: IB74b] KonigP , PoehlerJ , BarberoGJ . Long-term effects of albuterol (A) in cystic fibrosis (CF) - A controlled trial. Pediatric Pulmonology1996;Suppl 13:302. [CFGD REGISTER: IB74a] ">Konig 1996</a>; <a href="./references#CD013666-bbs2-0008" title="SerisierDJ , CaotesAD , BowlerSD . Inhaled salbutamol does not improve maximal exercise performance in cystic fibrosis . Respirology2006;11(Suppl 2):A58. [CFGD REGISTER: IB81c] SerisierDJ , CoatesAD , BowlerSD . Effect of albuterol on maximal exercise capacity in cystic fibrosis. Chest2007;131(4):1181-7. [CFGD REGISTER: IB81b] SerisierDJ , Rice-McDonaldG , BowlerSD , CoatesAC . ß-adrenergic agonists do not improve exercise capacity in cystic fibrosis. Pediatric Pulmonology2000;30 Suppl 20:305. [CFGD REGISTER: IB81a] ">Serisier 2000</a>), and salbutamol was used in four trials (<a href="./references#CD013666-bbs2-0001" title="DoddJ , BarryS , GallagherC . The effects of inhaled B2 agonists on maximal exercise in patients with cystic fibrosis . American Journal of Respiratory and Critical Care Medicine2001;163(5 Suppl):A88. [CFGD REGISTER: IB84a] DoddJD , BarrySC , DalyLE , GallagherCG . Inhaled beta-agonists improve lung function but not maximal exercise capacity in cystic fibrosis. Journal of Cystic Fibrosis2005;4(2):101-5. [CFGD REGISTER: IB84b] ">Dodd 2005</a>; <a href="./references#CD013666-bbs2-0002" title="DuncanFR , PenkethAR , HodsonME , BattenJC . The use of bronchodilators as an adjunct to physiotherapy, in adults with cystic fibrosis. In: 11th European Cystic Fibrosis Conference, 1982; Brussels. 1982:48. [CFGD REGISTER: IB70] ">Duncan 1982</a>; <a href="./references#CD013666-bbs2-0006" title="Pitcher-WilmottRW , MatthewDJ , IngramD , TysonSL . Improvement in lung function after nebulised salbutamol and ipratropium bromide in children with cystic fibrosis. In: 11th European Cystic Fibrosis Conference, 1982. Brussels. 1982:251. [CFGD REGISTER: IB77] ">Pitcher‐Wilmott 1982</a>; <a href="./references#CD013666-bbs2-0011" title="ZiebachR , Pietsch-BreitfeldB , BichlerM , BuschA , RiethmullerJ , SternM . Bronchodilatory effects of salbutamol, ipratropium bromide, and their combination: double-blind, placebo-controlled crossover study in cystic fibrosis. Pediatric Pulmonology2001;31(6):431-5. [CFGD REGISTER: IB82] ">Ziebach 2001</a>). Albuterol and salbutamol are the same biochemical molecule, but they are the generic names used in the USA and UK, respectively. We will use the name provided by the trial authors. </p> <p>One trial compared a beta‐2 agonist (albuterol) to a short‐acting inhaled muscarinic antagonist (ipratropium bromide) (<a href="./references#CD013666-bbs2-0007" title="SanchezI , HolbrowJ , ChernickV . Acute bronchodilator response to a combination of beta-adrenergic and anticholinergic agents in patients with cystic fibrosis. Journal of Pediatrics1992;120(3):486-8. [CFGD REGISTER: IB63] ">Sanchez 1992</a>). 2 mL inhalation (5.0 mg albuterol (1 mL) and 1 mL 0.9% saline solution) </p> <p>The dose of nebulised albuterol (salbutamol) ranged from 2.5 mg in <a href="./references#CD013666-bbs2-0004" title="HordvikNL , SammutPH , JudyCG , StrizekSJ , ColomboJL . The effects of albuterol on the lung function of hospitalized patients with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine1996;154(1):156-60. [CFGD REGISTER: IB75] ">Hordvik 1996</a> to 5.0 mg in <a href="./references#CD013666-bbs2-0002" title="DuncanFR , PenkethAR , HodsonME , BattenJC . The use of bronchodilators as an adjunct to physiotherapy, in adults with cystic fibrosis. In: 11th European Cystic Fibrosis Conference, 1982; Brussels. 1982:48. [CFGD REGISTER: IB70] ">Duncan 1982</a> and <a href="./references#CD013666-bbs2-0007" title="SanchezI , HolbrowJ , ChernickV . Acute bronchodilator response to a combination of beta-adrenergic and anticholinergic agents in patients with cystic fibrosis. Journal of Pediatrics1992;120(3):486-8. [CFGD REGISTER: IB63] ">Sanchez 1992</a>; in two trials the dose was adjusted for age (<a href="./references#CD013666-bbs2-0006" title="Pitcher-WilmottRW , MatthewDJ , IngramD , TysonSL . Improvement in lung function after nebulised salbutamol and ipratropium bromide in children with cystic fibrosis. In: 11th European Cystic Fibrosis Conference, 1982. Brussels. 1982:251. [CFGD REGISTER: IB77] ">Pitcher‐Wilmott 1982</a>; <a href="./references#CD013666-bbs2-0011" title="ZiebachR , Pietsch-BreitfeldB , BichlerM , BuschA , RiethmullerJ , SternM . Bronchodilatory effects of salbutamol, ipratropium bromide, and their combination: double-blind, placebo-controlled crossover study in cystic fibrosis. Pediatric Pulmonology2001;31(6):431-5. [CFGD REGISTER: IB82] ">Ziebach 2001</a>). The dose of albuterol (salbutamol) delivered by MDI inhaler ranged from 180 µg (<a href="./references#CD013666-bbs2-0003" title="EgglestonPA , RosensteinBJ , StackhouseCM , MellitsED , BaumgardnerRA . A controlled trial of long-term bronchodilator therapy in cystic fibrosis. Chest1991;99(5):1088-92. [CFGD REGISTER: IB61a] OrensteinD . Long-term inhaled bronchodilator therapy in cystic fibrosis. Comment on Eggleston PA, Rosenstein BJ, Stackhouse CM, Mellits ED, Baumgardner RA. A controlled trial of long-term bronchodilator therapy in cystic fibrosis. Chest 1991;99(5):1088-92. Chest1991;99(5):1061. [CFGD REGISTER: IB61b] ">Eggleston 1991</a>; <a href="./references#CD013666-bbs2-0005" title="KonigP , PoehlerJ , BarberoGJ . A placebo-controlled, double-blind trial of the long-term effects of albuterol administration in patients with cystic fibrosis. Pediatric Pulmonology1998;25(1):32-6. [CFGD REGISTER: IB74b] KonigP , PoehlerJ , BarberoGJ . Long-term effects of albuterol (A) in cystic fibrosis (CF) - A controlled trial. Pediatric Pulmonology1996;Suppl 13:302. [CFGD REGISTER: IB74a] ">Konig 1996</a>) to 600 µg (<a href="./references#CD013666-bbs2-0001" title="DoddJ , BarryS , GallagherC . The effects of inhaled B2 agonists on maximal exercise in patients with cystic fibrosis . American Journal of Respiratory and Critical Care Medicine2001;163(5 Suppl):A88. [CFGD REGISTER: IB84a] DoddJD , BarrySC , DalyLE , GallagherCG . Inhaled beta-agonists improve lung function but not maximal exercise capacity in cystic fibrosis. Journal of Cystic Fibrosis2005;4(2):101-5. [CFGD REGISTER: IB84b] ">Dodd 2005</a>; <a href="./references#CD013666-bbs2-0008" title="SerisierDJ , CaotesAD , BowlerSD . Inhaled salbutamol does not improve maximal exercise performance in cystic fibrosis . Respirology2006;11(Suppl 2):A58. [CFGD REGISTER: IB81c] SerisierDJ , CoatesAD , BowlerSD . Effect of albuterol on maximal exercise capacity in cystic fibrosis. Chest2007;131(4):1181-7. [CFGD REGISTER: IB81b] SerisierDJ , Rice-McDonaldG , BowlerSD , CoatesAC . ß-adrenergic agonists do not improve exercise capacity in cystic fibrosis. Pediatric Pulmonology2000;30 Suppl 20:305. [CFGD REGISTER: IB81a] ">Serisier 2000</a>). Six of the placebo‐controlled trials gave the intervention as a single dose (<a href="./references#CD013666-bbs2-0001" title="DoddJ , BarryS , GallagherC . The effects of inhaled B2 agonists on maximal exercise in patients with cystic fibrosis . American Journal of Respiratory and Critical Care Medicine2001;163(5 Suppl):A88. [CFGD REGISTER: IB84a] DoddJD , BarrySC , DalyLE , GallagherCG . Inhaled beta-agonists improve lung function but not maximal exercise capacity in cystic fibrosis. Journal of Cystic Fibrosis2005;4(2):101-5. [CFGD REGISTER: IB84b] ">Dodd 2005</a>; <a href="./references#CD013666-bbs2-0002" title="DuncanFR , PenkethAR , HodsonME , BattenJC . The use of bronchodilators as an adjunct to physiotherapy, in adults with cystic fibrosis. In: 11th European Cystic Fibrosis Conference, 1982; Brussels. 1982:48. [CFGD REGISTER: IB70] ">Duncan 1982</a>; <a href="./references#CD013666-bbs2-0004" title="HordvikNL , SammutPH , JudyCG , StrizekSJ , ColomboJL . The effects of albuterol on the lung function of hospitalized patients with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine1996;154(1):156-60. [CFGD REGISTER: IB75] ">Hordvik 1996</a>; <a href="./references#CD013666-bbs2-0006" title="Pitcher-WilmottRW , MatthewDJ , IngramD , TysonSL . Improvement in lung function after nebulised salbutamol and ipratropium bromide in children with cystic fibrosis. In: 11th European Cystic Fibrosis Conference, 1982. Brussels. 1982:251. [CFGD REGISTER: IB77] ">Pitcher‐Wilmott 1982</a>; <a href="./references#CD013666-bbs2-0008" title="SerisierDJ , CaotesAD , BowlerSD . Inhaled salbutamol does not improve maximal exercise performance in cystic fibrosis . Respirology2006;11(Suppl 2):A58. [CFGD REGISTER: IB81c] SerisierDJ , CoatesAD , BowlerSD . Effect of albuterol on maximal exercise capacity in cystic fibrosis. Chest2007;131(4):1181-7. [CFGD REGISTER: IB81b] SerisierDJ , Rice-McDonaldG , BowlerSD , CoatesAC . ß-adrenergic agonists do not improve exercise capacity in cystic fibrosis. Pediatric Pulmonology2000;30 Suppl 20:305. [CFGD REGISTER: IB81a] ">Serisier 2000</a>; <a href="./references#CD013666-bbs2-0011" title="ZiebachR , Pietsch-BreitfeldB , BichlerM , BuschA , RiethmullerJ , SternM . Bronchodilatory effects of salbutamol, ipratropium bromide, and their combination: double-blind, placebo-controlled crossover study in cystic fibrosis. Pediatric Pulmonology2001;31(6):431-5. [CFGD REGISTER: IB82] ">Ziebach 2001</a>) as did the albuterol versus ipatropium bromide trial (<a href="./references#CD013666-bbs2-0007" title="SanchezI , HolbrowJ , ChernickV . Acute bronchodilator response to a combination of beta-adrenergic and anticholinergic agents in patients with cystic fibrosis. Journal of Pediatrics1992;120(3):486-8. [CFGD REGISTER: IB63] ">Sanchez 1992</a>), whilst the <a href="./references#CD013666-bbs2-0003" title="EgglestonPA , RosensteinBJ , StackhouseCM , MellitsED , BaumgardnerRA . A controlled trial of long-term bronchodilator therapy in cystic fibrosis. Chest1991;99(5):1088-92. [CFGD REGISTER: IB61a] OrensteinD . Long-term inhaled bronchodilator therapy in cystic fibrosis. Comment on Eggleston PA, Rosenstein BJ, Stackhouse CM, Mellits ED, Baumgardner RA. A controlled trial of long-term bronchodilator therapy in cystic fibrosis. Chest 1991;99(5):1088-92. Chest1991;99(5):1061. [CFGD REGISTER: IB61b] ">Eggleston 1991</a> trial administered the intervention 4 times/day over a 2‐week period, and the <a href="./references#CD013666-bbs2-0005" title="KonigP , PoehlerJ , BarberoGJ . A placebo-controlled, double-blind trial of the long-term effects of albuterol administration in patients with cystic fibrosis. Pediatric Pulmonology1998;25(1):32-6. [CFGD REGISTER: IB74b] KonigP , PoehlerJ , BarberoGJ . Long-term effects of albuterol (A) in cystic fibrosis (CF) - A controlled trial. Pediatric Pulmonology1996;Suppl 13:302. [CFGD REGISTER: IB74a] ">Konig 1996</a> trial gave the intervention twice/day over 6 months. </p> </section> <section id="CD013666-sec-0049"> <h6 class="title">Short‐acting inhaled muscarinic antagonists</h6> <p>Four trials compared a short‐acting inhaled muscarinic antagonist (ipratropium bromide) against placebo (<a href="./references#CD013666-bbs2-0006" title="Pitcher-WilmottRW , MatthewDJ , IngramD , TysonSL . Improvement in lung function after nebulised salbutamol and ipratropium bromide in children with cystic fibrosis. In: 11th European Cystic Fibrosis Conference, 1982. Brussels. 1982:251. [CFGD REGISTER: IB77] ">Pitcher‐Wilmott 1982</a>; <a href="./references#CD013666-bbs2-0009" title="WeintraubSJ , EschenbacherWL . The inhaled bronchodilators ipratropium bromide and metaproterenol in adults with CF. Chest1989;95(4):861-4. [CFGD REGISTER: IB58] ">Weintraub 1989</a>; <a href="./references#CD013666-bbs2-0010" title="WiebickeW , PoynterA , MontgomeryM , PagtakhanR . The effect of ipratropium bromide on lung function in patients with cystic fibrosis. Pneumologie1990;44 Suppl 1(1):277-8. [CFGD REGISTER: IB59] ">Wiebicke 1990</a>; <a href="./references#CD013666-bbs2-0011" title="ZiebachR , Pietsch-BreitfeldB , BichlerM , BuschA , RiethmullerJ , SternM . Bronchodilatory effects of salbutamol, ipratropium bromide, and their combination: double-blind, placebo-controlled crossover study in cystic fibrosis. Pediatric Pulmonology2001;31(6):431-5. [CFGD REGISTER: IB82] ">Ziebach 2001</a>). As stated above, one trial compared a short‐acting inhaled muscarinic antagonist (ipratropium bromide) with a beta‐2 agonist (albuterol) (<a href="./references#CD013666-bbs2-0007" title="SanchezI , HolbrowJ , ChernickV . Acute bronchodilator response to a combination of beta-adrenergic and anticholinergic agents in patients with cystic fibrosis. Journal of Pediatrics1992;120(3):486-8. [CFGD REGISTER: IB63] ">Sanchez 1992</a>). </p> <p>The dose of nebulised ipratropium given was 0.25 mg in two trials (<a href="./references#CD013666-bbs2-0007" title="SanchezI , HolbrowJ , ChernickV . Acute bronchodilator response to a combination of beta-adrenergic and anticholinergic agents in patients with cystic fibrosis. Journal of Pediatrics1992;120(3):486-8. [CFGD REGISTER: IB63] ">Sanchez 1992</a>; <a href="./references#CD013666-bbs2-0010" title="WiebickeW , PoynterA , MontgomeryM , PagtakhanR . The effect of ipratropium bromide on lung function in patients with cystic fibrosis. Pneumologie1990;44 Suppl 1(1):277-8. [CFGD REGISTER: IB59] ">Wiebicke 1990</a>), and age‐specific in two trials (<a href="./references#CD013666-bbs2-0006" title="Pitcher-WilmottRW , MatthewDJ , IngramD , TysonSL . Improvement in lung function after nebulised salbutamol and ipratropium bromide in children with cystic fibrosis. In: 11th European Cystic Fibrosis Conference, 1982. Brussels. 1982:251. [CFGD REGISTER: IB77] ">Pitcher‐Wilmott 1982</a>; <a href="./references#CD013666-bbs2-0011" title="ZiebachR , Pietsch-BreitfeldB , BichlerM , BuschA , RiethmullerJ , SternM . Bronchodilatory effects of salbutamol, ipratropium bromide, and their combination: double-blind, placebo-controlled crossover study in cystic fibrosis. Pediatric Pulmonology2001;31(6):431-5. [CFGD REGISTER: IB82] ">Ziebach 2001</a>). The <a href="./references#CD013666-bbs2-0009" title="WeintraubSJ , EschenbacherWL . The inhaled bronchodilators ipratropium bromide and metaproterenol in adults with CF. Chest1989;95(4):861-4. [CFGD REGISTER: IB58] ">Weintraub 1989</a> trial delivered the treatment via a MDI and participants took a single dose of 40 µg. </p> </section> </section> <section id="CD013666-sec-0050"> <h5 class="title">Outcomes</h5> <p>All 11 trials reported a measure of FEV<sub>1</sub>. Six trials reported FEV<sub>1</sub> (L) either as per cent change (<a href="./references#CD013666-bbs2-0004" title="HordvikNL , SammutPH , JudyCG , StrizekSJ , ColomboJL . The effects of albuterol on the lung function of hospitalized patients with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine1996;154(1):156-60. [CFGD REGISTER: IB75] ">Hordvik 1996</a>; <a href="./references#CD013666-bbs2-0008" title="SerisierDJ , CaotesAD , BowlerSD . Inhaled salbutamol does not improve maximal exercise performance in cystic fibrosis . Respirology2006;11(Suppl 2):A58. [CFGD REGISTER: IB81c] SerisierDJ , CoatesAD , BowlerSD . Effect of albuterol on maximal exercise capacity in cystic fibrosis. Chest2007;131(4):1181-7. [CFGD REGISTER: IB81b] SerisierDJ , Rice-McDonaldG , BowlerSD , CoatesAC . ß-adrenergic agonists do not improve exercise capacity in cystic fibrosis. Pediatric Pulmonology2000;30 Suppl 20:305. [CFGD REGISTER: IB81a] ">Serisier 2000</a>; <a href="./references#CD013666-bbs2-0009" title="WeintraubSJ , EschenbacherWL . The inhaled bronchodilators ipratropium bromide and metaproterenol in adults with CF. Chest1989;95(4):861-4. [CFGD REGISTER: IB58] ">Weintraub 1989</a>; <a href="./references#CD013666-bbs2-0011" title="ZiebachR , Pietsch-BreitfeldB , BichlerM , BuschA , RiethmullerJ , SternM . Bronchodilatory effects of salbutamol, ipratropium bromide, and their combination: double-blind, placebo-controlled crossover study in cystic fibrosis. Pediatric Pulmonology2001;31(6):431-5. [CFGD REGISTER: IB82] ">Ziebach 2001</a>), post‐treatment absolute values (<a href="./references#CD013666-bbs2-0007" title="SanchezI , HolbrowJ , ChernickV . Acute bronchodilator response to a combination of beta-adrenergic and anticholinergic agents in patients with cystic fibrosis. Journal of Pediatrics1992;120(3):486-8. [CFGD REGISTER: IB63] ">Sanchez 1992</a>), or narratively (<a href="./references#CD013666-bbs2-0006" title="Pitcher-WilmottRW , MatthewDJ , IngramD , TysonSL . Improvement in lung function after nebulised salbutamol and ipratropium bromide in children with cystic fibrosis. In: 11th European Cystic Fibrosis Conference, 1982. Brussels. 1982:251. [CFGD REGISTER: IB77] ">Pitcher‐Wilmott 1982</a>). Five trials reported FEV<sub>1</sub> % predicted either as a per cent change (<a href="./references#CD013666-bbs2-0010" title="WiebickeW , PoynterA , MontgomeryM , PagtakhanR . The effect of ipratropium bromide on lung function in patients with cystic fibrosis. Pneumologie1990;44 Suppl 1(1):277-8. [CFGD REGISTER: IB59] ">Wiebicke 1990</a>), post‐treatment value (<a href="./references#CD013666-bbs2-0001" title="DoddJ , BarryS , GallagherC . The effects of inhaled B2 agonists on maximal exercise in patients with cystic fibrosis . American Journal of Respiratory and Critical Care Medicine2001;163(5 Suppl):A88. [CFGD REGISTER: IB84a] DoddJD , BarrySC , DalyLE , GallagherCG . Inhaled beta-agonists improve lung function but not maximal exercise capacity in cystic fibrosis. Journal of Cystic Fibrosis2005;4(2):101-5. [CFGD REGISTER: IB84b] ">Dodd 2005</a>), or narratively (<a href="./references#CD013666-bbs2-0002" title="DuncanFR , PenkethAR , HodsonME , BattenJC . The use of bronchodilators as an adjunct to physiotherapy, in adults with cystic fibrosis. In: 11th European Cystic Fibrosis Conference, 1982; Brussels. 1982:48. [CFGD REGISTER: IB70] ">Duncan 1982</a>; <a href="./references#CD013666-bbs2-0003" title="EgglestonPA , RosensteinBJ , StackhouseCM , MellitsED , BaumgardnerRA . A controlled trial of long-term bronchodilator therapy in cystic fibrosis. Chest1991;99(5):1088-92. [CFGD REGISTER: IB61a] OrensteinD . Long-term inhaled bronchodilator therapy in cystic fibrosis. Comment on Eggleston PA, Rosenstein BJ, Stackhouse CM, Mellits ED, Baumgardner RA. A controlled trial of long-term bronchodilator therapy in cystic fibrosis. Chest 1991;99(5):1088-92. Chest1991;99(5):1061. [CFGD REGISTER: IB61b] ">Eggleston 1991</a>; <a href="./references#CD013666-bbs2-0005" title="KonigP , PoehlerJ , BarberoGJ . A placebo-controlled, double-blind trial of the long-term effects of albuterol administration in patients with cystic fibrosis. Pediatric Pulmonology1998;25(1):32-6. [CFGD REGISTER: IB74b] KonigP , PoehlerJ , BarberoGJ . Long-term effects of albuterol (A) in cystic fibrosis (CF) - A controlled trial. Pediatric Pulmonology1996;Suppl 13:302. [CFGD REGISTER: IB74a] ">Konig 1996</a>). </p> <p>None of the trials reported on quality of life, and only one trial reported on the number of exacerbations, defined by number of hospitalisations, courses of oral, intravenous (IV) or inhaled antibiotics (<a href="./references#CD013666-bbs2-0005" title="KonigP , PoehlerJ , BarberoGJ . A placebo-controlled, double-blind trial of the long-term effects of albuterol administration in patients with cystic fibrosis. Pediatric Pulmonology1998;25(1):32-6. [CFGD REGISTER: IB74b] KonigP , PoehlerJ , BarberoGJ . Long-term effects of albuterol (A) in cystic fibrosis (CF) - A controlled trial. Pediatric Pulmonology1996;Suppl 13:302. [CFGD REGISTER: IB74a] ">Konig 1996</a>). </p> <p>One trial measured participant‐reported outcomes by way of a symptom score, which was reported narratively (<a href="./references#CD013666-bbs2-0003" title="EgglestonPA , RosensteinBJ , StackhouseCM , MellitsED , BaumgardnerRA . A controlled trial of long-term bronchodilator therapy in cystic fibrosis. Chest1991;99(5):1088-92. [CFGD REGISTER: IB61a] OrensteinD . Long-term inhaled bronchodilator therapy in cystic fibrosis. Comment on Eggleston PA, Rosenstein BJ, Stackhouse CM, Mellits ED, Baumgardner RA. A controlled trial of long-term bronchodilator therapy in cystic fibrosis. Chest 1991;99(5):1088-92. Chest1991;99(5):1061. [CFGD REGISTER: IB61b] ">Eggleston 1991</a>). Adverse events were commented on narratively in four trials (<a href="./references#CD013666-bbs2-0001" title="DoddJ , BarryS , GallagherC . The effects of inhaled B2 agonists on maximal exercise in patients with cystic fibrosis . American Journal of Respiratory and Critical Care Medicine2001;163(5 Suppl):A88. [CFGD REGISTER: IB84a] DoddJD , BarrySC , DalyLE , GallagherCG . Inhaled beta-agonists improve lung function but not maximal exercise capacity in cystic fibrosis. Journal of Cystic Fibrosis2005;4(2):101-5. [CFGD REGISTER: IB84b] ">Dodd 2005</a>; <a href="./references#CD013666-bbs2-0003" title="EgglestonPA , RosensteinBJ , StackhouseCM , MellitsED , BaumgardnerRA . A controlled trial of long-term bronchodilator therapy in cystic fibrosis. Chest1991;99(5):1088-92. [CFGD REGISTER: IB61a] OrensteinD . Long-term inhaled bronchodilator therapy in cystic fibrosis. Comment on Eggleston PA, Rosenstein BJ, Stackhouse CM, Mellits ED, Baumgardner RA. A controlled trial of long-term bronchodilator therapy in cystic fibrosis. Chest 1991;99(5):1088-92. Chest1991;99(5):1061. [CFGD REGISTER: IB61b] ">Eggleston 1991</a>; <a href="./references#CD013666-bbs2-0009" title="WeintraubSJ , EschenbacherWL . The inhaled bronchodilators ipratropium bromide and metaproterenol in adults with CF. Chest1989;95(4):861-4. [CFGD REGISTER: IB58] ">Weintraub 1989</a>; <a href="./references#CD013666-bbs2-0011" title="ZiebachR , Pietsch-BreitfeldB , BichlerM , BuschA , RiethmullerJ , SternM . Bronchodilatory effects of salbutamol, ipratropium bromide, and their combination: double-blind, placebo-controlled crossover study in cystic fibrosis. Pediatric Pulmonology2001;31(6):431-5. [CFGD REGISTER: IB82] ">Ziebach 2001</a>). </p> <p>Eight of the trials measured lung function outcomes other than FEV<sub>1</sub> (<a href="./references#CD013666-bbs2-0002" title="DuncanFR , PenkethAR , HodsonME , BattenJC . The use of bronchodilators as an adjunct to physiotherapy, in adults with cystic fibrosis. In: 11th European Cystic Fibrosis Conference, 1982; Brussels. 1982:48. [CFGD REGISTER: IB70] ">Duncan 1982</a>; <a href="./references#CD013666-bbs2-0003" title="EgglestonPA , RosensteinBJ , StackhouseCM , MellitsED , BaumgardnerRA . A controlled trial of long-term bronchodilator therapy in cystic fibrosis. Chest1991;99(5):1088-92. [CFGD REGISTER: IB61a] OrensteinD . Long-term inhaled bronchodilator therapy in cystic fibrosis. Comment on Eggleston PA, Rosenstein BJ, Stackhouse CM, Mellits ED, Baumgardner RA. A controlled trial of long-term bronchodilator therapy in cystic fibrosis. Chest 1991;99(5):1088-92. Chest1991;99(5):1061. [CFGD REGISTER: IB61b] ">Eggleston 1991</a>; <a href="./references#CD013666-bbs2-0004" title="HordvikNL , SammutPH , JudyCG , StrizekSJ , ColomboJL . The effects of albuterol on the lung function of hospitalized patients with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine1996;154(1):156-60. [CFGD REGISTER: IB75] ">Hordvik 1996</a>; <a href="./references#CD013666-bbs2-0005" title="KonigP , PoehlerJ , BarberoGJ . A placebo-controlled, double-blind trial of the long-term effects of albuterol administration in patients with cystic fibrosis. Pediatric Pulmonology1998;25(1):32-6. [CFGD REGISTER: IB74b] KonigP , PoehlerJ , BarberoGJ . Long-term effects of albuterol (A) in cystic fibrosis (CF) - A controlled trial. Pediatric Pulmonology1996;Suppl 13:302. [CFGD REGISTER: IB74a] ">Konig 1996</a>; <a href="./references#CD013666-bbs2-0006" title="Pitcher-WilmottRW , MatthewDJ , IngramD , TysonSL . Improvement in lung function after nebulised salbutamol and ipratropium bromide in children with cystic fibrosis. In: 11th European Cystic Fibrosis Conference, 1982. Brussels. 1982:251. [CFGD REGISTER: IB77] ">Pitcher‐Wilmott 1982</a>; <a href="./references#CD013666-bbs2-0007" title="SanchezI , HolbrowJ , ChernickV . Acute bronchodilator response to a combination of beta-adrenergic and anticholinergic agents in patients with cystic fibrosis. Journal of Pediatrics1992;120(3):486-8. [CFGD REGISTER: IB63] ">Sanchez 1992</a>; <a href="./references#CD013666-bbs2-0010" title="WiebickeW , PoynterA , MontgomeryM , PagtakhanR . The effect of ipratropium bromide on lung function in patients with cystic fibrosis. Pneumologie1990;44 Suppl 1(1):277-8. [CFGD REGISTER: IB59] ">Wiebicke 1990</a>; <a href="./references#CD013666-bbs2-0011" title="ZiebachR , Pietsch-BreitfeldB , BichlerM , BuschA , RiethmullerJ , SternM . Bronchodilatory effects of salbutamol, ipratropium bromide, and their combination: double-blind, placebo-controlled crossover study in cystic fibrosis. Pediatric Pulmonology2001;31(6):431-5. [CFGD REGISTER: IB82] ">Ziebach 2001</a>). FVC was reported by six trials (<a href="./references#CD013666-bbs2-0002" title="DuncanFR , PenkethAR , HodsonME , BattenJC . The use of bronchodilators as an adjunct to physiotherapy, in adults with cystic fibrosis. In: 11th European Cystic Fibrosis Conference, 1982; Brussels. 1982:48. [CFGD REGISTER: IB70] ">Duncan 1982</a>; <a href="./references#CD013666-bbs2-0003" title="EgglestonPA , RosensteinBJ , StackhouseCM , MellitsED , BaumgardnerRA . A controlled trial of long-term bronchodilator therapy in cystic fibrosis. Chest1991;99(5):1088-92. [CFGD REGISTER: IB61a] OrensteinD . Long-term inhaled bronchodilator therapy in cystic fibrosis. Comment on Eggleston PA, Rosenstein BJ, Stackhouse CM, Mellits ED, Baumgardner RA. A controlled trial of long-term bronchodilator therapy in cystic fibrosis. Chest 1991;99(5):1088-92. Chest1991;99(5):1061. [CFGD REGISTER: IB61b] ">Eggleston 1991</a>; <a href="./references#CD013666-bbs2-0004" title="HordvikNL , SammutPH , JudyCG , StrizekSJ , ColomboJL . The effects of albuterol on the lung function of hospitalized patients with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine1996;154(1):156-60. [CFGD REGISTER: IB75] ">Hordvik 1996</a>; <a href="./references#CD013666-bbs2-0005" title="KonigP , PoehlerJ , BarberoGJ . A placebo-controlled, double-blind trial of the long-term effects of albuterol administration in patients with cystic fibrosis. Pediatric Pulmonology1998;25(1):32-6. [CFGD REGISTER: IB74b] KonigP , PoehlerJ , BarberoGJ . Long-term effects of albuterol (A) in cystic fibrosis (CF) - A controlled trial. Pediatric Pulmonology1996;Suppl 13:302. [CFGD REGISTER: IB74a] ">Konig 1996</a>; <a href="./references#CD013666-bbs2-0007" title="SanchezI , HolbrowJ , ChernickV . Acute bronchodilator response to a combination of beta-adrenergic and anticholinergic agents in patients with cystic fibrosis. Journal of Pediatrics1992;120(3):486-8. [CFGD REGISTER: IB63] ">Sanchez 1992</a>; <a href="./references#CD013666-bbs2-0011" title="ZiebachR , Pietsch-BreitfeldB , BichlerM , BuschA , RiethmullerJ , SternM . Bronchodilatory effects of salbutamol, ipratropium bromide, and their combination: double-blind, placebo-controlled crossover study in cystic fibrosis. Pediatric Pulmonology2001;31(6):431-5. [CFGD REGISTER: IB82] ">Ziebach 2001</a>), FEF<sub>25-75</sub> by seven trials (<a href="./references#CD013666-bbs2-0003" title="EgglestonPA , RosensteinBJ , StackhouseCM , MellitsED , BaumgardnerRA . A controlled trial of long-term bronchodilator therapy in cystic fibrosis. Chest1991;99(5):1088-92. [CFGD REGISTER: IB61a] OrensteinD . Long-term inhaled bronchodilator therapy in cystic fibrosis. Comment on Eggleston PA, Rosenstein BJ, Stackhouse CM, Mellits ED, Baumgardner RA. A controlled trial of long-term bronchodilator therapy in cystic fibrosis. Chest 1991;99(5):1088-92. Chest1991;99(5):1061. [CFGD REGISTER: IB61b] ">Eggleston 1991</a>; <a href="./references#CD013666-bbs2-0004" title="HordvikNL , SammutPH , JudyCG , StrizekSJ , ColomboJL . The effects of albuterol on the lung function of hospitalized patients with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine1996;154(1):156-60. [CFGD REGISTER: IB75] ">Hordvik 1996</a>; <a href="./references#CD013666-bbs2-0005" title="KonigP , PoehlerJ , BarberoGJ . A placebo-controlled, double-blind trial of the long-term effects of albuterol administration in patients with cystic fibrosis. Pediatric Pulmonology1998;25(1):32-6. [CFGD REGISTER: IB74b] KonigP , PoehlerJ , BarberoGJ . Long-term effects of albuterol (A) in cystic fibrosis (CF) - A controlled trial. Pediatric Pulmonology1996;Suppl 13:302. [CFGD REGISTER: IB74a] ">Konig 1996</a>; <a href="./references#CD013666-bbs2-0006" title="Pitcher-WilmottRW , MatthewDJ , IngramD , TysonSL . Improvement in lung function after nebulised salbutamol and ipratropium bromide in children with cystic fibrosis. In: 11th European Cystic Fibrosis Conference, 1982. Brussels. 1982:251. [CFGD REGISTER: IB77] ">Pitcher‐Wilmott 1982</a>; <a href="./references#CD013666-bbs2-0007" title="SanchezI , HolbrowJ , ChernickV . Acute bronchodilator response to a combination of beta-adrenergic and anticholinergic agents in patients with cystic fibrosis. Journal of Pediatrics1992;120(3):486-8. [CFGD REGISTER: IB63] ">Sanchez 1992</a>; <a href="./references#CD013666-bbs2-0009" title="WeintraubSJ , EschenbacherWL . The inhaled bronchodilators ipratropium bromide and metaproterenol in adults with CF. Chest1989;95(4):861-4. [CFGD REGISTER: IB58] ">Weintraub 1989</a>; <a href="./references#CD013666-bbs2-0011" title="ZiebachR , Pietsch-BreitfeldB , BichlerM , BuschA , RiethmullerJ , SternM . Bronchodilatory effects of salbutamol, ipratropium bromide, and their combination: double-blind, placebo-controlled crossover study in cystic fibrosis. Pediatric Pulmonology2001;31(6):431-5. [CFGD REGISTER: IB82] ">Ziebach 2001</a>), but none of the trials measured lung clearance index or bronchial hyperreactivity. One trial gave a narrative account of airway clearance (<a href="./references#CD013666-bbs2-0002" title="DuncanFR , PenkethAR , HodsonME , BattenJC . The use of bronchodilators as an adjunct to physiotherapy, in adults with cystic fibrosis. In: 11th European Cystic Fibrosis Conference, 1982; Brussels. 1982:48. [CFGD REGISTER: IB70] ">Duncan 1982</a>). </p> </section> </section> <section id="CD013666-sec-0051"> <h4 class="title">Excluded studies</h4> <p>We excluded 17 trials from the review and have listed these along with reasons for exclusion (<a href="./references#CD013666-sec-0150" title="">Characteristics of excluded studies</a>). The most common reason for exclusion was where the trial did not measure our predefined outcomes (<a href="./references#CD013666-bbs2-0012" title="ChuaHL , MelJ , Le SouefPN . Prevention of ticarcillin-induced bronchoconstriction in cystic fibrosis by salbutamol pretreatment. American Review of Respiratory Disease1989;143(Suppl):A294. [CFGD REGISTER: IB73] ">Chua 1989</a>; <a href="./references#CD013666-bbs2-0013" title="ChuaHL , WalkerSL , LeSouefPN , SlyPD . Comparison of efficacy of salbutamol and sodium cromoglycate in the prevention of ticarcillin-induced bronchoconstriction. Pediatric Pulmonology1993;16(5):311-5. [CFGD REGISTER: IB68] ">Chua 1993</a>; <a href="./references#CD013666-bbs2-0020" title="MortensenJ , HansenA , FalkM , GrothS , KirketerpI . Lung mucociliary clearance in cystic fibrosis after inhalation of a beta-2-agonist. In: 17th European Cystic Fibrosis Conference, 1991 June 18‐21; Copenhagen, Denmark. 1991:119. [CFGD REGISTER: IB66a] MortensenJ , HansenA , FalkM , NielsenIK , GrothS . Reduced effect of inhaled beta 2-adrenergic agonists on lung mucociliary clearance in patients with cystic fibrosis. Chest1993;103(3):805-11. [CFGD REGISTER: IB66b] ">Mortensen 1993</a>; <a href="./references#CD013666-bbs2-0022" title="NCT03522831. A double-blind placebo-controlled crossover study to assess the effects of bronchodilation on dyspnea, ventilatory responses, and exercise tolerance in adults with cystic fibrosis. clinicaltrials.gov/ct2/show/NCT03522831 (first received 11 May 2018). ">NCT03522831</a>; <a href="./references#CD013666-bbs2-0023" title="OrlikT , SandsD , KlubaL . The influence of bronchodilators on chest physiotherapy effect in children with CF. In: 12th European Respiratory Society Annual Congress, 2002 Sept 14-18; Stockholm. 2002:P2173. [CFGD REGISTER: IB83a] OrlikT , SandsD , KlubaL . The influence of bronchodilators on chest physiotherapy effect in children with CF. Journal of Cystic Fibrosis2002;1(Suppl 1):S180. [CFGD REGISTER: IB83b] ">Orlik 2002</a>; <a href="./references#CD013666-bbs2-0024" title="OrlikT , SandsD . Use of beta-mimetic during chest physiotherapy in patients with cystic fibrosis [Zastosowanie β-mimetyku w fizjoterapii chorych na mukowiscydozȩ]. Pediatria Polska2004;79(9):672-8. [CFGD REGISTER: IB112] ">Orlik 2004</a>). Four trials looked at the effects of combined treatments such as a combination of enzymotherapy with nebuliser therapy or combined bronchodilators (<a href="./references#CD013666-bbs2-0015" title="KattanM , MansellA , LevisonH , CoreyM , KrastinsIR . Response to aerosol salbutamol, SCH 1000, and placebo in cystic fibrosis. Thorax1980;35(7):531-5. [CFGD REGISTER: IB53] ">Kattan 1980</a>; <a href="./references#CD013666-bbs2-0016" title="KovalevaLF , GuembitskaiaTE , GorbenkoIA , Aleshin YuN. Combined systemic enzymotherapy and nebulizer therapy in the management of cystic fibrosis (CF) patients. In: 13th International Cystic Fibrosis Congress, 2000 June 4-8; Stockholm, Sweden. 2000:155. [CFGD REGISTER: IB91] ">Kovaleva 2000</a>; <a href="./references#CD013666-bbs2-0026" title="SanchezI , De KosterJ , HolbrowJ , ChernickV . The effect of high doses of inhaled salbutamol and ipratropium bromide in patients with stable cystic fibrosis. Chest1993;104(3):842-6. [CFGD REGISTER: IB67a] SanchezI . Role of anticholinergic agents in the treatment of cystic fibrosis. Archives de Pediatrie1995;2 Suppl 2:154S-8S. [CFGD REGISTER: IB67b] ">Sanchez 1993</a>; <a href="./references#CD013666-bbs2-0028" title="HolsclawDS , TecklinJS . The effectiveness of bronchial drainage and aerosol inhalation in cystic fibrosis. In: BaranD , Bogaert van, editors(s). Chest Physical Therapy in Cystic Fibrosis. Ghent: European Press, 1977:230-8. [CFGD REGISTER: PE2b] TecklinJS , Holsclaw DS Jr. Bronchial drainage with aerosol medications in cystic fibrosis. Physical Therapy1976;56(9):999-1003. [CFGD REGISTER: PE2a] ">Tecklin 1976</a>). Two trials involved irrelevant indications, one discussing the relationship with physiotherapy (<a href="./references#CD013666-bbs2-0017" title="KraemerD , LiedtkeC , Casaulta AebischerC . Bronchodilator inhalation (BD) treatment in sequence with flutter VRP1 chest physiotherapy (CPT) in patients with cystic fibrosis. Israel Journal of Medical Sciences1996;32(Suppl):S192. [CFGD REGISTER: IB72a] LiedtkeD , Casaulta AebischerC , MartinN , SchiblerA , KraemerR . Mucociliary clearance in patients with cystic fibrosis (CF) - Efficacy of beta2-inhalation therapy (beta2) in combination with respiratory physiotherapy. Schweizerische Medizinische Wochenschrift1996;126(Suppl 78):29S. [CFGD REGISTER: IB72b] ">Kraemer 1996</a>), and one comparing delivery devices rather than bronchodilator therapy (<a href="./references#CD013666-bbs2-0019" title="MarksJH , FooyC , AndersonK , HomnickDN . Nebulized albuterol delivered with positive expiratory pressure (PEP) and the flutter device in patients with cystic fibrosis: an assessment of bronchodilator response compared to standard nebulizer therapy. American Journal of Respiratory and Critical Care Medicine1998;157(3 Suppl):A130. [CFGD REGISTER: IB86] ">Marks 1998</a>). One trial of N‐acetyl cysteine (<a href="./references#CD013666-bbs2-0018" title="MaayanC , Bar-YishayE , YaacobiT , MarcusY , KatznelsonD , YahavY , et al. Immediate effect of various treatments on lung function in infants with cystic fibrosis. Respiration; International Review of Thoracic Diseases1989;55(3):144-51. [CFGD REGISTER: IB56] ">Maayan 1989</a>), and one trial of tiotropium (<a href="./references#CD013666-bbs2-0025" title="BradleyJM , KokerP , DengQ , Moroni-ZentgrafP , RatjenF , GellerDE , et al. Testing two different doses of tiotropium Respimat® in cystic fibrosis: phase 2 randomized trial results. PloS one2014;9(9):e106195. [CFGD REGISTER: IB99d] ElbornJS , SharmaA , DengQ , KokerP . A randomised, double-blind, placebo-controlled parallel group study to investigate the safety and efficacy of two doses of tiotropium bromide (2.5 µg and 5 µg) administered once daily via the Respimat® device for 12 weeks in patients with cystic fibrosis. Journal of cystic fibrosis2011;10 Suppl 1:S21. [ABSTRACT NO.: 80] [CFGD REGISTER: IB99b] GellerD , KokerP , ElbornJS , Le MaulfF , KattenbeckS , Moroni-ZentgrafP , et al. Tiotropium in cystic fibrosis: pooled analysis of phase II and III randomized controlled trials. Journal of Cystic Fibrosis2013;12 Suppl 1:S64. [ABSTRACT NO.: 64] [CFGD REGISTER: IB99c // IB100c] NCT00737100. Safety and efficacy of 12-wk treatment with two doses of tiotropium respimat in cystic fibrosis. clinicaltrials.gov/ct2/show/NCT00737100 (first received 18 August 2008). [CFGD REGISTER: IB99a] RatjenF , KokerP , GellerDE , Langellier-CocteauxB , Le MaulfF , KattenbeckS , et al. Tiotropium respimat in cystic fibrosis: phase 3 and Pooled phase 2/3 randomized trials. Journal of Cystic Fibrosis2015;14(5):608-14. [CFGD REGISTER: IB100d // IB99e] RatjenF , KokerP , GellerDE , Langellier-CocteauxB , Le MaulfF , KattenbeckS , et al. Tiotropium respimat in cystic fibrosis: phase 3 and Pooled phase 2/3 randomized trials. Journal of Cystic Fibrosis2015;14(5):608-14. Online Appendix A: supplementary data. [CFGD REGISTER: IB99g // IB100f] SharmaA , GellerDE , Moroni-ZentgrafP , KattenbeckS , SchmidM , BolandK , et al. Pooled analysis of tiotropium Respimat(®) pharmacokinetics in cystic fibrosis. Pulmonary Pharmacology &amp; Therapeutics2014;29(2):217-23. [CFGD REGISTER: IB99f // IB100d // IB114d] ">Ratjen 2015</a>), did not report on our predefined bronchodilators; one trial compared the inhaled therapy to IV therapy which was not one of our predefined comparators (<a href="./references#CD013666-bbs2-0014" title="FinneganMJ , HughesDV , HodsonME . A randomised prospective double blind comparison of the use of intravenous or nebulised terbutaline in addition to standard treatment in the management of infective pulmonary exacerbations of cystic fibrosis. In: 16th Annual Meeting of the European Working Group for Cystic Fibrosis, 1989; Prague, Czechoslovakia. 1989:192. [CFGD REGISTER: IB65a] FinneganMJ , HughesDV , HodsonME . Comparison of nebulized and intravenous terbutaline during exacerbations of pulmonary infection in patients with cystic fibrosis. European Respiratory Journal1992;5(9):1089-91. [CFGD REGISTER: IB65b] ">Finnegan 1992</a>). It was unclear whether one trial was randomised (<a href="./references#CD013666-bbs2-0027" title="SheehanDW , GoldsteinA , WoodardS , McCoyK , CastileR . Factors influencing albuterol responsiveness in infants and young children with cystic fibrosis. Pediatric Pulmonology2003;36(Suppl 25):323. [CFGD REGISTER: IB87] ">Sheehan 2003</a>), and one trial has been suspended (<a href="./references#CD013666-bbs2-0021" title="NCT00005110. A multi-centered study of the long-term effect of salmeterol and albuterol in cystic fibrosis. clinicaltrials.gov/show/NCT00005110 (first received 14 April 2000). [CFGD REGISTER: IB130] ">NCT00005110</a>). </p> </section> </section> <section id="CD013666-sec-0052"> <h3 class="title">Risk of bias in included studies</h3> <p>We have presented a summary of our risk of bias judgements (<a href="#CD013666-fig-0002">Figure 2</a>). </p> <div class="figure" id="CD013666-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included trial." data-id="CD013666-fig-0002" src="/cdsr/doi/10.1002/14651858.CD013666.pub2/media/CDSR/CD013666/image_n/nCD013666-FIG-02.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included trial. </p> </div> </div> </div> <section id="CD013666-sec-0053"> <h4 class="title">Allocation</h4> <section id="CD013666-sec-0054"> <h5 class="title">Sequence generation</h5> <p>We judged five of the trials as being at low risk of bias for this domain as the process was described and involved a centrally‐generated computer code or table (<a href="./references#CD013666-bbs2-0003" title="EgglestonPA , RosensteinBJ , StackhouseCM , MellitsED , BaumgardnerRA . A controlled trial of long-term bronchodilator therapy in cystic fibrosis. Chest1991;99(5):1088-92. [CFGD REGISTER: IB61a] OrensteinD . Long-term inhaled bronchodilator therapy in cystic fibrosis. Comment on Eggleston PA, Rosenstein BJ, Stackhouse CM, Mellits ED, Baumgardner RA. A controlled trial of long-term bronchodilator therapy in cystic fibrosis. Chest 1991;99(5):1088-92. Chest1991;99(5):1061. [CFGD REGISTER: IB61b] ">Eggleston 1991</a>; <a href="./references#CD013666-bbs2-0004" title="HordvikNL , SammutPH , JudyCG , StrizekSJ , ColomboJL . The effects of albuterol on the lung function of hospitalized patients with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine1996;154(1):156-60. [CFGD REGISTER: IB75] ">Hordvik 1996</a>; <a href="./references#CD013666-bbs2-0005" title="KonigP , PoehlerJ , BarberoGJ . A placebo-controlled, double-blind trial of the long-term effects of albuterol administration in patients with cystic fibrosis. Pediatric Pulmonology1998;25(1):32-6. [CFGD REGISTER: IB74b] KonigP , PoehlerJ , BarberoGJ . Long-term effects of albuterol (A) in cystic fibrosis (CF) - A controlled trial. Pediatric Pulmonology1996;Suppl 13:302. [CFGD REGISTER: IB74a] ">Konig 1996</a>; <a href="./references#CD013666-bbs2-0008" title="SerisierDJ , CaotesAD , BowlerSD . Inhaled salbutamol does not improve maximal exercise performance in cystic fibrosis . Respirology2006;11(Suppl 2):A58. [CFGD REGISTER: IB81c] SerisierDJ , CoatesAD , BowlerSD . Effect of albuterol on maximal exercise capacity in cystic fibrosis. Chest2007;131(4):1181-7. [CFGD REGISTER: IB81b] SerisierDJ , Rice-McDonaldG , BowlerSD , CoatesAC . ß-adrenergic agonists do not improve exercise capacity in cystic fibrosis. Pediatric Pulmonology2000;30 Suppl 20:305. [CFGD REGISTER: IB81a] ">Serisier 2000</a>; <a href="./references#CD013666-bbs2-0011" title="ZiebachR , Pietsch-BreitfeldB , BichlerM , BuschA , RiethmullerJ , SternM . Bronchodilatory effects of salbutamol, ipratropium bromide, and their combination: double-blind, placebo-controlled crossover study in cystic fibrosis. Pediatric Pulmonology2001;31(6):431-5. [CFGD REGISTER: IB82] ">Ziebach 2001</a>). The remaining included trials all stated that they were randomised, but there was no description of the process and so we have deemed them to be at an unclear risk of bias (<a href="./references#CD013666-bbs2-0001" title="DoddJ , BarryS , GallagherC . The effects of inhaled B2 agonists on maximal exercise in patients with cystic fibrosis . American Journal of Respiratory and Critical Care Medicine2001;163(5 Suppl):A88. [CFGD REGISTER: IB84a] DoddJD , BarrySC , DalyLE , GallagherCG . Inhaled beta-agonists improve lung function but not maximal exercise capacity in cystic fibrosis. Journal of Cystic Fibrosis2005;4(2):101-5. [CFGD REGISTER: IB84b] ">Dodd 2005</a>; <a href="./references#CD013666-bbs2-0002" title="DuncanFR , PenkethAR , HodsonME , BattenJC . The use of bronchodilators as an adjunct to physiotherapy, in adults with cystic fibrosis. In: 11th European Cystic Fibrosis Conference, 1982; Brussels. 1982:48. [CFGD REGISTER: IB70] ">Duncan 1982</a>; <a href="./references#CD013666-bbs2-0006" title="Pitcher-WilmottRW , MatthewDJ , IngramD , TysonSL . Improvement in lung function after nebulised salbutamol and ipratropium bromide in children with cystic fibrosis. In: 11th European Cystic Fibrosis Conference, 1982. Brussels. 1982:251. [CFGD REGISTER: IB77] ">Pitcher‐Wilmott 1982</a>; <a href="./references#CD013666-bbs2-0007" title="SanchezI , HolbrowJ , ChernickV . Acute bronchodilator response to a combination of beta-adrenergic and anticholinergic agents in patients with cystic fibrosis. Journal of Pediatrics1992;120(3):486-8. [CFGD REGISTER: IB63] ">Sanchez 1992</a>; <a href="./references#CD013666-bbs2-0009" title="WeintraubSJ , EschenbacherWL . The inhaled bronchodilators ipratropium bromide and metaproterenol in adults with CF. Chest1989;95(4):861-4. [CFGD REGISTER: IB58] ">Weintraub 1989</a>; <a href="./references#CD013666-bbs2-0010" title="WiebickeW , PoynterA , MontgomeryM , PagtakhanR . The effect of ipratropium bromide on lung function in patients with cystic fibrosis. Pneumologie1990;44 Suppl 1(1):277-8. [CFGD REGISTER: IB59] ">Wiebicke 1990</a>). </p> </section> <section id="CD013666-sec-0055"> <h5 class="title">Allocation concealment</h5> <p>We judged allocation to be adequately concealed in four of the trials based on descriptions in the papers which stated that the code was allocated centrally or by an independent source, e.g. pharmacy department (<a href="./references#CD013666-bbs2-0003" title="EgglestonPA , RosensteinBJ , StackhouseCM , MellitsED , BaumgardnerRA . A controlled trial of long-term bronchodilator therapy in cystic fibrosis. Chest1991;99(5):1088-92. [CFGD REGISTER: IB61a] OrensteinD . Long-term inhaled bronchodilator therapy in cystic fibrosis. Comment on Eggleston PA, Rosenstein BJ, Stackhouse CM, Mellits ED, Baumgardner RA. A controlled trial of long-term bronchodilator therapy in cystic fibrosis. Chest 1991;99(5):1088-92. Chest1991;99(5):1061. [CFGD REGISTER: IB61b] ">Eggleston 1991</a>; <a href="./references#CD013666-bbs2-0004" title="HordvikNL , SammutPH , JudyCG , StrizekSJ , ColomboJL . The effects of albuterol on the lung function of hospitalized patients with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine1996;154(1):156-60. [CFGD REGISTER: IB75] ">Hordvik 1996</a>; <a href="./references#CD013666-bbs2-0008" title="SerisierDJ , CaotesAD , BowlerSD . Inhaled salbutamol does not improve maximal exercise performance in cystic fibrosis . Respirology2006;11(Suppl 2):A58. [CFGD REGISTER: IB81c] SerisierDJ , CoatesAD , BowlerSD . Effect of albuterol on maximal exercise capacity in cystic fibrosis. Chest2007;131(4):1181-7. [CFGD REGISTER: IB81b] SerisierDJ , Rice-McDonaldG , BowlerSD , CoatesAC . ß-adrenergic agonists do not improve exercise capacity in cystic fibrosis. Pediatric Pulmonology2000;30 Suppl 20:305. [CFGD REGISTER: IB81a] ">Serisier 2000</a>; <a href="./references#CD013666-bbs2-0011" title="ZiebachR , Pietsch-BreitfeldB , BichlerM , BuschA , RiethmullerJ , SternM . Bronchodilatory effects of salbutamol, ipratropium bromide, and their combination: double-blind, placebo-controlled crossover study in cystic fibrosis. Pediatric Pulmonology2001;31(6):431-5. [CFGD REGISTER: IB82] ">Ziebach 2001</a>). In the remaining trials there is no description of whether or how allocation was concealed and so we have deemed the risk of bias to be unclear (<a href="./references#CD013666-bbs2-0001" title="DoddJ , BarryS , GallagherC . The effects of inhaled B2 agonists on maximal exercise in patients with cystic fibrosis . American Journal of Respiratory and Critical Care Medicine2001;163(5 Suppl):A88. [CFGD REGISTER: IB84a] DoddJD , BarrySC , DalyLE , GallagherCG . Inhaled beta-agonists improve lung function but not maximal exercise capacity in cystic fibrosis. Journal of Cystic Fibrosis2005;4(2):101-5. [CFGD REGISTER: IB84b] ">Dodd 2005</a>; <a href="./references#CD013666-bbs2-0002" title="DuncanFR , PenkethAR , HodsonME , BattenJC . The use of bronchodilators as an adjunct to physiotherapy, in adults with cystic fibrosis. In: 11th European Cystic Fibrosis Conference, 1982; Brussels. 1982:48. [CFGD REGISTER: IB70] ">Duncan 1982</a>; <a href="./references#CD013666-bbs2-0005" title="KonigP , PoehlerJ , BarberoGJ . A placebo-controlled, double-blind trial of the long-term effects of albuterol administration in patients with cystic fibrosis. Pediatric Pulmonology1998;25(1):32-6. [CFGD REGISTER: IB74b] KonigP , PoehlerJ , BarberoGJ . Long-term effects of albuterol (A) in cystic fibrosis (CF) - A controlled trial. Pediatric Pulmonology1996;Suppl 13:302. [CFGD REGISTER: IB74a] ">Konig 1996</a>; <a href="./references#CD013666-bbs2-0006" title="Pitcher-WilmottRW , MatthewDJ , IngramD , TysonSL . Improvement in lung function after nebulised salbutamol and ipratropium bromide in children with cystic fibrosis. In: 11th European Cystic Fibrosis Conference, 1982. Brussels. 1982:251. [CFGD REGISTER: IB77] ">Pitcher‐Wilmott 1982</a>; <a href="./references#CD013666-bbs2-0007" title="SanchezI , HolbrowJ , ChernickV . Acute bronchodilator response to a combination of beta-adrenergic and anticholinergic agents in patients with cystic fibrosis. Journal of Pediatrics1992;120(3):486-8. [CFGD REGISTER: IB63] ">Sanchez 1992</a>; <a href="./references#CD013666-bbs2-0009" title="WeintraubSJ , EschenbacherWL . The inhaled bronchodilators ipratropium bromide and metaproterenol in adults with CF. Chest1989;95(4):861-4. [CFGD REGISTER: IB58] ">Weintraub 1989</a>; <a href="./references#CD013666-bbs2-0010" title="WiebickeW , PoynterA , MontgomeryM , PagtakhanR . The effect of ipratropium bromide on lung function in patients with cystic fibrosis. Pneumologie1990;44 Suppl 1(1):277-8. [CFGD REGISTER: IB59] ">Wiebicke 1990</a>). </p> </section> </section> <section id="CD013666-sec-0056"> <h4 class="title">Blinding</h4> <p>We deemed blinding of participants and trial personnel to be adequate in seven trials (<a href="./references#CD013666-bbs2-0001" title="DoddJ , BarryS , GallagherC . The effects of inhaled B2 agonists on maximal exercise in patients with cystic fibrosis . American Journal of Respiratory and Critical Care Medicine2001;163(5 Suppl):A88. [CFGD REGISTER: IB84a] DoddJD , BarrySC , DalyLE , GallagherCG . Inhaled beta-agonists improve lung function but not maximal exercise capacity in cystic fibrosis. Journal of Cystic Fibrosis2005;4(2):101-5. [CFGD REGISTER: IB84b] ">Dodd 2005</a>; <a href="./references#CD013666-bbs2-0003" title="EgglestonPA , RosensteinBJ , StackhouseCM , MellitsED , BaumgardnerRA . A controlled trial of long-term bronchodilator therapy in cystic fibrosis. Chest1991;99(5):1088-92. [CFGD REGISTER: IB61a] OrensteinD . Long-term inhaled bronchodilator therapy in cystic fibrosis. Comment on Eggleston PA, Rosenstein BJ, Stackhouse CM, Mellits ED, Baumgardner RA. A controlled trial of long-term bronchodilator therapy in cystic fibrosis. Chest 1991;99(5):1088-92. Chest1991;99(5):1061. [CFGD REGISTER: IB61b] ">Eggleston 1991</a>; <a href="./references#CD013666-bbs2-0004" title="HordvikNL , SammutPH , JudyCG , StrizekSJ , ColomboJL . The effects of albuterol on the lung function of hospitalized patients with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine1996;154(1):156-60. [CFGD REGISTER: IB75] ">Hordvik 1996</a>; <a href="./references#CD013666-bbs2-0007" title="SanchezI , HolbrowJ , ChernickV . Acute bronchodilator response to a combination of beta-adrenergic and anticholinergic agents in patients with cystic fibrosis. Journal of Pediatrics1992;120(3):486-8. [CFGD REGISTER: IB63] ">Sanchez 1992</a>; <a href="./references#CD013666-bbs2-0008" title="SerisierDJ , CaotesAD , BowlerSD . Inhaled salbutamol does not improve maximal exercise performance in cystic fibrosis . Respirology2006;11(Suppl 2):A58. [CFGD REGISTER: IB81c] SerisierDJ , CoatesAD , BowlerSD . Effect of albuterol on maximal exercise capacity in cystic fibrosis. Chest2007;131(4):1181-7. [CFGD REGISTER: IB81b] SerisierDJ , Rice-McDonaldG , BowlerSD , CoatesAC . ß-adrenergic agonists do not improve exercise capacity in cystic fibrosis. Pediatric Pulmonology2000;30 Suppl 20:305. [CFGD REGISTER: IB81a] ">Serisier 2000</a>; <a href="./references#CD013666-bbs2-0009" title="WeintraubSJ , EschenbacherWL . The inhaled bronchodilators ipratropium bromide and metaproterenol in adults with CF. Chest1989;95(4):861-4. [CFGD REGISTER: IB58] ">Weintraub 1989</a>; <a href="./references#CD013666-bbs2-0011" title="ZiebachR , Pietsch-BreitfeldB , BichlerM , BuschA , RiethmullerJ , SternM . Bronchodilatory effects of salbutamol, ipratropium bromide, and their combination: double-blind, placebo-controlled crossover study in cystic fibrosis. Pediatric Pulmonology2001;31(6):431-5. [CFGD REGISTER: IB82] ">Ziebach 2001</a>), but blinding of the outcome assessor only to be clear in five of the trials (<a href="./references#CD013666-bbs2-0003" title="EgglestonPA , RosensteinBJ , StackhouseCM , MellitsED , BaumgardnerRA . A controlled trial of long-term bronchodilator therapy in cystic fibrosis. Chest1991;99(5):1088-92. [CFGD REGISTER: IB61a] OrensteinD . Long-term inhaled bronchodilator therapy in cystic fibrosis. Comment on Eggleston PA, Rosenstein BJ, Stackhouse CM, Mellits ED, Baumgardner RA. A controlled trial of long-term bronchodilator therapy in cystic fibrosis. Chest 1991;99(5):1088-92. Chest1991;99(5):1061. [CFGD REGISTER: IB61b] ">Eggleston 1991</a>; <a href="./references#CD013666-bbs2-0004" title="HordvikNL , SammutPH , JudyCG , StrizekSJ , ColomboJL . The effects of albuterol on the lung function of hospitalized patients with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine1996;154(1):156-60. [CFGD REGISTER: IB75] ">Hordvik 1996</a>; <a href="./references#CD013666-bbs2-0007" title="SanchezI , HolbrowJ , ChernickV . Acute bronchodilator response to a combination of beta-adrenergic and anticholinergic agents in patients with cystic fibrosis. Journal of Pediatrics1992;120(3):486-8. [CFGD REGISTER: IB63] ">Sanchez 1992</a>; <a href="./references#CD013666-bbs2-0008" title="SerisierDJ , CaotesAD , BowlerSD . Inhaled salbutamol does not improve maximal exercise performance in cystic fibrosis . Respirology2006;11(Suppl 2):A58. [CFGD REGISTER: IB81c] SerisierDJ , CoatesAD , BowlerSD . Effect of albuterol on maximal exercise capacity in cystic fibrosis. Chest2007;131(4):1181-7. [CFGD REGISTER: IB81b] SerisierDJ , Rice-McDonaldG , BowlerSD , CoatesAC . ß-adrenergic agonists do not improve exercise capacity in cystic fibrosis. Pediatric Pulmonology2000;30 Suppl 20:305. [CFGD REGISTER: IB81a] ">Serisier 2000</a>; <a href="./references#CD013666-bbs2-0011" title="ZiebachR , Pietsch-BreitfeldB , BichlerM , BuschA , RiethmullerJ , SternM . Bronchodilatory effects of salbutamol, ipratropium bromide, and their combination: double-blind, placebo-controlled crossover study in cystic fibrosis. Pediatric Pulmonology2001;31(6):431-5. [CFGD REGISTER: IB82] ">Ziebach 2001</a>). Where trials have stated that the trial was double‐blind but the paper did not specify which parties were blinded, we judged the risk of bias to be unclear (<a href="./references#CD013666-bbs2-0001" title="DoddJ , BarryS , GallagherC . The effects of inhaled B2 agonists on maximal exercise in patients with cystic fibrosis . American Journal of Respiratory and Critical Care Medicine2001;163(5 Suppl):A88. [CFGD REGISTER: IB84a] DoddJD , BarrySC , DalyLE , GallagherCG . Inhaled beta-agonists improve lung function but not maximal exercise capacity in cystic fibrosis. Journal of Cystic Fibrosis2005;4(2):101-5. [CFGD REGISTER: IB84b] ">Dodd 2005</a>; <a href="./references#CD013666-bbs2-0010" title="WiebickeW , PoynterA , MontgomeryM , PagtakhanR . The effect of ipratropium bromide on lung function in patients with cystic fibrosis. Pneumologie1990;44 Suppl 1(1):277-8. [CFGD REGISTER: IB59] ">Wiebicke 1990</a>). The remaining four trials did not describe the blinding of outcome assessors (<a href="./references#CD013666-bbs2-0002" title="DuncanFR , PenkethAR , HodsonME , BattenJC . The use of bronchodilators as an adjunct to physiotherapy, in adults with cystic fibrosis. In: 11th European Cystic Fibrosis Conference, 1982; Brussels. 1982:48. [CFGD REGISTER: IB70] ">Duncan 1982</a>; <a href="./references#CD013666-bbs2-0005" title="KonigP , PoehlerJ , BarberoGJ . A placebo-controlled, double-blind trial of the long-term effects of albuterol administration in patients with cystic fibrosis. Pediatric Pulmonology1998;25(1):32-6. [CFGD REGISTER: IB74b] KonigP , PoehlerJ , BarberoGJ . Long-term effects of albuterol (A) in cystic fibrosis (CF) - A controlled trial. Pediatric Pulmonology1996;Suppl 13:302. [CFGD REGISTER: IB74a] ">Konig 1996</a>; <a href="./references#CD013666-bbs2-0006" title="Pitcher-WilmottRW , MatthewDJ , IngramD , TysonSL . Improvement in lung function after nebulised salbutamol and ipratropium bromide in children with cystic fibrosis. In: 11th European Cystic Fibrosis Conference, 1982. Brussels. 1982:251. [CFGD REGISTER: IB77] ">Pitcher‐Wilmott 1982</a>; <a href="./references#CD013666-bbs2-0009" title="WeintraubSJ , EschenbacherWL . The inhaled bronchodilators ipratropium bromide and metaproterenol in adults with CF. Chest1989;95(4):861-4. [CFGD REGISTER: IB58] ">Weintraub 1989</a>). </p> </section> <section id="CD013666-sec-0057"> <h4 class="title">Incomplete outcome data</h4> <p>Six trials reported outcome data on at least 85% of the participants and were deemed to be at low risk of bias from attrition (<a href="./references#CD013666-bbs2-0004" title="HordvikNL , SammutPH , JudyCG , StrizekSJ , ColomboJL . The effects of albuterol on the lung function of hospitalized patients with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine1996;154(1):156-60. [CFGD REGISTER: IB75] ">Hordvik 1996</a>; <a href="./references#CD013666-bbs2-0007" title="SanchezI , HolbrowJ , ChernickV . Acute bronchodilator response to a combination of beta-adrenergic and anticholinergic agents in patients with cystic fibrosis. Journal of Pediatrics1992;120(3):486-8. [CFGD REGISTER: IB63] ">Sanchez 1992</a>; <a href="./references#CD013666-bbs2-0008" title="SerisierDJ , CaotesAD , BowlerSD . Inhaled salbutamol does not improve maximal exercise performance in cystic fibrosis . Respirology2006;11(Suppl 2):A58. [CFGD REGISTER: IB81c] SerisierDJ , CoatesAD , BowlerSD . Effect of albuterol on maximal exercise capacity in cystic fibrosis. Chest2007;131(4):1181-7. [CFGD REGISTER: IB81b] SerisierDJ , Rice-McDonaldG , BowlerSD , CoatesAC . ß-adrenergic agonists do not improve exercise capacity in cystic fibrosis. Pediatric Pulmonology2000;30 Suppl 20:305. [CFGD REGISTER: IB81a] ">Serisier 2000</a>; <a href="./references#CD013666-bbs2-0009" title="WeintraubSJ , EschenbacherWL . The inhaled bronchodilators ipratropium bromide and metaproterenol in adults with CF. Chest1989;95(4):861-4. [CFGD REGISTER: IB58] ">Weintraub 1989</a>; <a href="./references#CD013666-bbs2-0010" title="WiebickeW , PoynterA , MontgomeryM , PagtakhanR . The effect of ipratropium bromide on lung function in patients with cystic fibrosis. Pneumologie1990;44 Suppl 1(1):277-8. [CFGD REGISTER: IB59] ">Wiebicke 1990</a>; <a href="./references#CD013666-bbs2-0011" title="ZiebachR , Pietsch-BreitfeldB , BichlerM , BuschA , RiethmullerJ , SternM . Bronchodilatory effects of salbutamol, ipratropium bromide, and their combination: double-blind, placebo-controlled crossover study in cystic fibrosis. Pediatric Pulmonology2001;31(6):431-5. [CFGD REGISTER: IB82] ">Ziebach 2001</a>). Of the remaining trials, we deemed the risk of attrition bias to be unclear for three trials (<a href="./references#CD013666-bbs2-0001" title="DoddJ , BarryS , GallagherC . The effects of inhaled B2 agonists on maximal exercise in patients with cystic fibrosis . American Journal of Respiratory and Critical Care Medicine2001;163(5 Suppl):A88. [CFGD REGISTER: IB84a] DoddJD , BarrySC , DalyLE , GallagherCG . Inhaled beta-agonists improve lung function but not maximal exercise capacity in cystic fibrosis. Journal of Cystic Fibrosis2005;4(2):101-5. [CFGD REGISTER: IB84b] ">Dodd 2005</a>; <a href="./references#CD013666-bbs2-0003" title="EgglestonPA , RosensteinBJ , StackhouseCM , MellitsED , BaumgardnerRA . A controlled trial of long-term bronchodilator therapy in cystic fibrosis. Chest1991;99(5):1088-92. [CFGD REGISTER: IB61a] OrensteinD . Long-term inhaled bronchodilator therapy in cystic fibrosis. Comment on Eggleston PA, Rosenstein BJ, Stackhouse CM, Mellits ED, Baumgardner RA. A controlled trial of long-term bronchodilator therapy in cystic fibrosis. Chest 1991;99(5):1088-92. Chest1991;99(5):1061. [CFGD REGISTER: IB61b] ">Eggleston 1991</a>; <a href="./references#CD013666-bbs2-0006" title="Pitcher-WilmottRW , MatthewDJ , IngramD , TysonSL . Improvement in lung function after nebulised salbutamol and ipratropium bromide in children with cystic fibrosis. In: 11th European Cystic Fibrosis Conference, 1982. Brussels. 1982:251. [CFGD REGISTER: IB77] ">Pitcher‐Wilmott 1982</a>), or high for two trials (<a href="./references#CD013666-bbs2-0002" title="DuncanFR , PenkethAR , HodsonME , BattenJC . The use of bronchodilators as an adjunct to physiotherapy, in adults with cystic fibrosis. In: 11th European Cystic Fibrosis Conference, 1982; Brussels. 1982:48. [CFGD REGISTER: IB70] ">Duncan 1982</a>; <a href="./references#CD013666-bbs2-0005" title="KonigP , PoehlerJ , BarberoGJ . A placebo-controlled, double-blind trial of the long-term effects of albuterol administration in patients with cystic fibrosis. Pediatric Pulmonology1998;25(1):32-6. [CFGD REGISTER: IB74b] KonigP , PoehlerJ , BarberoGJ . Long-term effects of albuterol (A) in cystic fibrosis (CF) - A controlled trial. Pediatric Pulmonology1996;Suppl 13:302. [CFGD REGISTER: IB74a] ">Konig 1996</a>). The <a href="./references#CD013666-bbs2-0001" title="DoddJ , BarryS , GallagherC . The effects of inhaled B2 agonists on maximal exercise in patients with cystic fibrosis . American Journal of Respiratory and Critical Care Medicine2001;163(5 Suppl):A88. [CFGD REGISTER: IB84a] DoddJD , BarrySC , DalyLE , GallagherCG . Inhaled beta-agonists improve lung function but not maximal exercise capacity in cystic fibrosis. Journal of Cystic Fibrosis2005;4(2):101-5. [CFGD REGISTER: IB84b] ">Dodd 2005</a> trial only recruited 10 participants and two of those were excluded from the analysis due to either a respiratory tract infection (n = 1) or because of a non‐maximal effort exercise test (n = 1); it is unclear how much of an effect this would have had on the results. In the <a href="./references#CD013666-bbs2-0003" title="EgglestonPA , RosensteinBJ , StackhouseCM , MellitsED , BaumgardnerRA . A controlled trial of long-term bronchodilator therapy in cystic fibrosis. Chest1991;99(5):1088-92. [CFGD REGISTER: IB61a] OrensteinD . Long-term inhaled bronchodilator therapy in cystic fibrosis. Comment on Eggleston PA, Rosenstein BJ, Stackhouse CM, Mellits ED, Baumgardner RA. A controlled trial of long-term bronchodilator therapy in cystic fibrosis. Chest 1991;99(5):1088-92. Chest1991;99(5):1061. [CFGD REGISTER: IB61b] ">Eggleston 1991</a> trial only 22 out of the 27 participants completed the trial; two participants were excluded due to non‐compliance, and three were excluded when they developed an exacerbation. Only 21 of the 30 recruited participants completed the <a href="./references#CD013666-bbs2-0005" title="KonigP , PoehlerJ , BarberoGJ . A placebo-controlled, double-blind trial of the long-term effects of albuterol administration in patients with cystic fibrosis. Pediatric Pulmonology1998;25(1):32-6. [CFGD REGISTER: IB74b] KonigP , PoehlerJ , BarberoGJ . Long-term effects of albuterol (A) in cystic fibrosis (CF) - A controlled trial. Pediatric Pulmonology1996;Suppl 13:302. [CFGD REGISTER: IB74a] ">Konig 1996</a> trial. With the power calculation based on 30 participants and more than a 15% dropout rate, we deemed this trial to be at high risk of bias from attrition. The <a href="./references#CD013666-bbs2-0002" title="DuncanFR , PenkethAR , HodsonME , BattenJC . The use of bronchodilators as an adjunct to physiotherapy, in adults with cystic fibrosis. In: 11th European Cystic Fibrosis Conference, 1982; Brussels. 1982:48. [CFGD REGISTER: IB70] ">Duncan 1982</a> trial reported within‐participant results for the salbutamol group only and did not give any results for the placebo arm. The Pitcher‐Wilmott trial was only published as an abstract and there was insufficient information to allow us to comment on attrition (<a href="./references#CD013666-bbs2-0006" title="Pitcher-WilmottRW , MatthewDJ , IngramD , TysonSL . Improvement in lung function after nebulised salbutamol and ipratropium bromide in children with cystic fibrosis. In: 11th European Cystic Fibrosis Conference, 1982. Brussels. 1982:251. [CFGD REGISTER: IB77] ">Pitcher‐Wilmott 1982</a>). </p> </section> <section id="CD013666-sec-0058"> <h4 class="title">Selective reporting</h4> <p>We found no evidence of selective reporting in eight of the included trials (<a href="./references#CD013666-bbs2-0001" title="DoddJ , BarryS , GallagherC . The effects of inhaled B2 agonists on maximal exercise in patients with cystic fibrosis . American Journal of Respiratory and Critical Care Medicine2001;163(5 Suppl):A88. [CFGD REGISTER: IB84a] DoddJD , BarrySC , DalyLE , GallagherCG . Inhaled beta-agonists improve lung function but not maximal exercise capacity in cystic fibrosis. Journal of Cystic Fibrosis2005;4(2):101-5. [CFGD REGISTER: IB84b] ">Dodd 2005</a>; <a href="./references#CD013666-bbs2-0003" title="EgglestonPA , RosensteinBJ , StackhouseCM , MellitsED , BaumgardnerRA . A controlled trial of long-term bronchodilator therapy in cystic fibrosis. Chest1991;99(5):1088-92. [CFGD REGISTER: IB61a] OrensteinD . Long-term inhaled bronchodilator therapy in cystic fibrosis. Comment on Eggleston PA, Rosenstein BJ, Stackhouse CM, Mellits ED, Baumgardner RA. A controlled trial of long-term bronchodilator therapy in cystic fibrosis. Chest 1991;99(5):1088-92. Chest1991;99(5):1061. [CFGD REGISTER: IB61b] ">Eggleston 1991</a>; <a href="./references#CD013666-bbs2-0004" title="HordvikNL , SammutPH , JudyCG , StrizekSJ , ColomboJL . The effects of albuterol on the lung function of hospitalized patients with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine1996;154(1):156-60. [CFGD REGISTER: IB75] ">Hordvik 1996</a>; <a href="./references#CD013666-bbs2-0005" title="KonigP , PoehlerJ , BarberoGJ . A placebo-controlled, double-blind trial of the long-term effects of albuterol administration in patients with cystic fibrosis. Pediatric Pulmonology1998;25(1):32-6. [CFGD REGISTER: IB74b] KonigP , PoehlerJ , BarberoGJ . Long-term effects of albuterol (A) in cystic fibrosis (CF) - A controlled trial. Pediatric Pulmonology1996;Suppl 13:302. [CFGD REGISTER: IB74a] ">Konig 1996</a>; <a href="./references#CD013666-bbs2-0008" title="SerisierDJ , CaotesAD , BowlerSD . Inhaled salbutamol does not improve maximal exercise performance in cystic fibrosis . Respirology2006;11(Suppl 2):A58. [CFGD REGISTER: IB81c] SerisierDJ , CoatesAD , BowlerSD . Effect of albuterol on maximal exercise capacity in cystic fibrosis. Chest2007;131(4):1181-7. [CFGD REGISTER: IB81b] SerisierDJ , Rice-McDonaldG , BowlerSD , CoatesAC . ß-adrenergic agonists do not improve exercise capacity in cystic fibrosis. Pediatric Pulmonology2000;30 Suppl 20:305. [CFGD REGISTER: IB81a] ">Serisier 2000</a>; <a href="./references#CD013666-bbs2-0009" title="WeintraubSJ , EschenbacherWL . The inhaled bronchodilators ipratropium bromide and metaproterenol in adults with CF. Chest1989;95(4):861-4. [CFGD REGISTER: IB58] ">Weintraub 1989</a>; <a href="./references#CD013666-bbs2-0010" title="WiebickeW , PoynterA , MontgomeryM , PagtakhanR . The effect of ipratropium bromide on lung function in patients with cystic fibrosis. Pneumologie1990;44 Suppl 1(1):277-8. [CFGD REGISTER: IB59] ">Wiebicke 1990</a>; <a href="./references#CD013666-bbs2-0011" title="ZiebachR , Pietsch-BreitfeldB , BichlerM , BuschA , RiethmullerJ , SternM . Bronchodilatory effects of salbutamol, ipratropium bromide, and their combination: double-blind, placebo-controlled crossover study in cystic fibrosis. Pediatric Pulmonology2001;31(6):431-5. [CFGD REGISTER: IB82] ">Ziebach 2001</a>). Both the <a href="./references#CD013666-bbs2-0002" title="DuncanFR , PenkethAR , HodsonME , BattenJC . The use of bronchodilators as an adjunct to physiotherapy, in adults with cystic fibrosis. In: 11th European Cystic Fibrosis Conference, 1982; Brussels. 1982:48. [CFGD REGISTER: IB70] ">Duncan 1982</a> trial and the <a href="./references#CD013666-bbs2-0006" title="Pitcher-WilmottRW , MatthewDJ , IngramD , TysonSL . Improvement in lung function after nebulised salbutamol and ipratropium bromide in children with cystic fibrosis. In: 11th European Cystic Fibrosis Conference, 1982. Brussels. 1982:251. [CFGD REGISTER: IB77] ">Pitcher‐Wilmott 1982</a> trial have only ever been published as an abstract, so we did not have enough information to judge whether there was reporting bias. We deemed the <a href="./references#CD013666-bbs2-0007" title="SanchezI , HolbrowJ , ChernickV . Acute bronchodilator response to a combination of beta-adrenergic and anticholinergic agents in patients with cystic fibrosis. Journal of Pediatrics1992;120(3):486-8. [CFGD REGISTER: IB63] ">Sanchez 1992</a> trial to be at high risk of reporting bias as the authors only reported outcome data for the nine out of 12 participants who had shown a previous response to bronchodilator therapy. </p> </section> <section id="CD013666-sec-0059"> <h4 class="title">Other potential sources of bias</h4> <p>The fact that the <a href="./references#CD013666-bbs2-0007" title="SanchezI , HolbrowJ , ChernickV . Acute bronchodilator response to a combination of beta-adrenergic and anticholinergic agents in patients with cystic fibrosis. Journal of Pediatrics1992;120(3):486-8. [CFGD REGISTER: IB63] ">Sanchez 1992</a> trial only reported on the participants who had shown a previous response to bronchodilator therapy biases the results in favour of bronchodilators. Similarly, the <a href="./references#CD013666-bbs2-0003" title="EgglestonPA , RosensteinBJ , StackhouseCM , MellitsED , BaumgardnerRA . A controlled trial of long-term bronchodilator therapy in cystic fibrosis. Chest1991;99(5):1088-92. [CFGD REGISTER: IB61a] OrensteinD . Long-term inhaled bronchodilator therapy in cystic fibrosis. Comment on Eggleston PA, Rosenstein BJ, Stackhouse CM, Mellits ED, Baumgardner RA. A controlled trial of long-term bronchodilator therapy in cystic fibrosis. Chest 1991;99(5):1088-92. Chest1991;99(5):1061. [CFGD REGISTER: IB61b] ">Eggleston 1991</a> trial recruited more methacholine responders than non‐responders, which could bias the results in favour of the bronchodilator. We have deemed both of these trials to be at high risk of bias from other sources (<a href="./references#CD013666-bbs2-0003" title="EgglestonPA , RosensteinBJ , StackhouseCM , MellitsED , BaumgardnerRA . A controlled trial of long-term bronchodilator therapy in cystic fibrosis. Chest1991;99(5):1088-92. [CFGD REGISTER: IB61a] OrensteinD . Long-term inhaled bronchodilator therapy in cystic fibrosis. Comment on Eggleston PA, Rosenstein BJ, Stackhouse CM, Mellits ED, Baumgardner RA. A controlled trial of long-term bronchodilator therapy in cystic fibrosis. Chest 1991;99(5):1088-92. Chest1991;99(5):1061. [CFGD REGISTER: IB61b] ">Eggleston 1991</a>; <a href="./references#CD013666-bbs2-0007" title="SanchezI , HolbrowJ , ChernickV . Acute bronchodilator response to a combination of beta-adrenergic and anticholinergic agents in patients with cystic fibrosis. Journal of Pediatrics1992;120(3):486-8. [CFGD REGISTER: IB63] ">Sanchez 1992</a>). </p> </section> </section> <section id="CD013666-sec-0060"> <h3 class="title" id="CD013666-sec-0060">Effects of interventions</h3> <p>See: <a href="./full#CD013666-tbl-0001"><b>Summary of findings 1</b> Short‐acting inhaled beta‐2 agonists compared with placebo for cystic fibrosis</a>; <a href="./full#CD013666-tbl-0002"><b>Summary of findings 2</b> Short‐acting inhaled muscarinic antagonists compared with placebo for cystic fibrosis</a>; <a href="./full#CD013666-tbl-0003"><b>Summary of findings 3</b> Short‐acting inhaled beta‐2 agonists compared with short‐acting inhaled muscarinic antagonists for cystic fibrosis</a> </p> <p>We graded the certainty of the evidence for those outcomes included in the summary of findings tables. For the definitions of these gradings, please refer to <a href="./full#CD013666-tbl-0001">summary of findings Table 1</a>; <a href="./full#CD013666-tbl-0002">summary of findings Table 2</a>; and <a href="./full#CD013666-tbl-0003">summary of findings Table 3</a>. We only report below those outcomes for which we have been able to record results. </p> <section id="CD013666-sec-0061"> <h4 class="title">Short‐acting inhaled beta‐2 agonists compared to placebo</h4> <p>Eight trials (158 participants) compared a beta‐2 agonist with placebo (<a href="./references#CD013666-bbs2-0001" title="DoddJ , BarryS , GallagherC . The effects of inhaled B2 agonists on maximal exercise in patients with cystic fibrosis . American Journal of Respiratory and Critical Care Medicine2001;163(5 Suppl):A88. [CFGD REGISTER: IB84a] DoddJD , BarrySC , DalyLE , GallagherCG . Inhaled beta-agonists improve lung function but not maximal exercise capacity in cystic fibrosis. Journal of Cystic Fibrosis2005;4(2):101-5. [CFGD REGISTER: IB84b] ">Dodd 2005</a>; <a href="./references#CD013666-bbs2-0002" title="DuncanFR , PenkethAR , HodsonME , BattenJC . The use of bronchodilators as an adjunct to physiotherapy, in adults with cystic fibrosis. In: 11th European Cystic Fibrosis Conference, 1982; Brussels. 1982:48. [CFGD REGISTER: IB70] ">Duncan 1982</a>; <a href="./references#CD013666-bbs2-0003" title="EgglestonPA , RosensteinBJ , StackhouseCM , MellitsED , BaumgardnerRA . A controlled trial of long-term bronchodilator therapy in cystic fibrosis. Chest1991;99(5):1088-92. [CFGD REGISTER: IB61a] OrensteinD . Long-term inhaled bronchodilator therapy in cystic fibrosis. Comment on Eggleston PA, Rosenstein BJ, Stackhouse CM, Mellits ED, Baumgardner RA. A controlled trial of long-term bronchodilator therapy in cystic fibrosis. Chest 1991;99(5):1088-92. Chest1991;99(5):1061. [CFGD REGISTER: IB61b] ">Eggleston 1991</a>; <a href="./references#CD013666-bbs2-0004" title="HordvikNL , SammutPH , JudyCG , StrizekSJ , ColomboJL . The effects of albuterol on the lung function of hospitalized patients with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine1996;154(1):156-60. [CFGD REGISTER: IB75] ">Hordvik 1996</a>; <a href="./references#CD013666-bbs2-0005" title="KonigP , PoehlerJ , BarberoGJ . A placebo-controlled, double-blind trial of the long-term effects of albuterol administration in patients with cystic fibrosis. Pediatric Pulmonology1998;25(1):32-6. [CFGD REGISTER: IB74b] KonigP , PoehlerJ , BarberoGJ . Long-term effects of albuterol (A) in cystic fibrosis (CF) - A controlled trial. Pediatric Pulmonology1996;Suppl 13:302. [CFGD REGISTER: IB74a] ">Konig 1996</a>; <a href="./references#CD013666-bbs2-0006" title="Pitcher-WilmottRW , MatthewDJ , IngramD , TysonSL . Improvement in lung function after nebulised salbutamol and ipratropium bromide in children with cystic fibrosis. In: 11th European Cystic Fibrosis Conference, 1982. Brussels. 1982:251. [CFGD REGISTER: IB77] ">Pitcher‐Wilmott 1982</a>; <a href="./references#CD013666-bbs2-0008" title="SerisierDJ , CaotesAD , BowlerSD . Inhaled salbutamol does not improve maximal exercise performance in cystic fibrosis . Respirology2006;11(Suppl 2):A58. [CFGD REGISTER: IB81c] SerisierDJ , CoatesAD , BowlerSD . Effect of albuterol on maximal exercise capacity in cystic fibrosis. Chest2007;131(4):1181-7. [CFGD REGISTER: IB81b] SerisierDJ , Rice-McDonaldG , BowlerSD , CoatesAC . ß-adrenergic agonists do not improve exercise capacity in cystic fibrosis. Pediatric Pulmonology2000;30 Suppl 20:305. [CFGD REGISTER: IB81a] ">Serisier 2000</a>; <a href="./references#CD013666-bbs2-0011" title="ZiebachR , Pietsch-BreitfeldB , BichlerM , BuschA , RiethmullerJ , SternM . Bronchodilatory effects of salbutamol, ipratropium bromide, and their combination: double-blind, placebo-controlled crossover study in cystic fibrosis. Pediatric Pulmonology2001;31(6):431-5. [CFGD REGISTER: IB82] ">Ziebach 2001</a>). Four trials (87 participants) looked at the effects of albuterol (<a href="./references#CD013666-bbs2-0003" title="EgglestonPA , RosensteinBJ , StackhouseCM , MellitsED , BaumgardnerRA . A controlled trial of long-term bronchodilator therapy in cystic fibrosis. Chest1991;99(5):1088-92. [CFGD REGISTER: IB61a] OrensteinD . Long-term inhaled bronchodilator therapy in cystic fibrosis. Comment on Eggleston PA, Rosenstein BJ, Stackhouse CM, Mellits ED, Baumgardner RA. A controlled trial of long-term bronchodilator therapy in cystic fibrosis. Chest 1991;99(5):1088-92. Chest1991;99(5):1061. [CFGD REGISTER: IB61b] ">Eggleston 1991</a>; <a href="./references#CD013666-bbs2-0004" title="HordvikNL , SammutPH , JudyCG , StrizekSJ , ColomboJL . The effects of albuterol on the lung function of hospitalized patients with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine1996;154(1):156-60. [CFGD REGISTER: IB75] ">Hordvik 1996</a>; <a href="./references#CD013666-bbs2-0005" title="KonigP , PoehlerJ , BarberoGJ . A placebo-controlled, double-blind trial of the long-term effects of albuterol administration in patients with cystic fibrosis. Pediatric Pulmonology1998;25(1):32-6. [CFGD REGISTER: IB74b] KonigP , PoehlerJ , BarberoGJ . Long-term effects of albuterol (A) in cystic fibrosis (CF) - A controlled trial. Pediatric Pulmonology1996;Suppl 13:302. [CFGD REGISTER: IB74a] ">Konig 1996</a>; <a href="./references#CD013666-bbs2-0008" title="SerisierDJ , CaotesAD , BowlerSD . Inhaled salbutamol does not improve maximal exercise performance in cystic fibrosis . Respirology2006;11(Suppl 2):A58. [CFGD REGISTER: IB81c] SerisierDJ , CoatesAD , BowlerSD . Effect of albuterol on maximal exercise capacity in cystic fibrosis. Chest2007;131(4):1181-7. [CFGD REGISTER: IB81b] SerisierDJ , Rice-McDonaldG , BowlerSD , CoatesAC . ß-adrenergic agonists do not improve exercise capacity in cystic fibrosis. Pediatric Pulmonology2000;30 Suppl 20:305. [CFGD REGISTER: IB81a] ">Serisier 2000</a>), and four trials (71 participants) looked at the effects of salbutamol (<a href="./references#CD013666-bbs2-0001" title="DoddJ , BarryS , GallagherC . The effects of inhaled B2 agonists on maximal exercise in patients with cystic fibrosis . American Journal of Respiratory and Critical Care Medicine2001;163(5 Suppl):A88. [CFGD REGISTER: IB84a] DoddJD , BarrySC , DalyLE , GallagherCG . Inhaled beta-agonists improve lung function but not maximal exercise capacity in cystic fibrosis. Journal of Cystic Fibrosis2005;4(2):101-5. [CFGD REGISTER: IB84b] ">Dodd 2005</a>; <a href="./references#CD013666-bbs2-0002" title="DuncanFR , PenkethAR , HodsonME , BattenJC . The use of bronchodilators as an adjunct to physiotherapy, in adults with cystic fibrosis. In: 11th European Cystic Fibrosis Conference, 1982; Brussels. 1982:48. [CFGD REGISTER: IB70] ">Duncan 1982</a>; <a href="./references#CD013666-bbs2-0006" title="Pitcher-WilmottRW , MatthewDJ , IngramD , TysonSL . Improvement in lung function after nebulised salbutamol and ipratropium bromide in children with cystic fibrosis. In: 11th European Cystic Fibrosis Conference, 1982. Brussels. 1982:251. [CFGD REGISTER: IB77] ">Pitcher‐Wilmott 1982</a>; <a href="./references#CD013666-bbs2-0011" title="ZiebachR , Pietsch-BreitfeldB , BichlerM , BuschA , RiethmullerJ , SternM . Bronchodilatory effects of salbutamol, ipratropium bromide, and their combination: double-blind, placebo-controlled crossover study in cystic fibrosis. Pediatric Pulmonology2001;31(6):431-5. [CFGD REGISTER: IB82] ">Ziebach 2001</a>). Six of the trials were single‐dose trials (<a href="./references#CD013666-bbs2-0001" title="DoddJ , BarryS , GallagherC . The effects of inhaled B2 agonists on maximal exercise in patients with cystic fibrosis . American Journal of Respiratory and Critical Care Medicine2001;163(5 Suppl):A88. [CFGD REGISTER: IB84a] DoddJD , BarrySC , DalyLE , GallagherCG . Inhaled beta-agonists improve lung function but not maximal exercise capacity in cystic fibrosis. Journal of Cystic Fibrosis2005;4(2):101-5. [CFGD REGISTER: IB84b] ">Dodd 2005</a>; <a href="./references#CD013666-bbs2-0002" title="DuncanFR , PenkethAR , HodsonME , BattenJC . The use of bronchodilators as an adjunct to physiotherapy, in adults with cystic fibrosis. In: 11th European Cystic Fibrosis Conference, 1982; Brussels. 1982:48. [CFGD REGISTER: IB70] ">Duncan 1982</a>; <a href="./references#CD013666-bbs2-0004" title="HordvikNL , SammutPH , JudyCG , StrizekSJ , ColomboJL . The effects of albuterol on the lung function of hospitalized patients with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine1996;154(1):156-60. [CFGD REGISTER: IB75] ">Hordvik 1996</a>; <a href="./references#CD013666-bbs2-0006" title="Pitcher-WilmottRW , MatthewDJ , IngramD , TysonSL . Improvement in lung function after nebulised salbutamol and ipratropium bromide in children with cystic fibrosis. In: 11th European Cystic Fibrosis Conference, 1982. Brussels. 1982:251. [CFGD REGISTER: IB77] ">Pitcher‐Wilmott 1982</a>; <a href="./references#CD013666-bbs2-0008" title="SerisierDJ , CaotesAD , BowlerSD . Inhaled salbutamol does not improve maximal exercise performance in cystic fibrosis . Respirology2006;11(Suppl 2):A58. [CFGD REGISTER: IB81c] SerisierDJ , CoatesAD , BowlerSD . Effect of albuterol on maximal exercise capacity in cystic fibrosis. Chest2007;131(4):1181-7. [CFGD REGISTER: IB81b] SerisierDJ , Rice-McDonaldG , BowlerSD , CoatesAC . ß-adrenergic agonists do not improve exercise capacity in cystic fibrosis. Pediatric Pulmonology2000;30 Suppl 20:305. [CFGD REGISTER: IB81a] ">Serisier 2000</a>; <a href="./references#CD013666-bbs2-0011" title="ZiebachR , Pietsch-BreitfeldB , BichlerM , BuschA , RiethmullerJ , SternM . Bronchodilatory effects of salbutamol, ipratropium bromide, and their combination: double-blind, placebo-controlled crossover study in cystic fibrosis. Pediatric Pulmonology2001;31(6):431-5. [CFGD REGISTER: IB82] ">Ziebach 2001</a>), one trial (22 participants) was short‐term and looked at the effects of each treatment arm over 2 weeks (<a href="./references#CD013666-bbs2-0003" title="EgglestonPA , RosensteinBJ , StackhouseCM , MellitsED , BaumgardnerRA . A controlled trial of long-term bronchodilator therapy in cystic fibrosis. Chest1991;99(5):1088-92. [CFGD REGISTER: IB61a] OrensteinD . Long-term inhaled bronchodilator therapy in cystic fibrosis. Comment on Eggleston PA, Rosenstein BJ, Stackhouse CM, Mellits ED, Baumgardner RA. A controlled trial of long-term bronchodilator therapy in cystic fibrosis. Chest 1991;99(5):1088-92. Chest1991;99(5):1061. [CFGD REGISTER: IB61b] ">Eggleston 1991</a>), and the remaining trial (21 participants) lasted over 1 year, with each treatment period lasting 6 months (<a href="./references#CD013666-bbs2-0005" title="KonigP , PoehlerJ , BarberoGJ . A placebo-controlled, double-blind trial of the long-term effects of albuterol administration in patients with cystic fibrosis. Pediatric Pulmonology1998;25(1):32-6. [CFGD REGISTER: IB74b] KonigP , PoehlerJ , BarberoGJ . Long-term effects of albuterol (A) in cystic fibrosis (CF) - A controlled trial. Pediatric Pulmonology1996;Suppl 13:302. [CFGD REGISTER: IB74a] ">Konig 1996</a>).  </p> <section id="CD013666-sec-0062"> <h5 class="title">Primary outcome</h5> <section id="CD013666-sec-0063"> <h6 class="title">1. Change from baseline in FEV<sub>1</sub> (L and % predicted) </h6> <p>All six of the single‐dose trials (115 participants) reported some measure of FEV<sub>1</sub> (<a href="./references#CD013666-bbs2-0001" title="DoddJ , BarryS , GallagherC . The effects of inhaled B2 agonists on maximal exercise in patients with cystic fibrosis . American Journal of Respiratory and Critical Care Medicine2001;163(5 Suppl):A88. [CFGD REGISTER: IB84a] DoddJD , BarrySC , DalyLE , GallagherCG . Inhaled beta-agonists improve lung function but not maximal exercise capacity in cystic fibrosis. Journal of Cystic Fibrosis2005;4(2):101-5. [CFGD REGISTER: IB84b] ">Dodd 2005</a>; <a href="./references#CD013666-bbs2-0002" title="DuncanFR , PenkethAR , HodsonME , BattenJC . The use of bronchodilators as an adjunct to physiotherapy, in adults with cystic fibrosis. In: 11th European Cystic Fibrosis Conference, 1982; Brussels. 1982:48. [CFGD REGISTER: IB70] ">Duncan 1982</a>; <a href="./references#CD013666-bbs2-0004" title="HordvikNL , SammutPH , JudyCG , StrizekSJ , ColomboJL . The effects of albuterol on the lung function of hospitalized patients with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine1996;154(1):156-60. [CFGD REGISTER: IB75] ">Hordvik 1996</a>; <a href="./references#CD013666-bbs2-0006" title="Pitcher-WilmottRW , MatthewDJ , IngramD , TysonSL . Improvement in lung function after nebulised salbutamol and ipratropium bromide in children with cystic fibrosis. In: 11th European Cystic Fibrosis Conference, 1982. Brussels. 1982:251. [CFGD REGISTER: IB77] ">Pitcher‐Wilmott 1982</a>; <a href="./references#CD013666-bbs2-0008" title="SerisierDJ , CaotesAD , BowlerSD . Inhaled salbutamol does not improve maximal exercise performance in cystic fibrosis . Respirology2006;11(Suppl 2):A58. [CFGD REGISTER: IB81c] SerisierDJ , CoatesAD , BowlerSD . Effect of albuterol on maximal exercise capacity in cystic fibrosis. Chest2007;131(4):1181-7. [CFGD REGISTER: IB81b] SerisierDJ , Rice-McDonaldG , BowlerSD , CoatesAC . ß-adrenergic agonists do not improve exercise capacity in cystic fibrosis. Pediatric Pulmonology2000;30 Suppl 20:305. [CFGD REGISTER: IB81a] ">Serisier 2000</a>; <a href="./references#CD013666-bbs2-0011" title="ZiebachR , Pietsch-BreitfeldB , BichlerM , BuschA , RiethmullerJ , SternM . Bronchodilatory effects of salbutamol, ipratropium bromide, and their combination: double-blind, placebo-controlled crossover study in cystic fibrosis. Pediatric Pulmonology2001;31(6):431-5. [CFGD REGISTER: IB82] ">Ziebach 2001</a>). Two longer trials (43 participants) also reported on FEV<sub>1</sub> % predicted (<a href="./references#CD013666-bbs2-0003" title="EgglestonPA , RosensteinBJ , StackhouseCM , MellitsED , BaumgardnerRA . A controlled trial of long-term bronchodilator therapy in cystic fibrosis. Chest1991;99(5):1088-92. [CFGD REGISTER: IB61a] OrensteinD . Long-term inhaled bronchodilator therapy in cystic fibrosis. Comment on Eggleston PA, Rosenstein BJ, Stackhouse CM, Mellits ED, Baumgardner RA. A controlled trial of long-term bronchodilator therapy in cystic fibrosis. Chest 1991;99(5):1088-92. Chest1991;99(5):1061. [CFGD REGISTER: IB61b] ">Eggleston 1991</a>; <a href="./references#CD013666-bbs2-0005" title="KonigP , PoehlerJ , BarberoGJ . A placebo-controlled, double-blind trial of the long-term effects of albuterol administration in patients with cystic fibrosis. Pediatric Pulmonology1998;25(1):32-6. [CFGD REGISTER: IB74b] KonigP , PoehlerJ , BarberoGJ . Long-term effects of albuterol (A) in cystic fibrosis (CF) - A controlled trial. Pediatric Pulmonology1996;Suppl 13:302. [CFGD REGISTER: IB74a] ">Konig 1996</a>). </p> <section id="CD013666-sec-0064"> <p><b>a. FEV<sub>1</sub> L </b></p> <p>Four trials (91 participants) measured FEV<sub>1</sub> L (<a href="./references#CD013666-bbs2-0004" title="HordvikNL , SammutPH , JudyCG , StrizekSJ , ColomboJL . The effects of albuterol on the lung function of hospitalized patients with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine1996;154(1):156-60. [CFGD REGISTER: IB75] ">Hordvik 1996</a>; <a href="./references#CD013666-bbs2-0006" title="Pitcher-WilmottRW , MatthewDJ , IngramD , TysonSL . Improvement in lung function after nebulised salbutamol and ipratropium bromide in children with cystic fibrosis. In: 11th European Cystic Fibrosis Conference, 1982. Brussels. 1982:251. [CFGD REGISTER: IB77] ">Pitcher‐Wilmott 1982</a>; <a href="./references#CD013666-bbs2-0008" title="SerisierDJ , CaotesAD , BowlerSD . Inhaled salbutamol does not improve maximal exercise performance in cystic fibrosis . Respirology2006;11(Suppl 2):A58. [CFGD REGISTER: IB81c] SerisierDJ , CoatesAD , BowlerSD . Effect of albuterol on maximal exercise capacity in cystic fibrosis. Chest2007;131(4):1181-7. [CFGD REGISTER: IB81b] SerisierDJ , Rice-McDonaldG , BowlerSD , CoatesAC . ß-adrenergic agonists do not improve exercise capacity in cystic fibrosis. Pediatric Pulmonology2000;30 Suppl 20:305. [CFGD REGISTER: IB81a] ">Serisier 2000</a>; <a href="./references#CD013666-bbs2-0011" title="ZiebachR , Pietsch-BreitfeldB , BichlerM , BuschA , RiethmullerJ , SternM . Bronchodilatory effects of salbutamol, ipratropium bromide, and their combination: double-blind, placebo-controlled crossover study in cystic fibrosis. Pediatric Pulmonology2001;31(6):431-5. [CFGD REGISTER: IB82] ">Ziebach 2001</a>), either as a per cent change from baseline or narratively.  </p> <p>The <a href="./references#CD013666-bbs2-0004" title="HordvikNL , SammutPH , JudyCG , StrizekSJ , ColomboJL . The effects of albuterol on the lung function of hospitalized patients with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine1996;154(1):156-60. [CFGD REGISTER: IB75] ">Hordvik 1996</a> trial used multiple doses of drug per day and showed a mean (standard error of mean; SEM) per cent increase in FEV<sub>1</sub> across the day with albuterol: 10.1% (2.8%); compared to saline: 3.9% (1.9%) (P = 0.036). The <a href="./references#CD013666-bbs2-0011" title="ZiebachR , Pietsch-BreitfeldB , BichlerM , BuschA , RiethmullerJ , SternM . Bronchodilatory effects of salbutamol, ipratropium bromide, and their combination: double-blind, placebo-controlled crossover study in cystic fibrosis. Pediatric Pulmonology2001;31(6):431-5. [CFGD REGISTER: IB82] ">Ziebach 2001</a> trial showed a significant increase in FEV<sub>1</sub> (SEM per cent change) with salbutamol: 7% (4%); compared to saline: ‐1% (0.3%). We were able to combine the data from these two trials in a meta‐analysis which showed a greater per cent change from baseline in FEV<sub>1</sub> L after beta‐2 agonists compared to placebo (MD 6.95%, 95% CI 1.88 to 12.02; 2 trials, 82 participants; <a href="./references#CD013666-fig-0003" title="">Analysis 1.1</a>).  </p> <p>The <a href="./references#CD013666-bbs2-0008" title="SerisierDJ , CaotesAD , BowlerSD . Inhaled salbutamol does not improve maximal exercise performance in cystic fibrosis . Respirology2006;11(Suppl 2):A58. [CFGD REGISTER: IB81c] SerisierDJ , CoatesAD , BowlerSD . Effect of albuterol on maximal exercise capacity in cystic fibrosis. Chest2007;131(4):1181-7. [CFGD REGISTER: IB81b] SerisierDJ , Rice-McDonaldG , BowlerSD , CoatesAC . ß-adrenergic agonists do not improve exercise capacity in cystic fibrosis. Pediatric Pulmonology2000;30 Suppl 20:305. [CFGD REGISTER: IB81a] ">Serisier 2000</a> trial reported that albuterol resulted in greater mean (standard deviation; SD) exercise‐induced bronchodilation than placebo: MD 0.3 L (0.15) compared to 0.15 L (0.11); MD 0.15 L, 95% CI 0.07 to 0.23; P &lt; 0.001; 1 trial, 20 participants (<a href="./references#CD013666-fig-0004" title="">Analysis 1.2</a>). </p> <p>The <a href="./references#CD013666-bbs2-0006" title="Pitcher-WilmottRW , MatthewDJ , IngramD , TysonSL . Improvement in lung function after nebulised salbutamol and ipratropium bromide in children with cystic fibrosis. In: 11th European Cystic Fibrosis Conference, 1982. Brussels. 1982:251. [CFGD REGISTER: IB77] ">Pitcher‐Wilmott 1982</a> trial narratively reported a significant increase in FEV<sub>1</sub> following salbutamol administration. </p> </section> <section id="CD013666-sec-0065"> <p><b>b. FEV<sub>1</sub> % predicted</b></p> <p>Four trials measured FEV<sub>1</sub> % predicted, but there were no analysable data (<a href="./references#CD013666-bbs2-0001" title="DoddJ , BarryS , GallagherC . The effects of inhaled B2 agonists on maximal exercise in patients with cystic fibrosis . American Journal of Respiratory and Critical Care Medicine2001;163(5 Suppl):A88. [CFGD REGISTER: IB84a] DoddJD , BarrySC , DalyLE , GallagherCG . Inhaled beta-agonists improve lung function but not maximal exercise capacity in cystic fibrosis. Journal of Cystic Fibrosis2005;4(2):101-5. [CFGD REGISTER: IB84b] ">Dodd 2005</a>; <a href="./references#CD013666-bbs2-0002" title="DuncanFR , PenkethAR , HodsonME , BattenJC . The use of bronchodilators as an adjunct to physiotherapy, in adults with cystic fibrosis. In: 11th European Cystic Fibrosis Conference, 1982; Brussels. 1982:48. [CFGD REGISTER: IB70] ">Duncan 1982</a>; <a href="./references#CD013666-bbs2-0003" title="EgglestonPA , RosensteinBJ , StackhouseCM , MellitsED , BaumgardnerRA . A controlled trial of long-term bronchodilator therapy in cystic fibrosis. Chest1991;99(5):1088-92. [CFGD REGISTER: IB61a] OrensteinD . Long-term inhaled bronchodilator therapy in cystic fibrosis. Comment on Eggleston PA, Rosenstein BJ, Stackhouse CM, Mellits ED, Baumgardner RA. A controlled trial of long-term bronchodilator therapy in cystic fibrosis. Chest 1991;99(5):1088-92. Chest1991;99(5):1061. [CFGD REGISTER: IB61b] ">Eggleston 1991</a>; <a href="./references#CD013666-bbs2-0005" title="KonigP , PoehlerJ , BarberoGJ . A placebo-controlled, double-blind trial of the long-term effects of albuterol administration in patients with cystic fibrosis. Pediatric Pulmonology1998;25(1):32-6. [CFGD REGISTER: IB74b] KonigP , PoehlerJ , BarberoGJ . Long-term effects of albuterol (A) in cystic fibrosis (CF) - A controlled trial. Pediatric Pulmonology1996;Suppl 13:302. [CFGD REGISTER: IB74a] ">Konig 1996</a>).  </p> <p><a href="./references#CD013666-bbs2-0001" title="DoddJ , BarryS , GallagherC . The effects of inhaled B2 agonists on maximal exercise in patients with cystic fibrosis . American Journal of Respiratory and Critical Care Medicine2001;163(5 Suppl):A88. [CFGD REGISTER: IB84a] DoddJD , BarrySC , DalyLE , GallagherCG . Inhaled beta-agonists improve lung function but not maximal exercise capacity in cystic fibrosis. Journal of Cystic Fibrosis2005;4(2):101-5. [CFGD REGISTER: IB84b] ">Dodd 2005</a> reported within‐group differences. In the salbutamol group the mean (SD) FEV<sub>1</sub> increased significantly post‐inhaler from 2.08% (0.81) to 2.30% (0.88) (P &lt; 0.001); and post‐exercise from 2.30% (0.88) to 2.37% (0.90) (P &lt; 0.05) compared to the placebo group where no statistically significant improvement was seen post‐inhaler (2.11% (0.80) to 2.13% (0.85), however a greater improvement was seen post‐exercise (2.13% (0.85) to 2.24% (0.90) (P &lt; 0.05)).  </p> <p>The <a href="./references#CD013666-bbs2-0002" title="DuncanFR , PenkethAR , HodsonME , BattenJC . The use of bronchodilators as an adjunct to physiotherapy, in adults with cystic fibrosis. In: 11th European Cystic Fibrosis Conference, 1982; Brussels. 1982:48. [CFGD REGISTER: IB70] ">Duncan 1982</a> trial reported an improvement in FEV<sub>1</sub> % predicted when nebulised salbutamol was given before physiotherapy, with a 15% improvement in 4 out of 16 participants and some improvement in 11 out of 16 participants, but no information was given for the placebo arm. </p> <p>A cross‐over trial (22 participants), where each treatment arm lasted 2 weeks (<a href="./references#CD013666-bbs2-0003" title="EgglestonPA , RosensteinBJ , StackhouseCM , MellitsED , BaumgardnerRA . A controlled trial of long-term bronchodilator therapy in cystic fibrosis. Chest1991;99(5):1088-92. [CFGD REGISTER: IB61a] OrensteinD . Long-term inhaled bronchodilator therapy in cystic fibrosis. Comment on Eggleston PA, Rosenstein BJ, Stackhouse CM, Mellits ED, Baumgardner RA. A controlled trial of long-term bronchodilator therapy in cystic fibrosis. Chest 1991;99(5):1088-92. Chest1991;99(5):1061. [CFGD REGISTER: IB61b] ">Eggleston 1991</a>), found that in responders to a methacholine challenge (a test of airway hyper‐responsiveness where a positive response suggests airway hyper‐reactivity), these participants are likely to respond better to bronchodilator therapy. Spirometry measures increased slightly whilst on albuterol and decreased when taking placebo, but these differences were not statistically significant. There was a 3% increase in FEV<sub>1</sub> % predicted after albuterol and a 3% decrease after placebo. In non‐responders there was a decrease from baseline in spirometry values after both albuterol and placebo; a 2% decrease in FEV<sub>1</sub> % predicted after albuterol and an 8% decrease after placebo. </p> <p>The longer‐term trial (21 participants) reported the change from baseline to the end of each 6‐month treatment period and found that FEV<sub>1</sub> % predicted increased by 12.1% in the albuterol arm (P &lt; 0.01) and 1.2% (not significant) in the placebo arm. Between group comparisons demonstrated no difference between albuterol and placebo (data not shown) (<a href="./references#CD013666-bbs2-0005" title="KonigP , PoehlerJ , BarberoGJ . A placebo-controlled, double-blind trial of the long-term effects of albuterol administration in patients with cystic fibrosis. Pediatric Pulmonology1998;25(1):32-6. [CFGD REGISTER: IB74b] KonigP , PoehlerJ , BarberoGJ . Long-term effects of albuterol (A) in cystic fibrosis (CF) - A controlled trial. Pediatric Pulmonology1996;Suppl 13:302. [CFGD REGISTER: IB74a] ">Konig 1996</a>). </p> <p>We deemed the certainty of the evidence for this outcome to be very low.</p> </section> </section> <section id="CD013666-sec-0066"> <h6 class="title">2. Quality of life</h6> <p>No trials reported on this outcome.</p> </section> <section id="CD013666-sec-0067"> <h6 class="title">3. Number of exacerbations of respiratory symptoms</h6> <section id="CD013666-sec-0068"> <p><b>a. Use of a scoring system</b></p> <p>No trial used a scoring system to define exacerbations.</p> </section> <section id="CD013666-sec-0069"> <p><b>b. Need for hospitalisation or antibiotics</b></p> <p>Only one longer‐term trial (21 participants) reported on exacerbations (number of hospitalisations; courses of oral, IV and inhaled antibiotics) (<a href="./references#CD013666-bbs2-0005" title="KonigP , PoehlerJ , BarberoGJ . A placebo-controlled, double-blind trial of the long-term effects of albuterol administration in patients with cystic fibrosis. Pediatric Pulmonology1998;25(1):32-6. [CFGD REGISTER: IB74b] KonigP , PoehlerJ , BarberoGJ . Long-term effects of albuterol (A) in cystic fibrosis (CF) - A controlled trial. Pediatric Pulmonology1996;Suppl 13:302. [CFGD REGISTER: IB74a] ">Konig 1996</a>). </p> <p>Trial investigators reported there were no statistically significant differences between albuterol and placebo with respect to the number of hospitalisations, although they observed a trend in favour of albuterol (1 day/participant on albuterol versus 2.6 days/participant on placebo). There were no differences in the number of courses or days of antibiotics between the albuterol and placebo groups (<a href="./references#CD013666-bbs2-0005" title="KonigP , PoehlerJ , BarberoGJ . A placebo-controlled, double-blind trial of the long-term effects of albuterol administration in patients with cystic fibrosis. Pediatric Pulmonology1998;25(1):32-6. [CFGD REGISTER: IB74b] KonigP , PoehlerJ , BarberoGJ . Long-term effects of albuterol (A) in cystic fibrosis (CF) - A controlled trial. Pediatric Pulmonology1996;Suppl 13:302. [CFGD REGISTER: IB74a] ">Konig 1996</a>). </p> <p>We graded the certainty of the evidence as very low.</p> </section> </section> </section> <section id="CD013666-sec-0070"> <h5 class="title">Secondary outcomes</h5> <section id="CD013666-sec-0071"> <h6 class="title">1. Participant‐reported outcomes</h6> <p>One trial (22 participants) used a symptom score to measure cough, wheeze and exercise tolerance. Investigators found that scores were low on average and did not change with treatment. Scores did not improve during the albuterol treatment periods in either methacholine challenge responders or non‐responders (<a href="./references#CD013666-bbs2-0003" title="EgglestonPA , RosensteinBJ , StackhouseCM , MellitsED , BaumgardnerRA . A controlled trial of long-term bronchodilator therapy in cystic fibrosis. Chest1991;99(5):1088-92. [CFGD REGISTER: IB61a] OrensteinD . Long-term inhaled bronchodilator therapy in cystic fibrosis. Comment on Eggleston PA, Rosenstein BJ, Stackhouse CM, Mellits ED, Baumgardner RA. A controlled trial of long-term bronchodilator therapy in cystic fibrosis. Chest 1991;99(5):1088-92. Chest1991;99(5):1061. [CFGD REGISTER: IB61b] ">Eggleston 1991</a>). We deemed the certainty of this evidence to be very low. </p> </section> <section id="CD013666-sec-0072"> <h6 class="title">2. Adverse events</h6> <section id="CD013666-sec-0073"> <p><b>a. Frequency of treatment‐related adverse events</b></p> <p>Three trials (47 participants) reported narratively on adverse events related to treatment. <a href="./references#CD013666-bbs2-0001" title="DoddJ , BarryS , GallagherC . The effects of inhaled B2 agonists on maximal exercise in patients with cystic fibrosis . American Journal of Respiratory and Critical Care Medicine2001;163(5 Suppl):A88. [CFGD REGISTER: IB84a] DoddJD , BarrySC , DalyLE , GallagherCG . Inhaled beta-agonists improve lung function but not maximal exercise capacity in cystic fibrosis. Journal of Cystic Fibrosis2005;4(2):101-5. [CFGD REGISTER: IB84b] ">Dodd 2005</a> stated there was no difference between salbutamol and placebo with regard to dyspnoea or leg discomfort. In the <a href="./references#CD013666-bbs2-0003" title="EgglestonPA , RosensteinBJ , StackhouseCM , MellitsED , BaumgardnerRA . A controlled trial of long-term bronchodilator therapy in cystic fibrosis. Chest1991;99(5):1088-92. [CFGD REGISTER: IB61a] OrensteinD . Long-term inhaled bronchodilator therapy in cystic fibrosis. Comment on Eggleston PA, Rosenstein BJ, Stackhouse CM, Mellits ED, Baumgardner RA. A controlled trial of long-term bronchodilator therapy in cystic fibrosis. Chest 1991;99(5):1088-92. Chest1991;99(5):1061. [CFGD REGISTER: IB61b] ">Eggleston 1991</a> trial, two participants reported mild tremors whilst taking albuterol; two participants also reported fatigue, difficulty concentrating or nervousness whilst taking albuterol, but one of these participants reported the same symptoms when taking the placebo. No adverse effects were reported in any treatment arm in the <a href="./references#CD013666-bbs2-0011" title="ZiebachR , Pietsch-BreitfeldB , BichlerM , BuschA , RiethmullerJ , SternM . Bronchodilatory effects of salbutamol, ipratropium bromide, and their combination: double-blind, placebo-controlled crossover study in cystic fibrosis. Pediatric Pulmonology2001;31(6):431-5. [CFGD REGISTER: IB82] ">Ziebach 2001</a> trial. We considered the certainty of evidence to be very low. </p> </section> <section id="CD013666-sec-0074"> <p><b>b. Severity of adverse events</b></p> <p>None of the trials reporting on adverse events presented these by severity.</p> </section> </section> <section id="CD013666-sec-0075"> <h6 class="title">3. Change from baseline in any other relevant measurements of lung function</h6> <section id="CD013666-sec-0076"> <p><b>a. FVC (L or % predicted)</b></p> <p>Three single‐dose trials (57 participants) reported on FVC (<a href="./references#CD013666-bbs2-0002" title="DuncanFR , PenkethAR , HodsonME , BattenJC . The use of bronchodilators as an adjunct to physiotherapy, in adults with cystic fibrosis. In: 11th European Cystic Fibrosis Conference, 1982; Brussels. 1982:48. [CFGD REGISTER: IB70] ">Duncan 1982</a>; <a href="./references#CD013666-bbs2-0004" title="HordvikNL , SammutPH , JudyCG , StrizekSJ , ColomboJL . The effects of albuterol on the lung function of hospitalized patients with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine1996;154(1):156-60. [CFGD REGISTER: IB75] ">Hordvik 1996</a>; <a href="./references#CD013666-bbs2-0011" title="ZiebachR , Pietsch-BreitfeldB , BichlerM , BuschA , RiethmullerJ , SternM . Bronchodilatory effects of salbutamol, ipratropium bromide, and their combination: double-blind, placebo-controlled crossover study in cystic fibrosis. Pediatric Pulmonology2001;31(6):431-5. [CFGD REGISTER: IB82] ">Ziebach 2001</a>); data from one trial only could be analysed (<a href="./references#CD013666-bbs2-0004" title="HordvikNL , SammutPH , JudyCG , StrizekSJ , ColomboJL . The effects of albuterol on the lung function of hospitalized patients with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine1996;154(1):156-60. [CFGD REGISTER: IB75] ">Hordvik 1996</a>). In the Hordvik trial, mean (SEM) FVC (L) increased across the day with albuterol (8.1% increase, 1.2%) compared to saline (3.5% increase, 1.4%); MD 4.60%, 95% CI 0.99 to 8.21; <a href="./references#CD013666-fig-0005" title="">Analysis 1.3</a>. <a href="./references#CD013666-bbs2-0002" title="DuncanFR , PenkethAR , HodsonME , BattenJC . The use of bronchodilators as an adjunct to physiotherapy, in adults with cystic fibrosis. In: 11th European Cystic Fibrosis Conference, 1982; Brussels. 1982:48. [CFGD REGISTER: IB70] ">Duncan 1982</a> reported little change in FVC on either salbutamol or placebo, and <a href="./references#CD013666-bbs2-0011" title="ZiebachR , Pietsch-BreitfeldB , BichlerM , BuschA , RiethmullerJ , SternM . Bronchodilatory effects of salbutamol, ipratropium bromide, and their combination: double-blind, placebo-controlled crossover study in cystic fibrosis. Pediatric Pulmonology2001;31(6):431-5. [CFGD REGISTER: IB82] ">Ziebach 2001</a> reported a significant improvement in FVC, but did not provide any data. </p> <p>The short‐term cross‐over trial (22 participants) reported a 1% increase in FVC after albuterol and a 2% decrease after placebo in methacholine challenge responders, while in non‐responders there was a 1% decrease in FVC after albuterol and a 5% decrease after placebo; none of the differences were statistically significant (<a href="./references#CD013666-bbs2-0003" title="EgglestonPA , RosensteinBJ , StackhouseCM , MellitsED , BaumgardnerRA . A controlled trial of long-term bronchodilator therapy in cystic fibrosis. Chest1991;99(5):1088-92. [CFGD REGISTER: IB61a] OrensteinD . Long-term inhaled bronchodilator therapy in cystic fibrosis. Comment on Eggleston PA, Rosenstein BJ, Stackhouse CM, Mellits ED, Baumgardner RA. A controlled trial of long-term bronchodilator therapy in cystic fibrosis. Chest 1991;99(5):1088-92. Chest1991;99(5):1061. [CFGD REGISTER: IB61b] ">Eggleston 1991</a>).  </p> <p>The longer‐term trial (21 participants) reported no difference in FVC between groups (<a href="./references#CD013666-bbs2-0005" title="KonigP , PoehlerJ , BarberoGJ . A placebo-controlled, double-blind trial of the long-term effects of albuterol administration in patients with cystic fibrosis. Pediatric Pulmonology1998;25(1):32-6. [CFGD REGISTER: IB74b] KonigP , PoehlerJ , BarberoGJ . Long-term effects of albuterol (A) in cystic fibrosis (CF) - A controlled trial. Pediatric Pulmonology1996;Suppl 13:302. [CFGD REGISTER: IB74a] ">Konig 1996</a>). </p> <p>We deemed the certainty of evidence to be very low.</p> </section> <section id="CD013666-sec-0077"> <p><b>b. FEF<sub>25-75</sub> </b></p> <p>Five trials (114 participants) reported on FEF<sub>25-75</sub> (<a href="./references#CD013666-bbs2-0003" title="EgglestonPA , RosensteinBJ , StackhouseCM , MellitsED , BaumgardnerRA . A controlled trial of long-term bronchodilator therapy in cystic fibrosis. Chest1991;99(5):1088-92. [CFGD REGISTER: IB61a] OrensteinD . Long-term inhaled bronchodilator therapy in cystic fibrosis. Comment on Eggleston PA, Rosenstein BJ, Stackhouse CM, Mellits ED, Baumgardner RA. A controlled trial of long-term bronchodilator therapy in cystic fibrosis. Chest 1991;99(5):1088-92. Chest1991;99(5):1061. [CFGD REGISTER: IB61b] ">Eggleston 1991</a>; <a href="./references#CD013666-bbs2-0004" title="HordvikNL , SammutPH , JudyCG , StrizekSJ , ColomboJL . The effects of albuterol on the lung function of hospitalized patients with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine1996;154(1):156-60. [CFGD REGISTER: IB75] ">Hordvik 1996</a>; <a href="./references#CD013666-bbs2-0005" title="KonigP , PoehlerJ , BarberoGJ . A placebo-controlled, double-blind trial of the long-term effects of albuterol administration in patients with cystic fibrosis. Pediatric Pulmonology1998;25(1):32-6. [CFGD REGISTER: IB74b] KonigP , PoehlerJ , BarberoGJ . Long-term effects of albuterol (A) in cystic fibrosis (CF) - A controlled trial. Pediatric Pulmonology1996;Suppl 13:302. [CFGD REGISTER: IB74a] ">Konig 1996</a>; <a href="./references#CD013666-bbs2-0006" title="Pitcher-WilmottRW , MatthewDJ , IngramD , TysonSL . Improvement in lung function after nebulised salbutamol and ipratropium bromide in children with cystic fibrosis. In: 11th European Cystic Fibrosis Conference, 1982. Brussels. 1982:251. [CFGD REGISTER: IB77] ">Pitcher‐Wilmott 1982</a>; <a href="./references#CD013666-bbs2-0011" title="ZiebachR , Pietsch-BreitfeldB , BichlerM , BuschA , RiethmullerJ , SternM . Bronchodilatory effects of salbutamol, ipratropium bromide, and their combination: double-blind, placebo-controlled crossover study in cystic fibrosis. Pediatric Pulmonology2001;31(6):431-5. [CFGD REGISTER: IB82] ">Ziebach 2001</a>). </p> <p>Three of these were single‐dose trials (<a href="./references#CD013666-bbs2-0004" title="HordvikNL , SammutPH , JudyCG , StrizekSJ , ColomboJL . The effects of albuterol on the lung function of hospitalized patients with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine1996;154(1):156-60. [CFGD REGISTER: IB75] ">Hordvik 1996</a>; <a href="./references#CD013666-bbs2-0006" title="Pitcher-WilmottRW , MatthewDJ , IngramD , TysonSL . Improvement in lung function after nebulised salbutamol and ipratropium bromide in children with cystic fibrosis. In: 11th European Cystic Fibrosis Conference, 1982. Brussels. 1982:251. [CFGD REGISTER: IB77] ">Pitcher‐Wilmott 1982</a>; <a href="./references#CD013666-bbs2-0011" title="ZiebachR , Pietsch-BreitfeldB , BichlerM , BuschA , RiethmullerJ , SternM . Bronchodilatory effects of salbutamol, ipratropium bromide, and their combination: double-blind, placebo-controlled crossover study in cystic fibrosis. Pediatric Pulmonology2001;31(6):431-5. [CFGD REGISTER: IB82] ">Ziebach 2001</a>), two of which reported a significant change in FEF<sub>25-75</sub> with salbutamol compared to saline, but provided no data (<a href="./references#CD013666-bbs2-0006" title="Pitcher-WilmottRW , MatthewDJ , IngramD , TysonSL . Improvement in lung function after nebulised salbutamol and ipratropium bromide in children with cystic fibrosis. In: 11th European Cystic Fibrosis Conference, 1982. Brussels. 1982:251. [CFGD REGISTER: IB77] ">Pitcher‐Wilmott 1982</a>; <a href="./references#CD013666-bbs2-0011" title="ZiebachR , Pietsch-BreitfeldB , BichlerM , BuschA , RiethmullerJ , SternM . Bronchodilatory effects of salbutamol, ipratropium bromide, and their combination: double-blind, placebo-controlled crossover study in cystic fibrosis. Pediatric Pulmonology2001;31(6):431-5. [CFGD REGISTER: IB82] ">Ziebach 2001</a>). Investigators in the <a href="./references#CD013666-bbs2-0004" title="HordvikNL , SammutPH , JudyCG , StrizekSJ , ColomboJL . The effects of albuterol on the lung function of hospitalized patients with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine1996;154(1):156-60. [CFGD REGISTER: IB75] ">Hordvik 1996</a> trial observed a non‐statistically significant increase in FEF<sub>25-75</sub> after albuterol compared to placebo, mean per cent change in the albuterol group was 9.7% compared to 2.6% with placebo (P = 0.23). </p> <p>The short‐term and longer‐term trials reported no effect of treatment on FEF<sub>25-75</sub> (<a href="./references#CD013666-bbs2-0003" title="EgglestonPA , RosensteinBJ , StackhouseCM , MellitsED , BaumgardnerRA . A controlled trial of long-term bronchodilator therapy in cystic fibrosis. Chest1991;99(5):1088-92. [CFGD REGISTER: IB61a] OrensteinD . Long-term inhaled bronchodilator therapy in cystic fibrosis. Comment on Eggleston PA, Rosenstein BJ, Stackhouse CM, Mellits ED, Baumgardner RA. A controlled trial of long-term bronchodilator therapy in cystic fibrosis. Chest 1991;99(5):1088-92. Chest1991;99(5):1061. [CFGD REGISTER: IB61b] ">Eggleston 1991</a>; <a href="./references#CD013666-bbs2-0005" title="KonigP , PoehlerJ , BarberoGJ . A placebo-controlled, double-blind trial of the long-term effects of albuterol administration in patients with cystic fibrosis. Pediatric Pulmonology1998;25(1):32-6. [CFGD REGISTER: IB74b] KonigP , PoehlerJ , BarberoGJ . Long-term effects of albuterol (A) in cystic fibrosis (CF) - A controlled trial. Pediatric Pulmonology1996;Suppl 13:302. [CFGD REGISTER: IB74a] ">Konig 1996</a>). </p> </section> <section id="CD013666-sec-0078"> <p><b>c. Lung clearance index</b></p> <p>No trial reported on lung function using lung clearance index.</p> </section> <section id="CD013666-sec-0079"> <p><b>d. Measures of bronchial hyper‐responsiveness and bronchodilator responsiveness</b></p> <p>No trial reported on this outcome.</p> </section> </section> <section id="CD013666-sec-0080"> <h6 class="title">4. Airway clearance</h6> <section id="CD013666-sec-0081"> <p><b>a. Sputum volume</b></p> <p>No trial reported on this outcome.</p> </section> <section id="CD013666-sec-0082"> <p><b>b. Weight (dry or wet) (g)</b></p> <p>One trial reported little change in sputum weight with either salbutamol or placebo, but provided no data and did not clarify if this was wet or dry weight (<a href="./references#CD013666-bbs2-0002" title="DuncanFR , PenkethAR , HodsonME , BattenJC . The use of bronchodilators as an adjunct to physiotherapy, in adults with cystic fibrosis. In: 11th European Cystic Fibrosis Conference, 1982; Brussels. 1982:48. [CFGD REGISTER: IB70] ">Duncan 1982</a>). We graded the certainty of this evidence as very low. </p> </section> </section> </section> </section> <section id="CD013666-sec-0083"> <h4 class="title">Short‐acting inhaled muscarinic antagonists compared to placebo</h4> <p>Four trials (68 participants) compared the effect of muscarinic antagonists to placebo. All were single‐dose cross‐over RCTs studying ipratropium bromide (<a href="./references#CD013666-bbs2-0006" title="Pitcher-WilmottRW , MatthewDJ , IngramD , TysonSL . Improvement in lung function after nebulised salbutamol and ipratropium bromide in children with cystic fibrosis. In: 11th European Cystic Fibrosis Conference, 1982. Brussels. 1982:251. [CFGD REGISTER: IB77] ">Pitcher‐Wilmott 1982</a>; <a href="./references#CD013666-bbs2-0009" title="WeintraubSJ , EschenbacherWL . The inhaled bronchodilators ipratropium bromide and metaproterenol in adults with CF. Chest1989;95(4):861-4. [CFGD REGISTER: IB58] ">Weintraub 1989</a>; <a href="./references#CD013666-bbs2-0010" title="WiebickeW , PoynterA , MontgomeryM , PagtakhanR . The effect of ipratropium bromide on lung function in patients with cystic fibrosis. Pneumologie1990;44 Suppl 1(1):277-8. [CFGD REGISTER: IB59] ">Wiebicke 1990</a>; <a href="./references#CD013666-bbs2-0011" title="ZiebachR , Pietsch-BreitfeldB , BichlerM , BuschA , RiethmullerJ , SternM . Bronchodilatory effects of salbutamol, ipratropium bromide, and their combination: double-blind, placebo-controlled crossover study in cystic fibrosis. Pediatric Pulmonology2001;31(6):431-5. [CFGD REGISTER: IB82] ">Ziebach 2001</a>). Three trials used nebulised ipratropium (<a href="./references#CD013666-bbs2-0006" title="Pitcher-WilmottRW , MatthewDJ , IngramD , TysonSL . Improvement in lung function after nebulised salbutamol and ipratropium bromide in children with cystic fibrosis. In: 11th European Cystic Fibrosis Conference, 1982. Brussels. 1982:251. [CFGD REGISTER: IB77] ">Pitcher‐Wilmott 1982</a>; <a href="./references#CD013666-bbs2-0010" title="WiebickeW , PoynterA , MontgomeryM , PagtakhanR . The effect of ipratropium bromide on lung function in patients with cystic fibrosis. Pneumologie1990;44 Suppl 1(1):277-8. [CFGD REGISTER: IB59] ">Wiebicke 1990</a>; <a href="./references#CD013666-bbs2-0011" title="ZiebachR , Pietsch-BreitfeldB , BichlerM , BuschA , RiethmullerJ , SternM . Bronchodilatory effects of salbutamol, ipratropium bromide, and their combination: double-blind, placebo-controlled crossover study in cystic fibrosis. Pediatric Pulmonology2001;31(6):431-5. [CFGD REGISTER: IB82] ">Ziebach 2001</a>), with the remaining trial using ipratropium delivered by MDI (<a href="./references#CD013666-bbs2-0009" title="WeintraubSJ , EschenbacherWL . The inhaled bronchodilators ipratropium bromide and metaproterenol in adults with CF. Chest1989;95(4):861-4. [CFGD REGISTER: IB58] ">Weintraub 1989</a>). </p> <section id="CD013666-sec-0084"> <h5 class="title">Primary outcomes</h5> <section id="CD013666-sec-0085"> <h6 class="title">1. Change from baseline in FEV<sub>1</sub> (L and % predicted) </h6> <p>One trial reported FEV<sub>1</sub> % predicted and stated that individual participants varied in their response to treatment (<a href="./references#CD013666-bbs2-0010" title="WiebickeW , PoynterA , MontgomeryM , PagtakhanR . The effect of ipratropium bromide on lung function in patients with cystic fibrosis. Pneumologie1990;44 Suppl 1(1):277-8. [CFGD REGISTER: IB59] ">Wiebicke 1990</a>). Mean values after inhalation of ipratropium or placebo were reported to be not significantly different, and the investigators concluded that before a person with CF is started on bronchodilator therapy, individual lung function tests should be performed (<a href="./references#CD013666-bbs2-0010" title="WiebickeW , PoynterA , MontgomeryM , PagtakhanR . The effect of ipratropium bromide on lung function in patients with cystic fibrosis. Pneumologie1990;44 Suppl 1(1):277-8. [CFGD REGISTER: IB59] ">Wiebicke 1990</a>). We graded the certainty of evidence as very low. </p> <p>The remaining three trials reported FEV<sub>1</sub> L (<a href="./references#CD013666-bbs2-0006" title="Pitcher-WilmottRW , MatthewDJ , IngramD , TysonSL . Improvement in lung function after nebulised salbutamol and ipratropium bromide in children with cystic fibrosis. In: 11th European Cystic Fibrosis Conference, 1982. Brussels. 1982:251. [CFGD REGISTER: IB77] ">Pitcher‐Wilmott 1982</a>; <a href="./references#CD013666-bbs2-0009" title="WeintraubSJ , EschenbacherWL . The inhaled bronchodilators ipratropium bromide and metaproterenol in adults with CF. Chest1989;95(4):861-4. [CFGD REGISTER: IB58] ">Weintraub 1989</a>; <a href="./references#CD013666-bbs2-0011" title="ZiebachR , Pietsch-BreitfeldB , BichlerM , BuschA , RiethmullerJ , SternM . Bronchodilatory effects of salbutamol, ipratropium bromide, and their combination: double-blind, placebo-controlled crossover study in cystic fibrosis. Pediatric Pulmonology2001;31(6):431-5. [CFGD REGISTER: IB82] ">Ziebach 2001</a>). <a href="./references#CD013666-bbs2-0006" title="Pitcher-WilmottRW , MatthewDJ , IngramD , TysonSL . Improvement in lung function after nebulised salbutamol and ipratropium bromide in children with cystic fibrosis. In: 11th European Cystic Fibrosis Conference, 1982. Brussels. 1982:251. [CFGD REGISTER: IB77] ">Pitcher‐Wilmott 1982</a> reported a significant increase in FEV<sub>1</sub> after ipratropium, but provided no data. <a href="./references#CD013666-bbs2-0009" title="WeintraubSJ , EschenbacherWL . The inhaled bronchodilators ipratropium bromide and metaproterenol in adults with CF. Chest1989;95(4):861-4. [CFGD REGISTER: IB58] ">Weintraub 1989</a> and <a href="./references#CD013666-bbs2-0011" title="ZiebachR , Pietsch-BreitfeldB , BichlerM , BuschA , RiethmullerJ , SternM . Bronchodilatory effects of salbutamol, ipratropium bromide, and their combination: double-blind, placebo-controlled crossover study in cystic fibrosis. Pediatric Pulmonology2001;31(6):431-5. [CFGD REGISTER: IB82] ">Ziebach 2001</a> reported the per cent change from baseline in FEV<sub>1</sub> L. The <a href="./references#CD013666-bbs2-0009" title="WeintraubSJ , EschenbacherWL . The inhaled bronchodilators ipratropium bromide and metaproterenol in adults with CF. Chest1989;95(4):861-4. [CFGD REGISTER: IB58] ">Weintraub 1989</a> trial reported a mean (SEM; range) decrease of 5% (1.6; ‐14.2% to 4.0%) after placebo compared with an increase of 17.1% (6.3; ‐5.7 to 64.7%) after ipratropium. While the authors reported the difference from baseline for each treatment group, we did not have appropriate data to be able to analyse the between‐group differences in this cross‐over trial. FEV<sub>1</sub> was reported to improve significantly after ipratropium compared to placebo in the <a href="./references#CD013666-bbs2-0011" title="ZiebachR , Pietsch-BreitfeldB , BichlerM , BuschA , RiethmullerJ , SternM . Bronchodilatory effects of salbutamol, ipratropium bromide, and their combination: double-blind, placebo-controlled crossover study in cystic fibrosis. Pediatric Pulmonology2001;31(6):431-5. [CFGD REGISTER: IB82] ">Ziebach 2001</a> trial (P = 0.0045). </p> </section> <section id="CD013666-sec-0086"> <h6 class="title">2. Quality of life</h6> <p>No trial reported on quality of life.</p> </section> <section id="CD013666-sec-0087"> <h6 class="title">3. Number of exacerbations of respiratory symptoms</h6> <section id="CD013666-sec-0088"> <p><b>a. Use of a scoring system</b></p> <p>No trial used a scoring system to define exacerbations.</p> </section> <section id="CD013666-sec-0089"> <p><b>b. Need for hospitalisation or antibiotics</b></p> <p>No trial reported on this outcome.</p> </section> </section> </section> <section id="CD013666-sec-0090"> <h5 class="title">Secondary outcomes</h5> <section id="CD013666-sec-0091"> <h6 class="title">1. Participant‐reported outcomes</h6> <p>No trial reported on this outcome.</p> </section> <section id="CD013666-sec-0092"> <h6 class="title">2. Adverse events</h6> <p>Two trials (27 participants) reported adverse events, but no data were available (<a href="./references#CD013666-bbs2-0009" title="WeintraubSJ , EschenbacherWL . The inhaled bronchodilators ipratropium bromide and metaproterenol in adults with CF. Chest1989;95(4):861-4. [CFGD REGISTER: IB58] ">Weintraub 1989</a>; <a href="./references#CD013666-bbs2-0011" title="ZiebachR , Pietsch-BreitfeldB , BichlerM , BuschA , RiethmullerJ , SternM . Bronchodilatory effects of salbutamol, ipratropium bromide, and their combination: double-blind, placebo-controlled crossover study in cystic fibrosis. Pediatric Pulmonology2001;31(6):431-5. [CFGD REGISTER: IB82] ">Ziebach 2001</a>). </p> <section id="CD013666-sec-0093"> <p><b>a. Frequency of treatment‐related adverse effects</b></p> <p><a href="./references#CD013666-bbs2-0009" title="WeintraubSJ , EschenbacherWL . The inhaled bronchodilators ipratropium bromide and metaproterenol in adults with CF. Chest1989;95(4):861-4. [CFGD REGISTER: IB58] ">Weintraub 1989</a> reported that a few participants noted some minor adverse effects; oral dryness was reported after ipatropium on two occasions, but abated within seconds. <a href="./references#CD013666-bbs2-0011" title="ZiebachR , Pietsch-BreitfeldB , BichlerM , BuschA , RiethmullerJ , SternM . Bronchodilatory effects of salbutamol, ipratropium bromide, and their combination: double-blind, placebo-controlled crossover study in cystic fibrosis. Pediatric Pulmonology2001;31(6):431-5. [CFGD REGISTER: IB82] ">Ziebach 2001</a> reported no adverse effects noted after either ipratropium or placebo. We deemed this evidence to be very low certainty. </p> </section> <section id="CD013666-sec-0094"> <p><b>b. Severity of adverse events</b></p> <p>Neither trial reported on adverse events by severity.</p> </section> </section> <section id="CD013666-sec-0095"> <h6 class="title">3. Change from baseline in any other relevant measurements of lung function</h6> <section id="CD013666-sec-0096"> <p><b>a. FVC (L or % predicted)</b></p> <p>Only <a href="./references#CD013666-bbs2-0011" title="ZiebachR , Pietsch-BreitfeldB , BichlerM , BuschA , RiethmullerJ , SternM . Bronchodilatory effects of salbutamol, ipratropium bromide, and their combination: double-blind, placebo-controlled crossover study in cystic fibrosis. Pediatric Pulmonology2001;31(6):431-5. [CFGD REGISTER: IB82] ">Ziebach 2001</a> reported on FVC (L) and stated that it did not change significantly after ipratropium compared to placebo. </p> </section> <section id="CD013666-sec-0097"> <p><b>b. FEF<sub>25-75</sub> </b></p> <p>Three trials (58 participants) reported on FEF<sub>25-75</sub> (<a href="./references#CD013666-bbs2-0006" title="Pitcher-WilmottRW , MatthewDJ , IngramD , TysonSL . Improvement in lung function after nebulised salbutamol and ipratropium bromide in children with cystic fibrosis. In: 11th European Cystic Fibrosis Conference, 1982. Brussels. 1982:251. [CFGD REGISTER: IB77] ">Pitcher‐Wilmott 1982</a>; <a href="./references#CD013666-bbs2-0010" title="WiebickeW , PoynterA , MontgomeryM , PagtakhanR . The effect of ipratropium bromide on lung function in patients with cystic fibrosis. Pneumologie1990;44 Suppl 1(1):277-8. [CFGD REGISTER: IB59] ">Wiebicke 1990</a>; <a href="./references#CD013666-bbs2-0011" title="ZiebachR , Pietsch-BreitfeldB , BichlerM , BuschA , RiethmullerJ , SternM . Bronchodilatory effects of salbutamol, ipratropium bromide, and their combination: double-blind, placebo-controlled crossover study in cystic fibrosis. Pediatric Pulmonology2001;31(6):431-5. [CFGD REGISTER: IB82] ">Ziebach 2001</a>). Few data are presented from the <a href="./references#CD013666-bbs2-0006" title="Pitcher-WilmottRW , MatthewDJ , IngramD , TysonSL . Improvement in lung function after nebulised salbutamol and ipratropium bromide in children with cystic fibrosis. In: 11th European Cystic Fibrosis Conference, 1982. Brussels. 1982:251. [CFGD REGISTER: IB77] ">Pitcher‐Wilmott 1982</a> trial, but the authors state that FEF<sub>25-75</sub> increased significantly in 18 out of 30 participants after ipratropium; this is a within‐group difference and no data are presented for the placebo group for comparison. <a href="./references#CD013666-bbs2-0010" title="WiebickeW , PoynterA , MontgomeryM , PagtakhanR . The effect of ipratropium bromide on lung function in patients with cystic fibrosis. Pneumologie1990;44 Suppl 1(1):277-8. [CFGD REGISTER: IB59] ">Wiebicke 1990</a> found that individual participant responses varied greatly, but that mean values were not significantly different after either ipratropium or placebo. <a href="./references#CD013666-bbs2-0011" title="ZiebachR , Pietsch-BreitfeldB , BichlerM , BuschA , RiethmullerJ , SternM . Bronchodilatory effects of salbutamol, ipratropium bromide, and their combination: double-blind, placebo-controlled crossover study in cystic fibrosis. Pediatric Pulmonology2001;31(6):431-5. [CFGD REGISTER: IB82] ">Ziebach 2001</a> found that FEF<sub>25-75</sub> improved significantly after ipratropium compared to placebo (P = 0.0001). </p> </section> <section id="CD013666-sec-0098"> <p><b>c. Lung clearance index</b></p> <p>Neither trial reported on lung function using lung clearance index.</p> </section> <section id="CD013666-sec-0099"> <p><b>d. Measures of bronchial hyper‐responsiveness and bronchodilator responsiveness</b></p> <p>Neither trial reported on this outcome.</p> </section> </section> <section id="CD013666-sec-0100"> <h6 class="title">4. Airway clearance</h6> <section id="CD013666-sec-0101"> <p><b>a. Sputum volume</b></p> <p>Neither trial reported on this outcome.</p> </section> <section id="CD013666-sec-0102"> <p><b>b. Weight (dry or wet) (g)</b></p> <p>Neither trial reported on this outcome.</p> </section> </section> </section> </section> <section id="CD013666-sec-0103"> <h4 class="title">Short‐acting inhaled beta‐2 agonists compared to short‐acting inhaled muscarinic antagonists</h4> <p>Three trials (59 participants) compared a short‐acting inhaled beta‐2 agonist with a short‐acting inhaled muscarinic antagonist (<a href="./references#CD013666-bbs2-0006" title="Pitcher-WilmottRW , MatthewDJ , IngramD , TysonSL . Improvement in lung function after nebulised salbutamol and ipratropium bromide in children with cystic fibrosis. In: 11th European Cystic Fibrosis Conference, 1982. Brussels. 1982:251. [CFGD REGISTER: IB77] ">Pitcher‐Wilmott 1982</a>; <a href="./references#CD013666-bbs2-0007" title="SanchezI , HolbrowJ , ChernickV . Acute bronchodilator response to a combination of beta-adrenergic and anticholinergic agents in patients with cystic fibrosis. Journal of Pediatrics1992;120(3):486-8. [CFGD REGISTER: IB63] ">Sanchez 1992</a>; <a href="./references#CD013666-bbs2-0011" title="ZiebachR , Pietsch-BreitfeldB , BichlerM , BuschA , RiethmullerJ , SternM . Bronchodilatory effects of salbutamol, ipratropium bromide, and their combination: double-blind, placebo-controlled crossover study in cystic fibrosis. Pediatric Pulmonology2001;31(6):431-5. [CFGD REGISTER: IB82] ">Ziebach 2001</a>). Pitcher‐Wilmott reports only the number of participants who improved after each treatment. </p> <section id="CD013666-sec-0104"> <h5 class="title">Primary outcomes</h5> <section id="CD013666-sec-0105"> <h6 class="title">1. Change from baseline in FEV<sub>1</sub> (L and % predicted) </h6> <p>All three trials reported FEV<sub>1</sub> L (<a href="./references#CD013666-bbs2-0006" title="Pitcher-WilmottRW , MatthewDJ , IngramD , TysonSL . Improvement in lung function after nebulised salbutamol and ipratropium bromide in children with cystic fibrosis. In: 11th European Cystic Fibrosis Conference, 1982. Brussels. 1982:251. [CFGD REGISTER: IB77] ">Pitcher‐Wilmott 1982</a>; <a href="./references#CD013666-bbs2-0007" title="SanchezI , HolbrowJ , ChernickV . Acute bronchodilator response to a combination of beta-adrenergic and anticholinergic agents in patients with cystic fibrosis. Journal of Pediatrics1992;120(3):486-8. [CFGD REGISTER: IB63] ">Sanchez 1992</a>; <a href="./references#CD013666-bbs2-0011" title="ZiebachR , Pietsch-BreitfeldB , BichlerM , BuschA , RiethmullerJ , SternM . Bronchodilatory effects of salbutamol, ipratropium bromide, and their combination: double-blind, placebo-controlled crossover study in cystic fibrosis. Pediatric Pulmonology2001;31(6):431-5. [CFGD REGISTER: IB82] ">Ziebach 2001</a>). </p> <p><a href="./references#CD013666-bbs2-0006" title="Pitcher-WilmottRW , MatthewDJ , IngramD , TysonSL . Improvement in lung function after nebulised salbutamol and ipratropium bromide in children with cystic fibrosis. In: 11th European Cystic Fibrosis Conference, 1982. Brussels. 1982:251. [CFGD REGISTER: IB77] ">Pitcher‐Wilmott 1982</a> reported a significant improvement in FEV<sub>1</sub> L after both salbutamol and ipratropium, but no data are provided to show between‐group differences.  </p> <p>The <a href="./references#CD013666-bbs2-0007" title="SanchezI , HolbrowJ , ChernickV . Acute bronchodilator response to a combination of beta-adrenergic and anticholinergic agents in patients with cystic fibrosis. Journal of Pediatrics1992;120(3):486-8. [CFGD REGISTER: IB63] ">Sanchez 1992</a> trial demonstrated an increase in FEV<sub>1</sub> L after both treatments in participants who responded to a methacholine challenge, but the greatest percentage increase observed was when ipratropium and albuterol were combined. Three participants who were non‐responders showed no improvement in FEV<sub>1</sub> with either treatment. </p> <p><a href="./references#CD013666-bbs2-0011" title="ZiebachR , Pietsch-BreitfeldB , BichlerM , BuschA , RiethmullerJ , SternM . Bronchodilatory effects of salbutamol, ipratropium bromide, and their combination: double-blind, placebo-controlled crossover study in cystic fibrosis. Pediatric Pulmonology2001;31(6):431-5. [CFGD REGISTER: IB82] ">Ziebach 2001</a> stated that ipratropium tended to be less effective than salbutamol or combined therapy for FEV<sub>1</sub> L, but they did not present data that we could extract. </p> </section> <section id="CD013666-sec-0106"> <h6 class="title">2. Quality of life</h6> <p>No trial reported on quality of life.</p> </section> <section id="CD013666-sec-0107"> <h6 class="title">3. Number of exacerbations of respiratory symptoms</h6> <section id="CD013666-sec-0108"> <p><b>a. Use of a scoring system</b></p> <p>No trial used a scoring system to define exacerbations.</p> </section> <section id="CD013666-sec-0109"> <p><b>b. Need for hospitalisation or antibiotics</b></p> <p>No trial reported on this outcome.</p> </section> </section> </section> <section id="CD013666-sec-0110"> <h5 class="title">Secondary outcomes</h5> <section id="CD013666-sec-0111"> <h6 class="title">1. Participant‐reported outcomes</h6> <p>No trial reported on this outcome.</p> </section> <section id="CD013666-sec-0112"> <h6 class="title">2. Adverse events</h6> <p>One trial (17 participants) reported adverse events narratively (<a href="./references#CD013666-bbs2-0011" title="ZiebachR , Pietsch-BreitfeldB , BichlerM , BuschA , RiethmullerJ , SternM . Bronchodilatory effects of salbutamol, ipratropium bromide, and their combination: double-blind, placebo-controlled crossover study in cystic fibrosis. Pediatric Pulmonology2001;31(6):431-5. [CFGD REGISTER: IB82] ">Ziebach 2001</a>). </p> <section id="CD013666-sec-0113"> <p><b>a. Frequency of treatment‐related adverse events</b></p> <p>No adverse events were experienced by participants on either treatment (<a href="./references#CD013666-bbs2-0011" title="ZiebachR , Pietsch-BreitfeldB , BichlerM , BuschA , RiethmullerJ , SternM . Bronchodilatory effects of salbutamol, ipratropium bromide, and their combination: double-blind, placebo-controlled crossover study in cystic fibrosis. Pediatric Pulmonology2001;31(6):431-5. [CFGD REGISTER: IB82] ">Ziebach 2001</a>). We deemed the certainty of this evidence to be very low. </p> </section> <section id="CD013666-sec-0114"> <p><b>b. Severity of adverse events</b></p> <p>No trial reported on adverse events by severity.</p> </section> </section> <section id="CD013666-sec-0115"> <h6 class="title">3. Change from baseline in any other relevant measurements of lung function</h6> <section id="CD013666-sec-0116"> <p><b>a. FVC (L or % predicted)</b></p> <p>Only <a href="./references#CD013666-bbs2-0011" title="ZiebachR , Pietsch-BreitfeldB , BichlerM , BuschA , RiethmullerJ , SternM . Bronchodilatory effects of salbutamol, ipratropium bromide, and their combination: double-blind, placebo-controlled crossover study in cystic fibrosis. Pediatric Pulmonology2001;31(6):431-5. [CFGD REGISTER: IB82] ">Ziebach 2001</a> reported on FVC (L) and stated that it did not change significantly after ipratropium compared to placebo. </p> </section> <section id="CD013666-sec-0117"> <p><b>b. FEF<sub>25-75</sub> </b></p> <p>Three trials (58 participants) reported on FEF<sub>25-75</sub> (<a href="./references#CD013666-bbs2-0006" title="Pitcher-WilmottRW , MatthewDJ , IngramD , TysonSL . Improvement in lung function after nebulised salbutamol and ipratropium bromide in children with cystic fibrosis. In: 11th European Cystic Fibrosis Conference, 1982. Brussels. 1982:251. [CFGD REGISTER: IB77] ">Pitcher‐Wilmott 1982</a>; <a href="./references#CD013666-bbs2-0010" title="WiebickeW , PoynterA , MontgomeryM , PagtakhanR . The effect of ipratropium bromide on lung function in patients with cystic fibrosis. Pneumologie1990;44 Suppl 1(1):277-8. [CFGD REGISTER: IB59] ">Wiebicke 1990</a>; <a href="./references#CD013666-bbs2-0011" title="ZiebachR , Pietsch-BreitfeldB , BichlerM , BuschA , RiethmullerJ , SternM . Bronchodilatory effects of salbutamol, ipratropium bromide, and their combination: double-blind, placebo-controlled crossover study in cystic fibrosis. Pediatric Pulmonology2001;31(6):431-5. [CFGD REGISTER: IB82] ">Ziebach 2001</a>). Few data are presented from the <a href="./references#CD013666-bbs2-0006" title="Pitcher-WilmottRW , MatthewDJ , IngramD , TysonSL . Improvement in lung function after nebulised salbutamol and ipratropium bromide in children with cystic fibrosis. In: 11th European Cystic Fibrosis Conference, 1982. Brussels. 1982:251. [CFGD REGISTER: IB77] ">Pitcher‐Wilmott 1982</a> trial, but the authors state that FEF<sub>25-75</sub> increased significantly in 18 out of 30 participants after ipratropium; this is a within‐group difference and no data are presented for the placebo group for comparison. <a href="./references#CD013666-bbs2-0010" title="WiebickeW , PoynterA , MontgomeryM , PagtakhanR . The effect of ipratropium bromide on lung function in patients with cystic fibrosis. Pneumologie1990;44 Suppl 1(1):277-8. [CFGD REGISTER: IB59] ">Wiebicke 1990</a> found that individual participant responses varied greatly, but that mean values were not significantly different after either ipratropium or placebo. <a href="./references#CD013666-bbs2-0011" title="ZiebachR , Pietsch-BreitfeldB , BichlerM , BuschA , RiethmullerJ , SternM . Bronchodilatory effects of salbutamol, ipratropium bromide, and their combination: double-blind, placebo-controlled crossover study in cystic fibrosis. Pediatric Pulmonology2001;31(6):431-5. [CFGD REGISTER: IB82] ">Ziebach 2001</a> found that FEF<sub>25-75</sub> improved significantly after ipratropium compared to placebo (P = 0.0001). </p> </section> <section id="CD013666-sec-0118"> <p><b>c. Lung clearance index</b></p> <p>No trial reported on lung function using lung clearance index.</p> </section> <section id="CD013666-sec-0119"> <p><b>d. Measures of bronchial hyper‐responsiveness and bronchodilator responsiveness</b></p> <p>No trial reported on this outcome.</p> </section> </section> <section id="CD013666-sec-0120"> <h6 class="title">4. Airway clearance</h6> <section id="CD013666-sec-0121"> <p><b>a. Sputum volume</b></p> <p>No trial reported on this outcome.</p> </section> <section id="CD013666-sec-0122"> <p><b>b. Weight (dry or wet) (g)</b></p> <p>No trial reported on this outcome.</p> </section> </section> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD013666-sec-0123" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD013666-sec-0123"></div> <section id="CD013666-sec-0124"> <h3 class="title" id="CD013666-sec-0124">Summary of main results</h3> <p>We aimed to evaluate the effectiveness of short‐acting inhaled bronchodilators in children and adults with CF. We included 11 trials (191 participants) from our systematic search which met our inclusion criteria. Eight trials compared two treatment arms and three trials compared three treatment arms. Eight trials contributed to the comparison of short‐acting inhaled beta‐2 agonists to placebo (<a href="./references#CD013666-bbs2-0001" title="DoddJ , BarryS , GallagherC . The effects of inhaled B2 agonists on maximal exercise in patients with cystic fibrosis . American Journal of Respiratory and Critical Care Medicine2001;163(5 Suppl):A88. [CFGD REGISTER: IB84a] DoddJD , BarrySC , DalyLE , GallagherCG . Inhaled beta-agonists improve lung function but not maximal exercise capacity in cystic fibrosis. Journal of Cystic Fibrosis2005;4(2):101-5. [CFGD REGISTER: IB84b] ">Dodd 2005</a>; <a href="./references#CD013666-bbs2-0002" title="DuncanFR , PenkethAR , HodsonME , BattenJC . The use of bronchodilators as an adjunct to physiotherapy, in adults with cystic fibrosis. In: 11th European Cystic Fibrosis Conference, 1982; Brussels. 1982:48. [CFGD REGISTER: IB70] ">Duncan 1982</a>; <a href="./references#CD013666-bbs2-0003" title="EgglestonPA , RosensteinBJ , StackhouseCM , MellitsED , BaumgardnerRA . A controlled trial of long-term bronchodilator therapy in cystic fibrosis. Chest1991;99(5):1088-92. [CFGD REGISTER: IB61a] OrensteinD . Long-term inhaled bronchodilator therapy in cystic fibrosis. Comment on Eggleston PA, Rosenstein BJ, Stackhouse CM, Mellits ED, Baumgardner RA. A controlled trial of long-term bronchodilator therapy in cystic fibrosis. Chest 1991;99(5):1088-92. Chest1991;99(5):1061. [CFGD REGISTER: IB61b] ">Eggleston 1991</a>; <a href="./references#CD013666-bbs2-0004" title="HordvikNL , SammutPH , JudyCG , StrizekSJ , ColomboJL . The effects of albuterol on the lung function of hospitalized patients with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine1996;154(1):156-60. [CFGD REGISTER: IB75] ">Hordvik 1996</a>; <a href="./references#CD013666-bbs2-0005" title="KonigP , PoehlerJ , BarberoGJ . A placebo-controlled, double-blind trial of the long-term effects of albuterol administration in patients with cystic fibrosis. Pediatric Pulmonology1998;25(1):32-6. [CFGD REGISTER: IB74b] KonigP , PoehlerJ , BarberoGJ . Long-term effects of albuterol (A) in cystic fibrosis (CF) - A controlled trial. Pediatric Pulmonology1996;Suppl 13:302. [CFGD REGISTER: IB74a] ">Konig 1996</a>; <a href="./references#CD013666-bbs2-0006" title="Pitcher-WilmottRW , MatthewDJ , IngramD , TysonSL . Improvement in lung function after nebulised salbutamol and ipratropium bromide in children with cystic fibrosis. In: 11th European Cystic Fibrosis Conference, 1982. Brussels. 1982:251. [CFGD REGISTER: IB77] ">Pitcher‐Wilmott 1982</a>; <a href="./references#CD013666-bbs2-0008" title="SerisierDJ , CaotesAD , BowlerSD . Inhaled salbutamol does not improve maximal exercise performance in cystic fibrosis . Respirology2006;11(Suppl 2):A58. [CFGD REGISTER: IB81c] SerisierDJ , CoatesAD , BowlerSD . Effect of albuterol on maximal exercise capacity in cystic fibrosis. Chest2007;131(4):1181-7. [CFGD REGISTER: IB81b] SerisierDJ , Rice-McDonaldG , BowlerSD , CoatesAC . ß-adrenergic agonists do not improve exercise capacity in cystic fibrosis. Pediatric Pulmonology2000;30 Suppl 20:305. [CFGD REGISTER: IB81a] ">Serisier 2000</a>; <a href="./references#CD013666-bbs2-0011" title="ZiebachR , Pietsch-BreitfeldB , BichlerM , BuschA , RiethmullerJ , SternM . Bronchodilatory effects of salbutamol, ipratropium bromide, and their combination: double-blind, placebo-controlled crossover study in cystic fibrosis. Pediatric Pulmonology2001;31(6):431-5. [CFGD REGISTER: IB82] ">Ziebach 2001</a>), four trials contributed to the comparison of short‐acting inhaled muscarinic antagonists to placebo (<a href="./references#CD013666-bbs2-0006" title="Pitcher-WilmottRW , MatthewDJ , IngramD , TysonSL . Improvement in lung function after nebulised salbutamol and ipratropium bromide in children with cystic fibrosis. In: 11th European Cystic Fibrosis Conference, 1982. Brussels. 1982:251. [CFGD REGISTER: IB77] ">Pitcher‐Wilmott 1982</a>; <a href="./references#CD013666-bbs2-0009" title="WeintraubSJ , EschenbacherWL . The inhaled bronchodilators ipratropium bromide and metaproterenol in adults with CF. Chest1989;95(4):861-4. [CFGD REGISTER: IB58] ">Weintraub 1989</a>; <a href="./references#CD013666-bbs2-0010" title="WiebickeW , PoynterA , MontgomeryM , PagtakhanR . The effect of ipratropium bromide on lung function in patients with cystic fibrosis. Pneumologie1990;44 Suppl 1(1):277-8. [CFGD REGISTER: IB59] ">Wiebicke 1990</a>; <a href="./references#CD013666-bbs2-0011" title="ZiebachR , Pietsch-BreitfeldB , BichlerM , BuschA , RiethmullerJ , SternM . Bronchodilatory effects of salbutamol, ipratropium bromide, and their combination: double-blind, placebo-controlled crossover study in cystic fibrosis. Pediatric Pulmonology2001;31(6):431-5. [CFGD REGISTER: IB82] ">Ziebach 2001</a>), and three trials contributed to the comparison of a short‐acting inhaled beta‐2 agonist to a short‐acting inhaled muscarinic antagonist (<a href="./references#CD013666-bbs2-0006" title="Pitcher-WilmottRW , MatthewDJ , IngramD , TysonSL . Improvement in lung function after nebulised salbutamol and ipratropium bromide in children with cystic fibrosis. In: 11th European Cystic Fibrosis Conference, 1982. Brussels. 1982:251. [CFGD REGISTER: IB77] ">Pitcher‐Wilmott 1982</a>; <a href="./references#CD013666-bbs2-0007" title="SanchezI , HolbrowJ , ChernickV . Acute bronchodilator response to a combination of beta-adrenergic and anticholinergic agents in patients with cystic fibrosis. Journal of Pediatrics1992;120(3):486-8. [CFGD REGISTER: IB63] ">Sanchez 1992</a>; <a href="./references#CD013666-bbs2-0011" title="ZiebachR , Pietsch-BreitfeldB , BichlerM , BuschA , RiethmullerJ , SternM . Bronchodilatory effects of salbutamol, ipratropium bromide, and their combination: double-blind, placebo-controlled crossover study in cystic fibrosis. Pediatric Pulmonology2001;31(6):431-5. [CFGD REGISTER: IB82] ">Ziebach 2001</a>). All were cross‐over RCTs with only small numbers of participants. We were only able to enter data into the analysis from three trials comparing short‐acting inhaled beta‐2 agonists to placebo (<a href="./references#CD013666-bbs2-0004" title="HordvikNL , SammutPH , JudyCG , StrizekSJ , ColomboJL . The effects of albuterol on the lung function of hospitalized patients with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine1996;154(1):156-60. [CFGD REGISTER: IB75] ">Hordvik 1996</a>; <a href="./references#CD013666-bbs2-0008" title="SerisierDJ , CaotesAD , BowlerSD . Inhaled salbutamol does not improve maximal exercise performance in cystic fibrosis . Respirology2006;11(Suppl 2):A58. [CFGD REGISTER: IB81c] SerisierDJ , CoatesAD , BowlerSD . Effect of albuterol on maximal exercise capacity in cystic fibrosis. Chest2007;131(4):1181-7. [CFGD REGISTER: IB81b] SerisierDJ , Rice-McDonaldG , BowlerSD , CoatesAC . ß-adrenergic agonists do not improve exercise capacity in cystic fibrosis. Pediatric Pulmonology2000;30 Suppl 20:305. [CFGD REGISTER: IB81a] ">Serisier 2000</a>; <a href="./references#CD013666-bbs2-0011" title="ZiebachR , Pietsch-BreitfeldB , BichlerM , BuschA , RiethmullerJ , SternM . Bronchodilatory effects of salbutamol, ipratropium bromide, and their combination: double-blind, placebo-controlled crossover study in cystic fibrosis. Pediatric Pulmonology2001;31(6):431-5. [CFGD REGISTER: IB82] ">Ziebach 2001</a>). We have reported other findings from the original papers narratively. Nine trials employed a single‐dose bronchodilator.  </p> <p>Two trials have only ever published results in abstract form, which contributed to the uncertainty of risk of bias judgements, as only limited information was available (<a href="./references#CD013666-bbs2-0002" title="DuncanFR , PenkethAR , HodsonME , BattenJC . The use of bronchodilators as an adjunct to physiotherapy, in adults with cystic fibrosis. In: 11th European Cystic Fibrosis Conference, 1982; Brussels. 1982:48. [CFGD REGISTER: IB70] ">Duncan 1982</a>; <a href="./references#CD013666-bbs2-0006" title="Pitcher-WilmottRW , MatthewDJ , IngramD , TysonSL . Improvement in lung function after nebulised salbutamol and ipratropium bromide in children with cystic fibrosis. In: 11th European Cystic Fibrosis Conference, 1982. Brussels. 1982:251. [CFGD REGISTER: IB77] ">Pitcher‐Wilmott 1982</a>). Risk of bias across the remaining trials was also unclear for several domains, and particularly around the process of randomisation and allocation concealment. One of the trials selected participants with evidence of bronchodilator responsiveness (<a href="./references#CD013666-bbs2-0007" title="SanchezI , HolbrowJ , ChernickV . Acute bronchodilator response to a combination of beta-adrenergic and anticholinergic agents in patients with cystic fibrosis. Journal of Pediatrics1992;120(3):486-8. [CFGD REGISTER: IB63] ">Sanchez 1992</a>), and two further trials carried out a methacholine challenge and reported results in both responders and non‐responders (<a href="./references#CD013666-bbs2-0003" title="EgglestonPA , RosensteinBJ , StackhouseCM , MellitsED , BaumgardnerRA . A controlled trial of long-term bronchodilator therapy in cystic fibrosis. Chest1991;99(5):1088-92. [CFGD REGISTER: IB61a] OrensteinD . Long-term inhaled bronchodilator therapy in cystic fibrosis. Comment on Eggleston PA, Rosenstein BJ, Stackhouse CM, Mellits ED, Baumgardner RA. A controlled trial of long-term bronchodilator therapy in cystic fibrosis. Chest 1991;99(5):1088-92. Chest1991;99(5):1061. [CFGD REGISTER: IB61b] ">Eggleston 1991</a>; <a href="./references#CD013666-bbs2-0008" title="SerisierDJ , CaotesAD , BowlerSD . Inhaled salbutamol does not improve maximal exercise performance in cystic fibrosis . Respirology2006;11(Suppl 2):A58. [CFGD REGISTER: IB81c] SerisierDJ , CoatesAD , BowlerSD . Effect of albuterol on maximal exercise capacity in cystic fibrosis. Chest2007;131(4):1181-7. [CFGD REGISTER: IB81b] SerisierDJ , Rice-McDonaldG , BowlerSD , CoatesAC . ß-adrenergic agonists do not improve exercise capacity in cystic fibrosis. Pediatric Pulmonology2000;30 Suppl 20:305. [CFGD REGISTER: IB81a] ">Serisier 2000</a>). </p> <p>All included trials reported on the effect of short‐acting inhaled bronchodilators on FEV<sub>1</sub>, either as % predicted or L, but there was much less information on the remaining outcomes in this review. None of the trials reported on a measure of quality of life, there was limited information on adverse events, and only one trial presented participant‐reported outcomes (<a href="./references#CD013666-bbs2-0003" title="EgglestonPA , RosensteinBJ , StackhouseCM , MellitsED , BaumgardnerRA . A controlled trial of long-term bronchodilator therapy in cystic fibrosis. Chest1991;99(5):1088-92. [CFGD REGISTER: IB61a] OrensteinD . Long-term inhaled bronchodilator therapy in cystic fibrosis. Comment on Eggleston PA, Rosenstein BJ, Stackhouse CM, Mellits ED, Baumgardner RA. A controlled trial of long-term bronchodilator therapy in cystic fibrosis. Chest 1991;99(5):1088-92. Chest1991;99(5):1061. [CFGD REGISTER: IB61b] ">Eggleston 1991</a>). Only one trial assessed sputum production as a measure of airway clearance (<a href="./references#CD013666-bbs2-0002" title="DuncanFR , PenkethAR , HodsonME , BattenJC . The use of bronchodilators as an adjunct to physiotherapy, in adults with cystic fibrosis. In: 11th European Cystic Fibrosis Conference, 1982; Brussels. 1982:48. [CFGD REGISTER: IB70] ">Duncan 1982</a>). Again, only one trial reported on the frequency of exacerbations (<a href="./references#CD013666-bbs2-0005" title="KonigP , PoehlerJ , BarberoGJ . A placebo-controlled, double-blind trial of the long-term effects of albuterol administration in patients with cystic fibrosis. Pediatric Pulmonology1998;25(1):32-6. [CFGD REGISTER: IB74b] KonigP , PoehlerJ , BarberoGJ . Long-term effects of albuterol (A) in cystic fibrosis (CF) - A controlled trial. Pediatric Pulmonology1996;Suppl 13:302. [CFGD REGISTER: IB74a] ">Konig 1996</a>), but this may be due to the fact that this is the only trial which was carried out over a longer time period. </p> <section id="CD013666-sec-0125"> <h4 class="title">Short‐acting inhaled beta‐2 agonists compared to placebo</h4> <p>All single‐dose trials reported an improvement in FEV<sub>1</sub> either as % predicted or L, but it was unclear how this compared to the effect in the placebo group due to the limited data presented. We are uncertain whether beta‐2 agonists improve FEV<sub>1</sub> compared to placebo. In the longer‐term trials (2 weeks in <a href="./references#CD013666-bbs2-0003" title="EgglestonPA , RosensteinBJ , StackhouseCM , MellitsED , BaumgardnerRA . A controlled trial of long-term bronchodilator therapy in cystic fibrosis. Chest1991;99(5):1088-92. [CFGD REGISTER: IB61a] OrensteinD . Long-term inhaled bronchodilator therapy in cystic fibrosis. Comment on Eggleston PA, Rosenstein BJ, Stackhouse CM, Mellits ED, Baumgardner RA. A controlled trial of long-term bronchodilator therapy in cystic fibrosis. Chest 1991;99(5):1088-92. Chest1991;99(5):1061. [CFGD REGISTER: IB61b] ">Eggleston 1991</a>; 6 months in <a href="./references#CD013666-bbs2-0005" title="KonigP , PoehlerJ , BarberoGJ . A placebo-controlled, double-blind trial of the long-term effects of albuterol administration in patients with cystic fibrosis. Pediatric Pulmonology1998;25(1):32-6. [CFGD REGISTER: IB74b] KonigP , PoehlerJ , BarberoGJ . Long-term effects of albuterol (A) in cystic fibrosis (CF) - A controlled trial. Pediatric Pulmonology1996;Suppl 13:302. [CFGD REGISTER: IB74a] ">Konig 1996</a>), no difference was observed between beta‐2 agonists and placebo, although the certainty of this evidence is again, very low. </p> <p>Exacerbations were only measured and reported in the longer‐term trial, which showed that beta‐2 agonists may make little or no difference to the rate of exacerbations, as measured by hospitalisations or antibiotic treatment, or both. Similarly, there may be little or no difference in symptom scores when taking albuterol compared to placebo (<a href="./references#CD013666-bbs2-0003" title="EgglestonPA , RosensteinBJ , StackhouseCM , MellitsED , BaumgardnerRA . A controlled trial of long-term bronchodilator therapy in cystic fibrosis. Chest1991;99(5):1088-92. [CFGD REGISTER: IB61a] OrensteinD . Long-term inhaled bronchodilator therapy in cystic fibrosis. Comment on Eggleston PA, Rosenstein BJ, Stackhouse CM, Mellits ED, Baumgardner RA. A controlled trial of long-term bronchodilator therapy in cystic fibrosis. Chest 1991;99(5):1088-92. Chest1991;99(5):1061. [CFGD REGISTER: IB61b] ">Eggleston 1991</a>). </p> <p>Overall, there were very few reports of adverse events and those that were reported were mild and occurred in both treatment arms. Due to the small number of participants and short‐term nature of most of the trials, we are unable to say with certainty that this is a true finding. </p> <p>We are uncertain whether beta‐2 agonists affect other measures of lung function such as FVC and FEF<sub>25-75</sub> and similarly whether there is an effect on sputum weight (very low‐certainty evidence). </p> </section> <section id="CD013666-sec-0126"> <h4 class="title">Short‐acting inhaled muscarinic antagonists compared to placebo</h4> <p>All of the trials we found looked at the effects of ipratropium bromide, but in different doses and via different delivery methods. We found very low‐certainty evidence that ipratropium had any effect on FEV<sub>1</sub> % predicted. Four trials reported an improvement in FEV<sub>1</sub> L after ipratropium, but there were not enough data available for us to analyse this against placebo. We are uncertain whether adverse events are more or less common after ipratropium than placebo. None of the remaining outcomes in the review were reported by our included trials of ipratropium versus placebo. </p> </section> <section id="CD013666-sec-0127"> <h4 class="title">Short‐acting inhaled beta‐2 agonists compared to short‐acting inhaled muscarinic antagonists</h4> <p>None of the trials of muscarinic antagonists compared to beta‐2 agonists provided data for analysis. The original papers report that both treatments led to an improvement in FEV<sub>1</sub>, although one trial found that ipratropium tended to be less effective than salbutamol (<a href="./references#CD013666-bbs2-0011" title="ZiebachR , Pietsch-BreitfeldB , BichlerM , BuschA , RiethmullerJ , SternM . Bronchodilatory effects of salbutamol, ipratropium bromide, and their combination: double-blind, placebo-controlled crossover study in cystic fibrosis. Pediatric Pulmonology2001;31(6):431-5. [CFGD REGISTER: IB82] ">Ziebach 2001</a>). Only one trial reported on adverse events, and no participants experienced side effects with either treatment (<a href="./references#CD013666-bbs2-0011" title="ZiebachR , Pietsch-BreitfeldB , BichlerM , BuschA , RiethmullerJ , SternM . Bronchodilatory effects of salbutamol, ipratropium bromide, and their combination: double-blind, placebo-controlled crossover study in cystic fibrosis. Pediatric Pulmonology2001;31(6):431-5. [CFGD REGISTER: IB82] ">Ziebach 2001</a>). </p> </section> </section> <section id="CD013666-sec-0128"> <h3 class="title" id="CD013666-sec-0128">Overall completeness and applicability of evidence</h3> <p>We are confident that we have identified all the trials that attempt to answer our review question, but they were all conducted more than 10 years ago and CF therapy has changed over this time, particularly in recent years. Furthermore, some of the information that was lacking is likely to be due to changes in the reporting of trials. The included trials did enrol both children and adults, so results can be assumed to be applicable to people with CF of all ages. </p> <p>We only found two trials which looked at the effects of bronchodilator therapy over a longer period of time, although the longest trial was only 6 months in duration. Whilst short‐acting bronchodilator therapy is commonly used before physiotherapy and airway clearance, meaning that immediate effects are important, it would also be useful to know what the longer‐term effects of using this treatment are, particularly where use could lead to potential harm (e.g. 'paradoxical bronchoconstriction'). None of our included trials reported a measure of quality of life, and only very few looked at the effect on airway clearance, participant‐reported outcomes (symptom scores) or frequency of exacerbations. This is to be expected when the trials are studying the more immediate effects of treatment, but for a treatment which is commonly used by people with CF (<a href="./references#CD013666-bbs2-0068" title="UK CF Trust. Additional data from UK CF Registry 2019. Email to: S Smith 15 September 2020.">UK CF Trust 2019 [pers comm]</a>), the longer‐term effects are also important. </p> </section> <section id="CD013666-sec-0129"> <h3 class="title" id="CD013666-sec-0129">Certainty of the evidence</h3> <p>As stated above, some of the gaps in information are potentially due to changes in how trials are reported; we judged six out of the 11 trials to have an unclear risk of bias in the domains of randomisation and allocation concealment, which is possibly due to poor reporting, rather than the randomisation process not being carried out correctly. </p> <p>We graded all of the evidence included in the review as very low in certainty. This is due to the fact that all trials had small numbers of participants and used a cross‐over design with limited data available to extract and analyse. There is likely to be imprecision in the results in any trial that includes only small numbers of participants. In a trial using a cross‐over design, whilst reducing the total number of participants needed as each participant acts as their own control, there is the risk of unwanted carry‐over effects between treatment phases. This is likely to be less of an issue in the single‐dose trials, and all of our included trials had a washout period of at least 12 hours, but in longer‐term trials of a chronic condition, a cross‐over design is likely to introduce bias from groups not being similar at baseline and carry‐over effects. </p> </section> <section id="CD013666-sec-0130"> <h3 class="title" id="CD013666-sec-0130">Potential biases in the review process</h3> <p>None of the authors of this update had any involvement with the trials included in the review and all processes followed strict Cochrane methodology. Two review authors scanned titles and extracted data independently to reduce bias and to detect errors in data extraction or interpretation. </p> </section> <section id="CD013666-sec-0131"> <h3 class="title" id="CD013666-sec-0131">Agreements and disagreements with other studies or reviews</h3> <p>Since the previously published version of the review which looked at both short‐ and long‐acting inhaled bronchodilators (<a href="./references#CD013666-bbs2-0071" title="HalfhideC , EvansHJ , CourielJ . Inhaled bronchodilators for cystic fibrosis. Cochrane Database of Systematic Reviews2016, Issue 2. Art. No: CD003428. [DOI: 10.1002/14651858.CD003428.pub3]">Halfhide 2016</a>), there has been no additional evidence published with respect to the use of short‐acting inhaled bronchodilators in people with CF, and our conclusions remain the same. The USA CF pulmonary guidelines state that the evidence for the long‐term use of inhaled beta‐2 agonists is insufficient to recommend for or against (<a href="./references#CD013666-bbs2-0055" title="Mogayzel PJ Jr, NaureckasET , RobinsonKA , MuellerG , HadjiliadisD , HoagJB , et al. Cystic fibrosis pulmonary guidelines. Chronic medications for maintenance of lung health. American Journal of Respiratory &amp; Critical Care Medicine2013;187(7):680-9.">Mogayzel 2013</a>), and we have no further evidence to change this statement. The same conclusion is true of treatment with inhaled muscarinic antagonists (<a href="./references#CD013666-bbs2-0055" title="Mogayzel PJ Jr, NaureckasET , RobinsonKA , MuellerG , HadjiliadisD , HoagJB , et al. Cystic fibrosis pulmonary guidelines. Chronic medications for maintenance of lung health. American Journal of Respiratory &amp; Critical Care Medicine2013;187(7):680-9.">Mogayzel 2013</a>). Short‐acting inhaled bronchodilators are commonly used before airway clearance techniques to open the airways and promote secretion of mucus. A systematic review looking at pharmacological agents for airway clearance found only one cross‐over RCT looking at the effects of nebulised albuterol in those who were mechanically‐ventilated and one cross‐over RCT looking at the effects of ipratropium bromide in people with chronic bronchitis (<a href="./references#CD013666-bbs2-0062" title="SatheNA , KrishnaswamiS , AndrewsJ , FiczereC , McPheetersML . Pharmacologic agents that promote airway clearance in hospitalized subjects: a systematic review. Respiratory Care2015;60(7):1061-70.">Sathe 2015</a>). The participants in these trials are both very different groups from people with CF, and the trial findings related to sputum volume (neither trial reported any difference between groups for this outcome). Consistent with our findings, neither trial reported adverse events (<a href="./references#CD013666-bbs2-0062" title="SatheNA , KrishnaswamiS , AndrewsJ , FiczereC , McPheetersML . Pharmacologic agents that promote airway clearance in hospitalized subjects: a systematic review. Respiratory Care2015;60(7):1061-70.">Sathe 2015</a>). </p> <p>A review of inhaled bronchodilator therapy carried out more recently reported the same challenges that we have found, i.e. interpretation was hindered by the age of the trials and the variation in treatment schedules, doses and durations (<a href="./references#CD013666-bbs2-0032" title="BarryPJ , FlumePA . Bronchodilators in cystic fibrosis: a critical analysis. Expert Review of Respiratory Medicine2017;11(1):13-20.">Barry 2017</a>). </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD013666-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013666.pub2/media/CDSR/CD013666/urn:x-wiley:14651858:media:CD013666:CD013666-FIG-01" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD013666-fig-0001" src="/cdsr/doi/10.1002/14651858.CD013666.pub2/media/CDSR/CD013666/image_n/nCD013666-FIG-01.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013666.pub2/media/CDSR/CD013666/image_t/tCD013666-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013666.pub2/full#CD013666-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013666.pub2/media/CDSR/CD013666/image_n/nCD013666-FIG-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013666-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013666.pub2/media/CDSR/CD013666/urn:x-wiley:14651858:media:CD013666:CD013666-FIG-02" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included trial." data-id="CD013666-fig-0002" src="/cdsr/doi/10.1002/14651858.CD013666.pub2/media/CDSR/CD013666/image_n/nCD013666-FIG-02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013666.pub2/media/CDSR/CD013666/image_t/tCD013666-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included trial. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013666.pub2/full#CD013666-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013666.pub2/media/CDSR/CD013666/image_n/nCD013666-FIG-02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013666-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013666.pub2/media/CDSR/CD013666/urn:x-wiley:14651858:media:CD013666:CD013666-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Short‐acting inhaled beta‐2 agonists versus placebo, Outcome 1: Per cent change from baseline in FEV1 L" data-id="CD013666-fig-0003" src="/cdsr/doi/10.1002/14651858.CD013666.pub2/media/CDSR/CD013666/image_n/nCD013666-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013666.pub2/media/CDSR/CD013666/image_t/tCD013666-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: Short‐acting inhaled beta‐2 agonists versus placebo, Outcome 1: Per cent change from baseline in FEV<sub>1</sub> L </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013666.pub2/references#CD013666-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013666.pub2/media/CDSR/CD013666/image_n/nCD013666-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013666-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013666.pub2/media/CDSR/CD013666/urn:x-wiley:14651858:media:CD013666:CD013666-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Short‐acting inhaled beta‐2 agonists versus placebo, Outcome 2: Change from baseline in FEV1 L" data-id="CD013666-fig-0004" src="/cdsr/doi/10.1002/14651858.CD013666.pub2/media/CDSR/CD013666/image_n/nCD013666-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013666.pub2/media/CDSR/CD013666/image_t/tCD013666-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: Short‐acting inhaled beta‐2 agonists versus placebo, Outcome 2: Change from baseline in FEV<sub>1</sub> L </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013666.pub2/references#CD013666-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013666.pub2/media/CDSR/CD013666/image_n/nCD013666-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013666-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013666.pub2/media/CDSR/CD013666/urn:x-wiley:14651858:media:CD013666:CD013666-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Short‐acting inhaled beta‐2 agonists versus placebo, Outcome 3: Per cent change from baseline in FVC L" data-id="CD013666-fig-0005" src="/cdsr/doi/10.1002/14651858.CD013666.pub2/media/CDSR/CD013666/image_n/nCD013666-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013666.pub2/media/CDSR/CD013666/image_t/tCD013666-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: Short‐acting inhaled beta‐2 agonists versus placebo, Outcome 3: Per cent change from baseline in FVC L </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013666.pub2/references#CD013666-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013666.pub2/media/CDSR/CD013666/image_n/nCD013666-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD013666-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Short‐acting inhaled beta‐2 agonists compared with placebo for cystic fibrosis</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Short‐acting inhaled beta‐2 agonists compared with placebo for cystic fibrosis</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> children and adults with cystic fibrosis </p> <p><b>Settings:</b> inpatient and outpatient </p> <p><b>Intervention:</b> inhaled beta‐2 agonist (albuterol or salbutamol) </p> <p><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>No of Participants<br/>(trials)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Inhaled beta‐2 agonist</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Change from baseline in FEV<sub>1</sub> (% predicted)</b> </p> <p> </p> <p>Follow‐up: single dose, 2 weeks, 6 months</p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p><i>Single‐dose trials</i> </p> <p>FEV<sub>1</sub> % predicted was shown to improve after inhaled albuterol (or salbutamol) compared to placebo (<a href="./references#CD013666-bbs2-0001" title="DoddJ , BarryS , GallagherC . The effects of inhaled B2 agonists on maximal exercise in patients with cystic fibrosis . American Journal of Respiratory and Critical Care Medicine2001;163(5 Suppl):A88. [CFGD REGISTER: IB84a] DoddJD , BarrySC , DalyLE , GallagherCG . Inhaled beta-agonists improve lung function but not maximal exercise capacity in cystic fibrosis. Journal of Cystic Fibrosis2005;4(2):101-5. [CFGD REGISTER: IB84b] ">Dodd 2005</a>). A further trial showed an improvement after salbutamol, but did not report the effect in the placebo group (<a href="./references#CD013666-bbs2-0002" title="DuncanFR , PenkethAR , HodsonME , BattenJC . The use of bronchodilators as an adjunct to physiotherapy, in adults with cystic fibrosis. In: 11th European Cystic Fibrosis Conference, 1982; Brussels. 1982:48. [CFGD REGISTER: IB70] ">Duncan 1982</a>). </p> <p> </p> <p><i>Short‐term trial</i> </p> <p>FEV<sub>1</sub> % predicted increased by 3% after albuterol and decreased by 3% in the placebo arm in methacholine challenge responders, but analysis showed this difference not to be significant. No improvement was seen in either group in the methacholine non‐responder group (<a href="./references#CD013666-bbs2-0003" title="EgglestonPA , RosensteinBJ , StackhouseCM , MellitsED , BaumgardnerRA . A controlled trial of long-term bronchodilator therapy in cystic fibrosis. Chest1991;99(5):1088-92. [CFGD REGISTER: IB61a] OrensteinD . Long-term inhaled bronchodilator therapy in cystic fibrosis. Comment on Eggleston PA, Rosenstein BJ, Stackhouse CM, Mellits ED, Baumgardner RA. A controlled trial of long-term bronchodilator therapy in cystic fibrosis. Chest 1991;99(5):1088-92. Chest1991;99(5):1061. [CFGD REGISTER: IB61b] ">Eggleston 1991</a>). </p> <p> </p> <p><i>Long‐term trial</i> </p> <p>Between‐group comparisons showed there to be no statistically significant difference between albuterol and placebo (<a href="./references#CD013666-bbs2-0005" title="KonigP , PoehlerJ , BarberoGJ . A placebo-controlled, double-blind trial of the long-term effects of albuterol administration in patients with cystic fibrosis. Pediatric Pulmonology1998;25(1):32-6. [CFGD REGISTER: IB74b] KonigP , PoehlerJ , BarberoGJ . Long-term effects of albuterol (A) in cystic fibrosis (CF) - A controlled trial. Pediatric Pulmonology1996;Suppl 13:302. [CFGD REGISTER: IB74a] ">Konig 1996</a>). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>67<br/>(4) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low<sup>a,b</sup> </b> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We were not able to enter any of the data into our analyses due to the cross‐over design and few data in the original papers. </p> <p> </p> <p>The <a href="./references#CD013666-bbs2-0002" title="DuncanFR , PenkethAR , HodsonME , BattenJC . The use of bronchodilators as an adjunct to physiotherapy, in adults with cystic fibrosis. In: 11th European Cystic Fibrosis Conference, 1982; Brussels. 1982:48. [CFGD REGISTER: IB70] ">Duncan 1982</a> trial was presented only as an abstract; we have not found a full paper. </p> <p>Four further trials reported FEV<sub>1</sub> (L); all reported an improvement in FEV<sub>1</sub> compared to placebo, but all were small cross‐over trials with limited data available. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life</b> </p> <p> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>This outcome was not reported.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of exacerbations</b> <b>(as reported by number of hospitalisations and number of courses and days on antibiotics)</b> </p> <p> </p> <p>Follow‐up: 6 months</p> <p> </p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>There were no statistically significant differences between albuterol and placebo with respect to the number of hospitalisations, although there was a trend in favour of albuterol (1 day/participant on albuterol versus 2.6 days/participant on placebo). </p> <p>There were no differences in the number of courses or days of antibiotics between the albuterol and placebo group (<a href="./references#CD013666-bbs2-0005" title="KonigP , PoehlerJ , BarberoGJ . A placebo-controlled, double-blind trial of the long-term effects of albuterol administration in patients with cystic fibrosis. Pediatric Pulmonology1998;25(1):32-6. [CFGD REGISTER: IB74b] KonigP , PoehlerJ , BarberoGJ . Long-term effects of albuterol (A) in cystic fibrosis (CF) - A controlled trial. Pediatric Pulmonology1996;Suppl 13:302. [CFGD REGISTER: IB74a] ">Konig 1996</a>). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21<br/>(1) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Very low<sup>c,d</sup> </b> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Only 1 trial looked at the effects of inhaled beta‐2 agonists on a longer‐term basis and was therefore able to capture information on exacerbations. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participant‐reported symptom score: cough, wheeze and exercise tolerance</b> </p> <p> </p> <p>Follow‐up: 2 weeks</p> <p> </p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>Symptom scores were low on average and did not change with treatment. Scores did not improve during the albuterol treatment periods in either methacholine challenge responders or non‐responders. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22<br/>(1) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Very</b> <b>low<sup>d,e</sup> </b> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events</b> </p> <p> </p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>Very few adverse effects were reported and there was little difference between the active treatment and placebo arms. In 1 trial, 2 participants reported mild tremors when taking albuterol and 2 participants reported fatigue, difficulty concentrating or nervousness whilst taking albuterol; but 1 of these participants reported the same symptoms when taking the placebo (<a href="./references#CD013666-bbs2-0003" title="EgglestonPA , RosensteinBJ , StackhouseCM , MellitsED , BaumgardnerRA . A controlled trial of long-term bronchodilator therapy in cystic fibrosis. Chest1991;99(5):1088-92. [CFGD REGISTER: IB61a] OrensteinD . Long-term inhaled bronchodilator therapy in cystic fibrosis. Comment on Eggleston PA, Rosenstein BJ, Stackhouse CM, Mellits ED, Baumgardner RA. A controlled trial of long-term bronchodilator therapy in cystic fibrosis. Chest 1991;99(5):1088-92. Chest1991;99(5):1061. [CFGD REGISTER: IB61b] ">Eggleston 1991</a>). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>47<br/>(3) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low<sup>a,b</sup> </b> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The original papers reported all adverse effects narratively and there were no data to extract. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Change from baseline in FVC (% predicted)</b> </p> <p> </p> <p>Follow‐up: single dose, 2 weeks, 6 months</p> <p> </p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p><i>Single‐dose trials</i> </p> <p>Two out of three trials reported an improvement in FVC after albuterol (or salbutamol), with the third reporting no difference. </p> <p> </p> <p><i>Short‐term trial</i> </p> <p>No difference in FVC was reported between treatment groups (<a href="./references#CD013666-bbs2-0003" title="EgglestonPA , RosensteinBJ , StackhouseCM , MellitsED , BaumgardnerRA . A controlled trial of long-term bronchodilator therapy in cystic fibrosis. Chest1991;99(5):1088-92. [CFGD REGISTER: IB61a] OrensteinD . Long-term inhaled bronchodilator therapy in cystic fibrosis. Comment on Eggleston PA, Rosenstein BJ, Stackhouse CM, Mellits ED, Baumgardner RA. A controlled trial of long-term bronchodilator therapy in cystic fibrosis. Chest 1991;99(5):1088-92. Chest1991;99(5):1061. [CFGD REGISTER: IB61b] ">Eggleston 1991</a>). </p> <p> </p> <p><i>Long‐term trial</i> </p> <p>There was no difference in FVC between groups (<a href="./references#CD013666-bbs2-0005" title="KonigP , PoehlerJ , BarberoGJ . A placebo-controlled, double-blind trial of the long-term effects of albuterol administration in patients with cystic fibrosis. Pediatric Pulmonology1998;25(1):32-6. [CFGD REGISTER: IB74b] KonigP , PoehlerJ , BarberoGJ . Long-term effects of albuterol (A) in cystic fibrosis (CF) - A controlled trial. Pediatric Pulmonology1996;Suppl 13:302. [CFGD REGISTER: IB74a] ">Konig 1996</a>). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100<br/>(5) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low<sup>a,b</sup> </b> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We were not able to enter any of the data into our analyses due to the cross‐over design and there being little data in the original papers. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Sputum volume (mL)</b> </p> <p> </p> <p>Follow‐up: single dose</p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>One trial reported little change in sputum weight on either salbutamol or placebo.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16<br/>(1) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low<sup>b,f</sup> </b> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across trials) is provided in footnotes. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>FEV<sub>1</sub> </b> : forced expiratory volume in 1 second; <b>FVC</b>: forced vital capacity. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence</p> <p><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect. </p> <p><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different. </p> <p><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect. </p> <p><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded twice due to risk of bias. All trials had a cross‐over design and reported limited data. Some trials reported within‐group differences as evidence of an effect.<br/><sup>b</sup>Downgraded once due to imprecision caused by very small numbers of participants.<br/><sup>c</sup>Downgraded once due to risk of bias from the trial design. This is a cross‐over trial and although there was a washout period between treatments, the progressive nature of CF may mean there were inherent differences between groups if the active treatment was given in the first phase rather than the second. There is also an issue around risk of bias due to incomplete outcome data as more than 15% of participants dropped out of the trial.<br/><sup>d</sup>Downgraded twice due to very small participant numbers causing imprecision.<br/><sup>e</sup>Downgraded once due to risk of bias from the trial design as more methacholine responders than non‐responders were included in the trial, which would introduce a bias in favour of active treatment.<br/><sup>f</sup>Downgraded twice due to risk of bias in this single trial. There was an unclear or a high risk of bias across all domains and very little data to include. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Short‐acting inhaled beta‐2 agonists compared with placebo for cystic fibrosis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013666.pub2/full#CD013666-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD013666-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Short‐acting inhaled muscarinic antagonists compared with placebo for cystic fibrosis</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Short‐acting inhaled muscarinic antagonists compared with placebo for cystic fibrosis</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> children and adults with cystic fibrosis </p> <p><b>Settings:</b> outpatient </p> <p><b>Intervention:</b> inhaled muscarinic antagonist (ipratropium bromide) </p> <p><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>No of Participants<br/>(trials)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Inhaled muscarinic antagonist</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Change from baseline in FEV<sub>1</sub> (% predicted)</b> </p> <p> </p> <p>Follow‐up: single dose (120 min)</p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>Mean values after inhalation of ipratropium or placebo were not significantly different</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11<br/>(1) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low<sup>a,b</sup> </b> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We were not able to enter any of the data into our analyses due to the cross‐over design and there being little data in the original paper (<a href="./references#CD013666-bbs2-0010" title="WiebickeW , PoynterA , MontgomeryM , PagtakhanR . The effect of ipratropium bromide on lung function in patients with cystic fibrosis. Pneumologie1990;44 Suppl 1(1):277-8. [CFGD REGISTER: IB59] ">Wiebicke 1990</a>). </p> <p> </p> <p>Four trials reported FEV<sub>1</sub> (L) and all found ipratropium to improve FEV<sub>1</sub>; however, there were very few data that we could analyse and the trial reported within‐group differences. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life</b> </p> <p> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>This outcome was not reported.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of exacerbations</b> </p> <p> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>This outcome was not reported.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participant‐reported symptom score</b> </p> <p> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>This outcome was not reported.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events</b> </p> <p> </p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>The only reported adverse effect of treatment was mild and resolved quickly (oral dryness). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27<br/>(2) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low<sup>a,b</sup> </b> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No data were available for analysis and results have been taken directly from the original papers (<a href="./references#CD013666-bbs2-0009" title="WeintraubSJ , EschenbacherWL . The inhaled bronchodilators ipratropium bromide and metaproterenol in adults with CF. Chest1989;95(4):861-4. [CFGD REGISTER: IB58] ">Weintraub 1989</a>; <a href="./references#CD013666-bbs2-0011" title="ZiebachR , Pietsch-BreitfeldB , BichlerM , BuschA , RiethmullerJ , SternM . Bronchodilatory effects of salbutamol, ipratropium bromide, and their combination: double-blind, placebo-controlled crossover study in cystic fibrosis. Pediatric Pulmonology2001;31(6):431-5. [CFGD REGISTER: IB82] ">Ziebach 2001</a>). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Change from baseline in FVC (% predicted)</b> </p> <p> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>This outcome was not reported.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>One trial reported FVC (L) and found no change after ipratropium compared to placebo (<a href="./references#CD013666-bbs2-0011" title="ZiebachR , Pietsch-BreitfeldB , BichlerM , BuschA , RiethmullerJ , SternM . Bronchodilatory effects of salbutamol, ipratropium bromide, and their combination: double-blind, placebo-controlled crossover study in cystic fibrosis. Pediatric Pulmonology2001;31(6):431-5. [CFGD REGISTER: IB82] ">Ziebach 2001</a>). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Sputum volume (mL)</b> </p> <p> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>This outcome was not reported.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across trials) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>FEV<sub>1</sub> </b> : forced expiratory volume in 1 second; <b>FVC</b>: forced vital capacity. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence</p> <p><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect. </p> <p><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different. </p> <p><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect. </p> <p><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded due to imprecision resulting from very small participant numbers and a single trial reporting this outcome.<br/><sup>b</sup>Downgraded twice due to risk of bias within the cross‐over trial design and an unclear risk of bias across 5 of the 7 domains. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Short‐acting inhaled muscarinic antagonists compared with placebo for cystic fibrosis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013666.pub2/full#CD013666-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD013666-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Short‐acting inhaled beta‐2 agonists compared with short‐acting inhaled muscarinic antagonists for cystic fibrosis</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Short‐acting inhaled beta‐2 agonists compared with short‐acting inhaled muscarinic antagonists for cystic fibrosis</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> children and adults with cystic fibrosis </p> <p><b>Settings:</b> outpatients </p> <p><b>Intervention:</b> inhaled muscarinic antagonist </p> <p><b>Comparison:</b> inhaled beta‐2 agonist </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>No of Participants<br/>(trials)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Beta‐2 agonist</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Muscarinic antagonist</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Change from baseline in FEV<sub>1</sub> (% predicted)</b> </p> <p> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>This outcome was not reported ‐ see comments.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None of the trials for this outcome reported FEV<sub>1</sub> % predicted, but 3 reported FEV<sub>1</sub> (L). 2 trials stated that FEV<sub>1</sub> improved after both treatments (<a href="./references#CD013666-bbs2-0006" title="Pitcher-WilmottRW , MatthewDJ , IngramD , TysonSL . Improvement in lung function after nebulised salbutamol and ipratropium bromide in children with cystic fibrosis. In: 11th European Cystic Fibrosis Conference, 1982. Brussels. 1982:251. [CFGD REGISTER: IB77] ">Pitcher‐Wilmott 1982</a>; <a href="./references#CD013666-bbs2-0007" title="SanchezI , HolbrowJ , ChernickV . Acute bronchodilator response to a combination of beta-adrenergic and anticholinergic agents in patients with cystic fibrosis. Journal of Pediatrics1992;120(3):486-8. [CFGD REGISTER: IB63] ">Sanchez 1992</a>), whilst 1 trial stated that ipratropium tended to be less effective than salbutamol (<a href="./references#CD013666-bbs2-0011" title="ZiebachR , Pietsch-BreitfeldB , BichlerM , BuschA , RiethmullerJ , SternM . Bronchodilatory effects of salbutamol, ipratropium bromide, and their combination: double-blind, placebo-controlled crossover study in cystic fibrosis. Pediatric Pulmonology2001;31(6):431-5. [CFGD REGISTER: IB82] ">Ziebach 2001</a>). None of these trials provided data for analysis. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life</b> </p> <p> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>This outcome was not reported.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of exacerbations</b> </p> <p> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>This outcome was not reported.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participant‐reported symptom score</b> </p> <p> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>This outcome was not reported.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events</b> </p> <p> </p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>No adverse effects were experienced by participants on either treatment (<a href="./references#CD013666-bbs2-0011" title="ZiebachR , Pietsch-BreitfeldB , BichlerM , BuschA , RiethmullerJ , SternM . Bronchodilatory effects of salbutamol, ipratropium bromide, and their combination: double-blind, placebo-controlled crossover study in cystic fibrosis. Pediatric Pulmonology2001;31(6):431-5. [CFGD REGISTER: IB82] ">Ziebach 2001</a>). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17<br/>(1) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very</b> <b>low<sup>a,b</sup> </b> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Change from baseline in FVC (% predicted)</b> </p> <p> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>This outcome was not reported.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Sputum volume (mL)</b> </p> <p> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>This outcome was not reported.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across trials) is provided in footnotes. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>FEV<sub>1</sub> </b> : forced expiratory volume in 1 second; <b>FVC</b>: forced vital capacity. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence</p> <p><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect. </p> <p><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different. </p> <p><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect. </p> <p><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded twice due to imprecision resulting from very small participant numbers and a single trial reporting this outcome.<br/><sup>b</sup>Downgraded once due to risk of bias within the cross‐over trial design. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Short‐acting inhaled beta‐2 agonists compared with short‐acting inhaled muscarinic antagonists for cystic fibrosis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013666.pub2/full#CD013666-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013666-tbl-0004"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Short‐acting inhaled beta‐2 agonists versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 Per cent change from baseline in FEV<sub>1</sub> L <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.1 Single dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>82</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.95 [1.88, 12.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 Change from baseline in FEV<sub>1</sub> L <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.1 Single dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.15 [0.07, 0.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 Per cent change from baseline in FVC L <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.1 Single dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.60 [0.99, 8.21]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Short‐acting inhaled beta‐2 agonists versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013666.pub2/references#CD013666-tbl-0004">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD013666.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD013666-note-0013">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD013666-note-0011">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD013666-note-0012">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD013666-note-0010">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ja#CD013666-note-0009">日本語</a> </li> <li class="section-language"> <a class="" href="ko#CD013666-note-0007">한국어</a> </li> <li class="section-language"> <a class="" href="ms#CD013666-note-0008">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD013666-note-0006">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013666\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013666\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013666\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013666\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013666\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013666\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013666\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013666\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013666\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013666\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013666\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013666\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013666\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013666\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013666\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013666\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013666\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013666\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=mV7VuqgF&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013666.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD013666.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD013666.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD013666.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013666.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740729109700"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD013666.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"/> <span class="taglib-text hide-accessible">Sign In</span> </span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740729109703"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD013666.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918ed4dc4c36f56f',t:'MTc0MDcyOTExMC4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 